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Ebola virus (EBOV) was first identified in 1976 and, since then, small outbreaks have 
been occurring in central and West African countries. The largest EBOV outbreak until 
now, taking place from year 2013 to 2016, left more than 28.000 cases and 11.000 
deaths. EBOV is a highly contagious and virulent pathogen with no FDA-licensed 
therapeutic available yet. Huge efforts are currently being made for the development 
of effective antiviral therapeutics and the investigation of viral evolution dynamics in 
correlation with its virulence. Viruses are obliged parasites of the host cell in order to 
accomplish every stage of their biological life cycle. For viral RNA synthesis, occurring 
in the cell cytoplasm, Ebola virus must interact with host proteins, which at the same 
time can be exploited as potential antiviral targets. In this study, co-
immunoprecipitation and high-throughput label-free proteomics are used to 
elucidate novel protein associations between EBOV VP35, L and host factors. 
Biological importance of the host proteins DYNLL1 and CALM on Ebola virus life cycle 
is assessed by using small molecule inhibitors in an EBOV minigenome system in 
cellular culture, resulting in a significant decrease of viral replication when either of 
the cellular factors is antagonised. The study of VP35 is taken further and the 
phenotypic changes on the protein functionality during the early beginning of the 
2013-2016 West African outbreak are characterised, demonstrating slight differences 
on the viral protein performance that could help understand better Ebola virus 
virulence. Overall, this thesis provides a better understanding of the interactions that 
Ebola virus establishes with its host, the implications that single mutations can have 
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1.1. Introduction to the Ebola virus biology 
 
1.1.1. Taxonomy and classification  
1.1.1.1. Order Mononegavirales 
 
The genus Ebolavirus belongs to the order Mononegavirales. The name is derived 
from the Greek adjective μóνος (monos; alluding to the monopartite and single-
stranded genome), the latin verb negare (alluding the negative polarity of the 
genome) and the suffix –virales (denoting a viral order). The order Mononegavirales 
was first established in 1991, comprising related viruses with non-segmented, linear, 
single-stranded negative-sense RNA genomes. In 2017, the taxonomy of 
Mononegavirales was extended and accepted by the Committee on Taxonomy of 
Viruses (ICTV). The update comprised 8 families; Bornaviridae, Filoviridae, 
Mymonaviridae, Nyamiviridae, Paramyxoviridae, Pneumoviridae, Rhabdoviridae, and 
Sunviridae (Amarasinghe et al., 2017).  
 
The order Mononegavirales include the viruses that share the following 
characteristics (Amarasinghe et al., 2017):  
• Linear genome, non-segmented, single-stranded non-infectious RNA of 
negative polarity. The genome has inverse-complementary 3’ and 5’ termini 
and is not covalently linked to a protein.  
• The genome has a specific and characteristic gene order 3’-UTR Leader à core 
protein genes à envelope protein genes à RNA-dependent RNA polymerase 
gene à Trailer 5’-UTR.  
• The genome has a single promoter located at the 3’ end and produces 
monocistronic mRNAs via polar sequential transcription, following a stop-
start mechanism between genes. 
• The genome replicates by synthesising complete antigenomes.  
• The viral genome synthesis forms infectious helical ribonucleocapsids as the 
templates for the production of mRNAs and for replication.  
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• The RNA-dependent RNA polymerase encoded in the viral genome is highly 
homologous among mononegaviruses. 
 
1.1.1.2. Family Filoviridae 
 
The terminology of the family Filoviridae comes from the Latin filo (thread-like), 
referring to their filamentous rod-like shape. The family currently comprises of 3 
genera and 7 species (Table 1.1). Comparison of filoviral genomes with other families 
within the order Mononegavirales demonstrates similar genome structure and 
suggests comparable mechanisms of transcription and replication. However, 
comparative sequence analyses of single genes indicate that filoviruses are 
phylogenetically distinct from other members of the same order. The different 
members of the order Mononegavirales share five proteins in common. These are 
the nucleoprotein (NP), the viral proteins 35 and 40 (VP35 and VP40), the 
glycoprotein (GP) and the RNA-dependent RNA polymerase (L). Only the viral protein 
24 (VP24) appears to be unique to filoviruses (Mühlberger, 2007).  
 
Within the family Filoviridae, all of the genes show conservation in gene organisation 
but only cuevaviruses and ebolaviruses present significant amino acid sequence 
similarity with a cut-off of 50% minimum sequence identity over at least 50% of the 
sequence length (Jun et al., 2015). Ebola virus and Marburg virus differ by 
approximately 67% at the amino acid level and 55% at the genomic level (Elshabrawy 
et al., 2015).  
 
There are five known and broadly accepted Ebolavirus species. Four of them cause 
Ebolavirus haemorrhagic fever. These are Ebola virus (EBOV), with the highest case-
fatality rate in humans (57-90%), followed by Sudan virus (SUDV) (41-65%), 
Bundibugyo virus (BDBV) (40%) and Taï Forest virus (TAFV), with only two known non-
fatal human infections. To date, Reston virus (RESTV) is the only Ebola virus species 
that causes an asymptomatic infection to humans (Moghadam et al., 2015). Between 
the five species, they differ by 37-40% at the nucleotide level and by 34-43% by the 
amino acid level (Elshabrawy et al., 2015). Late in 2018, the genome of a new putative 
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Ebolavirus species was sampled from 4 bats in Sierra Leone. Bombali ebolavirus 
(BOMV) was named after the location where bats were sampled. Its nucleotide and 
amino acid identities to other Ebola viruses was 55-59% and 64-72%, respectively 
(Goldstein et al., 2018).  
 
Table 1.1. ICTV-accepted taxonomy of the family Filoviridae as of 2017.  
Genus Species Virus (Abbreviations) 
Cuevavirus Lloviu cuevavirus Lloviu virus (LLOV) 
Ebolavirus Bundibugyo ebolavirus Bundibugyo virus (BDBV) 
 Reston ebolavirus Reston virus (RESTV) 
 Sudan ebolavirus Sudan virus (SUDV) 
 Taï Forest ebolavirus Taï Forest virus (TAFV) 
 Zaire ebolavirus Ebola virus (EBOV) 
 *Bombali ebolavirus *Bombali virus (BOMV) 
Marburgvirus Marburg marburgvirus Marburg virus (MARV) 
  Ravn virus (RAVV) 
*Putative new species discovered in 2018 (Goldstein et al., 2018), not included in the 
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1.1.2. Genome organisation and Ebola virus genetics 
 
The genome of Ebola virus consists of a non-segmented single stranded, negative-
sense RNA molecule of about 19kb in length, consisting of seven genes, which encode 
9 proteins in the following order: NP (Nucleoprotein) – VP35 (viral protein 35) – VP40 
(viral protein 40) – GP (Glycoprotein). It also encodes the small glycoprotein and the 
soluble small glycoprotein (sGP and ssGP, respectively) – VP30 (viral protein 30) – 
VP24 (viral protein 24) – L (RNA-dependent RNA polymerase) (Sanchez et al., 1993) 
(Figure 1.1). Each gene contains the respective open reading frame (ORF) and are 
flanked by highly conserved transcriptional gene start (GS) and gene end (GE) signals 
(Brauburger et al., 2016). Transcription stop and start signals in Ebolavirus genes are 
separated by intergenic regions (IGRs) that differ in length. They overlap in three gene 
boundaries, which share the nucleotide sequence ATTAA and are found between 
genes VP35-VP40, GP-VP30 and VP24-L (Sanchez et al., 1993). The leader and trailer 
sequences are extragenic regions located at the ends of the genome and contain the 
promoters required for transcription and replication (Neumann et al., 2009). The end 
of the genome consists of short non-transcribed regions containing cis-acting signals 
important for replication, transcription initiation and encapsidation of the genomic 




Figure 1.1. Schematic representation of the genomic organisation of Zaire 
ebolavirus (EBOV). Boxes represent the open-reading frames (ORF) that encode each 
viral protein. Intergenic regions overlap between VP35-VP40, GP-VP30 and VP24-L 
genes. Post-translational modifications (PTMs) of GP result in the subunits sGP and 
ssGP by host cell furin cleavage. Image representation based on Cantoni and 
Rossman, 2018. 
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1.1.3. Mutation rate and defecting interfering particles (DIPs) 
 
In RNA viruses, the evolution rate is estimated to be between 10-5 and 10-2 
substitutions per year (Jenkins et al., 2002; Hanada et al., 2004). According to 
sequences analysed from the 2013-2016 Ebola virus West African Outbreak, which is 
also the largest to date, the evolution rate of Zaire ebolavirus was estimated to be 
1.42 x 10-3 substitutions per site per year (Carroll et al., 2015). The activity of the 
error-prone viral replicase is thought to be the reason why defective interfering 
particles (DIPs) have been seen in nearly all RNA viruses like Ebola virus, vesicular 
stomatitis virus or influenza virus (Calain et al., 1999; Galet et al., 1976; von Magnus, 
1954). DIPs are defined as infectious truncated viral genomes derived from the 
parental RNA genome that require the presence of a full-length non-defective helper 
virus for their replication and propagation. DIPs are created spontaneously during 
viral replication and contain all the cis-acting replication elements but lack the 
capacity to encode all the viral proteins necessary for independent transcription and 
replication. These fusion events are maintained in natural viral infections and 
compete with the helper virus for viral and host factors (reviewed in Pathak and Nagy, 
2009). Due to this property, DIPs are considered interesting alternatives for potential 
antiviral therapies (Dimmock and Easton, 2014). 
 
1.1.4. Ebolavirus replication cycle  
 
Filoviruses replicate in the cytoplasm. The negative-sense single stranded RNA is first 
transcribed, producing seven monocistronic mRNA, which will be translated into the 
viral proteins. Replication and secondary transcription take place when the viral RNA 
polymerase switches to replication mode with the increase of translated viral 
proteins. There is a transcription gradient in EBOV, with transcripts whose genes are 
located closer to the 3’ end being more abundant than the transcripts whose genes 
are closer to the 5’ end of the template (Shabman et al., 2013; Albariño et al., 2018). 
A balance between replication, secondary transcription and translation leads 
towards the assembly and release of the viral progeny (Figure 1.2).  
 




Figure 1.2. Schematic representation of the Ebola virus life cycle.  
 
 
1.1.5.  Attachment and entry  
 
EBOV particles attachment to the cell membrane is mediated by the N-and O-glycans 
on the viral protein GP and is dependent on C-type lectin receptors, including 
dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN) and liver and lymph 
node SIGN (L-SIGN), and glycosaminoglycans (Simmons et al., 2003). The viral 
particles also interact with other entry-mediators cell surface proteins, such as 
integrins, mucin-domain-containing (TIM) proteins, tyrosine protein kinase receptor 
3 (TYRO3) family members, and T cell immunoglobulin (Wang et al., 2016). Virions 
are then internalised through macropinocytosis (Saeed et al., 2010). In the 
endosome, cleavage of GP and other unknown factors trigger the uncoating of the 
nucleocapsid. The interaction between cleaved GP with Niemann-Pick C1 (NPC1) 
transporter protein and two-pore channel 2 (TPC2) induces EBOV and cellular 
membrane fusion, allowing the release of the core to the cytoplasm (Wang et al., 























Chapter 1: Introduction 
 30 
1.1.6. Transcription and replication 
 
Replication and transcription are conserved among the nsNS RNA viruses. Both 
processes require the ribonucleoprotein (RNP) complex as a template. Due to the 
negative polarity of NS virus genomes, transcription is mandatory the first step in the 
virus gene expression process. Therefore, naked genomic RNA is not infectious. For 
Ebola virus, minigenome systems have demonstrated that the protein requirements 
for viral replication lay in the RNP complex, composed of RNA, NP, VP30, VP35 and L 
(Mühlberger et al., 1998; Muhlberger et al., 1999; Conzelmann, 2004). The replication 
promoters of the filoviruses are located at the 3’ end of both the viral genome and 
antigenome. Therefore, the viral RdRp can only access the RNA template at the 3’ 
end. The minimal length for the genome and antigenome promoters are 155 and 176 
nucleotides, respectively (Calain et al., 1999). The viral polymerase is thought to stop 
and resume transcription at each gene boundary. Ebola virus messenger RNAs 
(mRNAs) are presumed to be modified with a 5’-7-methylguanosine cap and a 3’ 
poly(A) tail by the viral RNA polymerase (Weik et al., 2002). After primary 
transcription, where the negative stranded RNA is used as a template for sequential 
transcription of mRNA for translation of viral proteins, the viral RNA polymerase 
switches to a replicative mode and generates positive-sense RNA genomes, the 
above-mentioned antigenomes. These serve as templates for the generation of new 
viral genomes.  
 
1.1.7.  Virion assembly and release  
 
Nucleocapsid formation occurs in inclusion bodies in regions close to the nucleus and 
are transported to the budding sites (Dolnik et al., 2015). Transport of the 
nucleocapsid relies on NP, VP35 and VP40, which are essential and sufficient to form 
transport-competent nucleocapsid-like (NC-like) structures. VP40 is the most 
abundant protein found under the viral envelope and enhances the efficiency of 
nucleocapsid recruitment into filopodia for EBOV budding (Takamatsu et al., 2018). 
A model for virion release has been proposed where NP self-assembles into helical 
tubes (Noda et al., 2006). VP35 and VP24 interact with NP, constituting NC structures. 
VP40 mediates the transport of NC-like particles via microtubules towards the cell 
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surface. Finally, NC-like particles are incorporated into virions and bud from the cell 
membrane (Noda et al., 2006; Wan et al., 2017).  
 
1.1.8.  Viral proteins 
 
Ebolavirus particles are filamentous and are surrounded by an envelope, which is 
acquired during the budding process from the plasma membrane of the host cell. The 
glycoprotein is the only viral protein on the surface of the viral particle and it is 
essential for host membrane fusion and viral release. The viral matrix proteins VP24 
and VP40 are found in the inner side of the envelope and provide structural support 
to the virion. Inside the viral particle, the genomic RNA is associated with the viral 
RNA-dependent RNA polymerase L, NP, VP30 and 35, forming the RNP complex 
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1.1.1.3. Nucleoprotein (NP) 
 
NP is one of the RNP complex components and coats the viral genome (Mühlberger 
et al., 1999). Together with VP24 and VP35, they build a helical nucleocapsid of 
~50nm in diameter and 1000nm of length. As part of the RNP complex, it has a critical 
role in protecting viral RNA (vRNA) from degradation.  
 
1.1.1.4. Viral protein 35 (VP35) 
 
VP35, the viral RNA dependent RNA polymerase cofactor, is the functional equivalent 
of the phosphoprotein P of other nsNS RNA viruses, such as paramyxoviruses and 
rhabdoviruses (Mühlberger et al., 1999; Brzózka et al., 2005; Fuentes et al., 2010). 
VP35 is also an antagonist of the host IFN type I response. It is able to inhibit the 
phosphorylation of IRF-3 and thus blocking a pathway that leads to the type I IFN 
gene expression (Basler et al., 2003), the activation of the dsRNA-dependent protein 
kinase PKR (Schumann et al., 2009) and supresses RNA silencing (Haasnoot et al., 
2007). VP35 forms homotrimers mediated by a coiled-coil domain, facilitating the 
antagonism of IFN-α/β (Reid et al., 2005). VP35 functions as a structural bridge 
between L and NP, leading to the formation of trimeric complexes (Groseth et al., 
2009). VP35 also dissociates RNA-NP oligomers, allowing the release of the genomic 
RNA for replication (Kirchdoerfer et al., 2015).  
 
1.1.1.5. Viral protein 40 (VP40)  
 
VP40 is a multifunctional protein with different roles in the EBOV life cycle depending 
on the structural rearrangements it presents. EBOV VP40 exists in three different 
structural forms; the dimeric conformation associates with the plasma membrane 
and oligomerises into hexamers. The hexametric structure of the protein forms 
filaments, which makes up the viral matrix, provides support to the new EBOV virion 
particles. Hence, it has a role in the budding process (Ruigrok et al., 2000; Bornholdt 
et al., 2013; Gerstman and Chapagain, 2017). The third structure the viral protein can 
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be rearranged in is an octamer, which has a role on the viral genome replication and 
RNA binding (Timmins et al., 2003).  
 
1.1.1.6. Glycoprotein (GP) 
 
GP is the only surface capsid protein of Ebola virus and plays an important role in 
interacting with host cell receptors in order to activate viral attachment and entry. 
The GP gene encodes three different forms of GP. GP1 is the full-length protein and 
has a receptor binding function. It is located on the virion surface and it is responsible 
for the cell attachment and membrane fusion (Lee and Saphire, 2009). GP2 subunits 
are involved in the viral fusion. The soluble GP (sGP) lacks the transmembrane 
domain. The small soluble GP (ssGP), also called Δ-peptide, is a smaller fragment 
product of the furin cleavage of sGP. These different products are due to the 
transcriptional editing performed by the viral RNA polymerase L (Mehedi et al., 2011). 
Overexpression of GP results toxic for the infected cell (Sullivan et al., 2005). Its 
expression is restricted by the gene transcriptional editing and conversion into 
recombinant GP (Volchkov et al., 2001).  
 
1.1.1.7. Viral protein 30 (VP30) 
 
VP30 is a phosphoprotein and the minor component of the RNP. It has an important 
role in viral transcription initiation and reinitiation (Martínez et al., 2008) and it is also 
involved in nucleocapsid assembly as it has the capacity of interacting with NP. Its 
phosphorylation state negatively regulates transcription, enabling binding to NP 
(Modrof et al., 2002). VP30 can also interfere with RNA silencing due to its interaction 
with the protein Dicer and potentially prevents this antiviral mechanism in the host 
(Li et al., 2013). VP30 has a zinc-binding motif, which facilitates RNA binding and 
enhances viral genome transcription (Modrof et al., 2003; Schlereth et al., 2016). The 
C-terminal domain of VP30 is homologous in structure to the respiratory syncytial 
virus (RSV) protein M2-1, giving more evidence in the transcriptional regulation 
strategies shared by nsNS viruses (Blondot et al., 2012).  
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1.1.1.8. Viral protein 24 (VP24) 
 
VP24 is a minor component of virions, a secondary matrix protein and has a direct 
role in genome packaging and nucleocapsid condensation. The viral protein presents 
a strong association with lipid membranes (Han et al., 2003). The function of the viral 
protein is dependent on the interaction with NP (Banadyga et al., 2017). VP24 also 
has a critical role on the viral evasion of IFNs by binding transporter molecules to 
prevent STAT1 translocation (Reid et al., 2006). Another described function of VP24 
is the regulation of viral replication, as it has a key role in the nucleocapsid assembly 
and the silencing of the expression of this viral protein prevents the release of EBOV 
(Mateo et al., 2011).  
 
1.1.1.9. RNA-dependent RNA polymerase (L) 
 
The L protein is 2212 amino acids in length and has an estimated size of 253 kDa 
(Volchkov et al., 1999). It has catalytic activity and is responsible for mRNA synthesis 
and modification, and generation of progeny genomes (Ortín and Martín-Benito, 
2015). The viral polymerase binds to the genomic RNA at the 3’ leader promoter and 
transcribes the viral genes with a decreasing efficiency towards the 5’ end (Albariño 
et al., 2018). EBOV L protein displays conserved sequence blocks, which are 
separated by more variable regions. This suggests it has a structural organisation in 
three functional domains called motifs A-C, conserved among the order 
Mononegavidae. Motif A (aa 553-571) comprises an RNA binding element; motif B 
(aa 738-744) represents a putative RNA template recognition and/or phosphodiester 
bond formation domain; and motif C (aa 1815-1841) is an ATP and-or purine 
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1.2. Reverse genetics 
 
Reverse genetics is the term used to define the generation, replication and 
transcription of full or truncated recombinant RNA genome viruses de novo from 
cloned complementary DNA (cDNA). Reverse genetics enable the study of different 
aspects of the virus life cycle, the development of targeted antiviral therapies, the 
functionality of host factors for the virus biology, specific properties of clonal 
subpopulations and also represent attractive biotechnological tools for the 
development of live attenuated vaccines. When reverse genetics apply to cDNA that 
encodes a truncated genome analogue, these systems are useful to model the 
replication of the virus life cycle. Included in this category are minigenome (or 
minireplicon) systems, and transcription and replication competent virus-like particle 
(trVLP) systems. These systems revolutionised the study of nsNS RNA viruses and 




1.2.1. History of reverse genetics and replicon systems 
 
The beginning of reverse genetics took place in positive sense single stranded RNA 
viruses when in 1978 Taniguchi et al. made a full-length cDNA of bacteriophage Qβ 
RNA capable of forming plaques after transfection in E. coli (Taniguchi et al., 1978). 
Following this, in 1981, Racaniello and Baltimore generated poliovirus type I clones 
from cDNA of the virus genome (Racaniello and Baltimore, 1981). The first reverse 
genetics were accomplished on positive-sense RNA viruses since transfection of its 
full deproteinated genome in eukaryotic cells allows direct viral transcription and 
subsequent translation of the viral proteins. In contrast, the RNP complex is required 
for the initiation of viral transcription and replication of negative-sense RNA viruses. 
These need their own RNA polymerase to mediate the synthesis of de novo proteins. 
Therefore, their genome alone is not infectious in permissive cells unless the RNP 
complex is supplied in trans. It was not until 1989 that Palese and colleagues 
established the first reverse genetic system in a negative-single stranded RNA virus, 
influenza A virus (Luytjes et al., 1989). In 1991, Park et al. used synthetic defective 
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interfering particles (DIPs) derived from the 5’ or 3’ end of Sendai virus (SeV) fused 
to chloramphenicol acetyl transferase (CAT) gene and achieved CAT activity in 
transfected cells after helper virus infection (Park et al., 1991). That same year, 
Pattnaik and Wertz established the first plasmid-based minigenome system by co-
transfecting vesicular stomatitis virus (VSV) DIPs together with M, G, N, NS and L viral 
proteins-encoding plasmids (Pattnaik and Wertz, 1991). Two years after, Collins et al. 
achieved recovery of DIPs derived of RSV (Collins et al., 1993). In 1994, Schnell et al. 
rescued the first member of the Mononegavirales, Rabies virus, from its anti-genomic 
strand (Schnell et al., 1994). EBOV Mayinga strain virus was first rescued from cDNA 
by using the positive-sense antigenomic RNA (Volchkov et al., 2001) and one year 
later, the negative-sense genomic RNA (Neumann et al., 2002). All these studies 
demonstrated that the viral polymerase complex is required for the amplification of 
negative single stranded RNA genome viruses.  
 
 
1.2.2. EBOV replicon system 
 
Ebola virus is classified as a Biosafety level 4 (BSL-4) pathogen, requiring high 
containment facilities for the study of its biology. Minigenome systems allow 
researchers to study EBOV replication aspects under less restrictive facilities - BSL-2 
laboratories - and without the risk of workers being exposed to virions. Minigenomes 
are monocistronic truncated genome cDNA analogues were the viral genes have 
been replaced with a reporter gene. They contain all the necessary cis-acting signals 
for EBOV polymerase to lead minigenome replication and reporter gene transcription 
(Jasenosky et al., 2010). Four separated support plasmids encode the four viral 
proteins that are constituents of the RNP complex. These are NP, VP30, VP35 and L. 
The first minireplicon system for EBOV was made in 1999 (Mühlberger et al., 1999), 
one year after the creation of the minireplicon system of another member of the 
family Filoviridae, Marburg virus (MBGV) (Mühlberger et al., 1998). While replication 
of MARV minigenome only required three of the nucleoproteins – NP, VP35 and L -, 
EBOV minigenome transcription was observed to be dependent on VP30 as well.  
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In the piece of work described in this thesis, BSR-T7 cells constitutively expressing the 
phage T7 RNA polymerase are co-transfected with the minigenome encoding 
plasmid, the four supporting plasmids encoding the RNP complex proteins under the 
control of a T7 RNA polymerase promoter (Figure 1.4) (García-Dorival et al., 2016). 
The T7 polymerase produces transcripts from the cDNA encoding the supportive 
proteins for its translation. The T7 promoter/terminator system has the advantage of 
being high in expression levels in a cellular environment whereas the T7 polymerase 
is not used for the cellular cytoplasmic production of RNAs. As for the minigenome 
cDNA plasmid, the reporter gene Firefly luciferase is surrounded by the leader and 
trailer sequences of the EBOV genome and the whole construct is comprised 
between the T7 promoter and a hepatitis D virus (HDV) ribozyme. These features 
allow an exactly defined 3’ end by the self-cleavage of the HDV ribozyme, and an 
exact 5’ end corresponding to the very end of the EBOV genome (Pattnaik et al., 1992; 
Mühlberger et al., 1999). The translated supportive EBOV proteins lead to 
transcription, replication and eventually translation of the minigenome system. The 
transcription and replication rate can be measured by the luciferase activity. 
Luciferase reporter assays have a high sensitivity and are semi-quantitative methods 
to assess gene expression. Firefly luciferase (Photinus pyralis) gene encodes a 61kDa 
protein that can oxidate D-luciferin in the presence of ATP, magnesium and oxygen, 
producing light. This reporter activity is proportional to the steady-state level of 








Figure 1.4. Schematic representation of the EBOV minigenome system.  
 
 
1.3. EBOV virus-like particles (VLP) 
 
Minigenome systems are only suitable to study viral transcription and replication. To 
overcome this limitation, VLP systems were developed (Warfield et al., 2003; 
Watanabe et al., 2004). In these systems, the minigenome plasmid is co-transfected 
together with plasmids encoding the seven EBOV proteins. Virions are created but 
cannot make new virions, as they don’t contain the viral genome but the 
minigenome. Also, the maintenance of VLPs requires the constant transfection of 
plasmids encoding the RNP complex proteins. 
 
1.4. Ebola Virus Disease  
 
Ebola virus disease (EVD) or Ebola virus haemorrhagic fever (EHF) is a zoonotic and 
acute disease affecting humans and non-human primates. It is characterised by a 
multi-organ shock caused by an imbalance of the immune system, disordered 
coagulation and tissue damage, leading to severe bleeding (Baseler et al., 2017). 
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Although EVD is known for its haemorrhagic feature, it is not the major cause of 
death. EVD is also associated to a high case-fatality rate with an average of 50% and 
a range between 20-90%.  
 
1.4.1. EBOV discovery, epidemiology, economic and social impact 
 
1.4.1.1. EBOV discovery  
 
On the 22nd of August of 1976, a 42-year old man from Yadongi Village (Democratic 
Republic of Congo), returned from an excursion to northern Zaire, where he had 
consumed antelope and smoked monkey meat. Four days after, he was treated at 
Yambuku Mission Hospital (YMH) for malaria as he was suffering chills and fever. He 
died on the 6th of September from a haemorrhagic symptom of unknown cause. In 
early September, several patients and those who received injections at YMH and their 
contacts presented a similar haemorrhagic febrile syndrome and died in about one 
week (reviewed in Breman et al., 2016). The cases in that first outbreak were 318, 
with 280 deaths (case-fatality rate 88%) (Burke et al., 1978). Shortly after the first 
outbreak in Zaire, that same year, another outbreak took place in southern Sudan, 
which caused 284 cases and 151 deaths (case-fatality rate 53%). Virologic 
investigations were taken to elucidate the unknown etiological pathogen, finding that 
it was a virus similar to the previously described Marburg virus (MARV) and was 
dubbed Ebola virus by Peter Piot, from the Institute of Tropical Medicine in Antwerp, 




According to the Centers for Disease Control and Prevention (CDC), since EBOV 
discovery in 1976, there have been at least 31,000 cases of EBOV infected individuals 
and 12,900 deaths, giving a case-fatality rate of ~42%. The EBOV species that produce 
disease in humans are Zaire ebolavirus, Sudan ebolavirus and Bundibugyo ebolavirus, 
although one EVD case was reported to be caused by Taï Forest ebolavirus in 1994 in 
Côte d’Ivoire.  
Chapter 1: Introduction 
 40 
EBOV outbreaks have occurred across the Equatorial belt of Africa, being it more 
prevalent in western Central and West Africa, and SUDV and BDBV being most 
common in eastern Central Africa (Pigott et al., 2016). A total of 20 confirmed 
outbreaks and 17 minor or single cases have occurred from 1976 in 19 countries as 
of October 2018 (“Ebola Virus Disease Distribution Map: Cases of Ebola Virus Disease 
in Africa Since 1976 | 2014-2016 Outbreak West Africa | History | Ebola (Ebola Virus 
Disease) | CDC,” 2018). 
 
1.4.1.3. Economic and social impact 
 
The 2013-2016 EBOV West African outbreak in Liberia, Guinea and Sierra Leone had 
an estimated cost of $2.2 billion in the gross domestic product. The outbreak 
provoked a substantial loss in the private sector growth, the cross-border trade, and 
the agricultural production. Also, among healthcare workers, those at the higher risk 
of contracting the disease, there were a total of 881 confirmed infected and 513 
deaths between Liberia, Guinea and Sierra Leone, according to the World Health 
Organisation (“Ebola Situation Report - 4 November 2015 | Ebola”, 2015). By 
December 2015, the cost of the response was more than $3.6 billion for technical 
expertise resources and emergency operations centres, being the top donators the 
United States of America, the United Kingdom and Germany (Evans et al., 2015).  
  
Ignorance, lack of preparedness of the health systems and population fear and 
distrust contributed to the spread of EVD. Women were more affected by the virus 
than men, probably by their role within the family as caregivers. Moreover, they were 
giving birth outside the health facilities, making them even more vulnerable. The 
increasing number of orphans will represent a long-term human development impact 
in the countries affected by EBOV outbreaks. Also, due to the impact of EVD, poverty 
in countries affected by the disease show a very strong increase in poverty and 
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1.4.2. Reservoirs, transmission and persistence 
 
The reservoir of EBOV is currently unknown, although EBOV-specific IgG antibodies 
and viral nucleotide sequences have been found in three species of fruit bats: 
Hypsignathus monstrosus, Epomops franqueti and Myonycteris torquata (Leroy et al., 
2005). EBOV-specific antibodies only have been found in other fruit bat species, like 
Eidolon helvum in Ghana and Gabon (Olival and Hayman, 2014; Weyer et al., 2015). 
The role of vectors is not known, and spillover epidemics have been observed in small 
mammals, duikers, primates and humans.  
 
Transmission of EBOV occurs through contact with skin and secretions of an infected 
individual suffering from active infection. The virus can be transmitted through urine, 
sweat, saliva, semen, faeces, blood, vomitus, breast milk and virus-contaminated 
objects. The infection of EBOV needs a relatively low viral dose, with 10 or fewer viral 
particles to infect a human being (Osterholm et al., 2015). Transmission is not likely 
to occur before the onset of symptoms (Elshabrawy, et al., 2015). The major route 
between humans requires direct contact with blood, body fluids or injured skin. 
There is no known connection of virus spread with any vector. There is virologic 
evidence that EBOV can persist for months and without causing cytopathic effects in 
immune-privileged tissues and their fluids, such as semen, breast milk, cerebrospinal 
fluid and aqueous humour (Vetter et al., 2016).  
 
1.4.3.  Pathogenesis and host immune response 
 
Ebola virus disease (EVD) remains not completely understood due to the many 
different cell targets and manifestations of the systemic disease. The clinical outcome 
depends not only on the virus strain but the host immune system and genetics (Liu 
et al., 2017). Entry into a host occurs through exposure of infected body fluids to 
mucosal surfaces, wounds or through parental transmission. The first targets of 
infection are the dendritic cells (DCs) and the macrophages, where the viral proteins 
directly trigger unbalanced proinflammatory responses (e.g. IL-6, IP-10) and supress 
induction of antiviral host cell functions. Additional susceptible antigen-presenting 
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cells are recruited to the site of infection by this unregulated secretion of 
proinflammatory cytokines and chemokines, becoming subsequently infected. This 
proinflammatory gene expression occurs very early in infection and appears to be 
induced by EBOV GP during entry to the cell (Wahl-jensen et al., 2005). Infected 
macrophages and DCs will both spread the virus to secondary lymph nodes, where 
more susceptible myeloid antigen-presenting cells will be infected and induce 
apoptosis in lymphocytes. Adaptive immunity drives viral clearance. Early production 
of IgM and isotype switch to IgG was observed to be correlated with positive outcome 
in EVD, while diminished IgM and IgG responses have been associated with fatal cases 
(Baize et al., 2002; Ksiazek et al., 1999). Antibody responses play many roles during 
EVD, including antibody-dependent killing of infected cells, complement activation 
and neutralization. CD8+ and CD4+ T cells are essential for virus clearance and can 
only be activated by DCs. In both fatal and surviving cases and unrelated to 
treatment, EVD is characterised by a robust T cell activation. Nevertheless, a lack of 
T cell effectiveness is thought to be related to high expression of T cell co-inhibitor 
molecules, programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated 
protein 4 (CTLA-4) in T cells, which leads to T cell exhaustion (Mohamadzadeh et al., 
2007; Ruibal et al., 2016). High viremia occurs due to the increasing number of 
infected DCs and macrophages, giving rise to the infection of hepatocytes and Kupffer 
cells in the liver, accompanied by progressive acute hepatitis (Bradfute et al., 2010). 
In late stages of infection, endothelial cells lining the blood vessels become infected 
and activated, resulting in an increase of the cardiovascular barrier permeability, 
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Figure 1.5. Observed symptoms associated to EVD. Schematic representation based 
on Mendoza et al. observations (Mendoza et al., 2016). 
 
 
1.4.4.  EBOV suppression of host antiviral responses 
 
EBOV interferes with the immune response by blocking the interferon (IFN) 
production signalling by the VP35 and VP24 proteins and by the GP/sGP-based 
immune diversion. VP35 functions as a type-I IFN antagonist by blocking the 
activation of IFN regulatory factor 3 (IRF-3), possibly by preventing transcription of 
IFN-β and by impeding the detection of the dsRNA stage of viral 
replication/transcription (Feldmann and Geisbert, 2011), while VP24 blocks a number 
of IFN signalling pathways. Together, VP35 and VP24 ensure the poor production of 
IFN and therefore the infected cell is unable to respond (Audet and Kobinger, 2015). 
Moreover, maturation of DCs is inhibited by VP35, which interferes with RIG-I 
signalling pathway. It prevents the up-regulation of co-stimulatory molecules CD40, 
CD80 and CD86, MHC-1 and MHC-2. Therefore, antigen presentation to CD8+ and 
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CD4+ T cells gets impaired as well as B cell activation (Baseler et al., 2017). VP40 plays 
a role in EBOV immune evasion by suppressing RNAi and via exosome-bystander cell 
death (García et al., 2012). Ebola virus GP also contributes to escape the host immune 
detection by hiding MHC-1 on the surface of the cells (Francica et al., 2010) and by 
preventing Fas-mediated apoptosis of EBOV infected cells (Noyori et al., 2013). It also 
counteracts tetherin (Kaletsky et al., 2009). sGP neutralises the humoral immune 
response by adsorbing anti-GP antibodies (Mohan et al., 2012). 
 
1.5. Therapeutics for EVD  
 
Although Ebola virus was first described more than 40 years ago, neither vaccine nor 
treatment has been approved for use in humans. The impact on West African 
population of the largest ever EBOV outbreak, occurring between 2013-2016, 
highlighted the urgent need to find effective therapeutics against EVD and gave the 
chance to evaluate several vaccine candidates. Nevertheless, EBOV-infected patients 
received supportive care, which remains the mainstay of treatment due to non-
licensed therapy for humans against EVD (as of April 2019).  
 
1.5.1. Current state of vaccine development 
 
There is currently no FDA-licensed vaccine to prevent EVD (as of April 2019). As an 
emergency response to the 2013-2016 Ebola virus epidemic in West Africa, several 
candidate vector-based vaccines have been tested in trials. During 2015, a phase-2 
clinical trial was performed in Sierra Leone to test the efficacy of a recombinant 
adenovirus type-5 vector-based Ebola (Ad5-EBOV) vaccine expressing the viral 
glycoprotein of the Makona strain. Non-human primates were used for a preclinical 
challenge trial with the Ad5-EBOV vaccine and showed 77% protection against death. 
Nevertheless, durability of the vaccine-elicited GP-specific antibodies was not 
sufficiently long lasting and robust (Zhu et al., 2017). Moreover, a large proportion of 
adults worldwide have immunity against adenoviral vectors, which compromises the 
efficacy of this vaccination platform.  
 
Chapter 1: Introduction 
 45 
The effect of the recombinant, replication-competent vesicular stomatitis virus-
based trial vaccine expressing Zaire Ebola virus Mayinga strain surface GP protein 
(rVSV-ZEBOV) was tested during the 2013-2016 in Guinea. No cases among 
vaccinated people from day 10 post-vaccination demonstrated substantial protection 
against EVD, showing 100% efficacy (CI 74.7-100%) in 7651 individuals enrolled in the 
ring vaccination trial (Henao-Restrepo et al., 2017).  
 
1.5.2. Current state of treatment development 
 
Small molecule inhibitors comprise repurposed drugs, newly developed nucleic acid-
based products (small interfering RNA; siRNA) and immune-based therapeutics, 
including plasma transfusions, interferons and monoclonal antibodies (mAbs) against 
EBOV.  
 
1.5.2.1. Small molecule inhibitors 
 
Many small molecules have shown protection in cellular culture but the one that 
stands out is Favipiravir (6-fluoro-3-hydroxy-2-pyrazinecarboxamide), which is a 
broad spectrum inhibitor of viral RNA polymerase activity of RNA viruses (Furuta, et 
al., 2017). Favipiravir has shown increased survival rates in individuals suffering from 
EVD and a significant reduction in viral RNA load (>100 fold difference) determined 
by (q)RT-PCR (Bai et al., 2016). Nevertheless, monotherapy with Flavipiravir is unlikely 
to be effective in patients with very high viral loads (Ct value < 20) (Sissoko et al., 
2016). 
 
1.5.2.1. Immune-based therapeutics 
 
ZMapp is a cocktail composed of three chimeric, humanised, monoclonal antibodies 
that target different sites of the Mayinga EBOV-GP. The three antibodies that 
compose the ZMapp cocktail were sourced from MB003 and ZMab, which are 
previous anti-EBOV GP antibody collections (Tran et al., 2016). ZMapp was used as a 
complementary therapy to treat EBOV-infected patients during the West African 
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EBOV outbreak and showed an increased chance of survival. However, its 
effectiveness could not be assessed as this therapeutic was administered with other 
treatments such convalescent plasma transfusion (Davey et al., 2016; Mendoza et al., 
2016). Convalescent whole blood (CWB) and convalescent plasma (CP) from those 
patients who have recovered from EVD carry specific antibodies. CP and CWB have 
been used to treat EBOV-infected patients but its effectiveness remains inconclusive. 
Interferons (IFNs) have also been used in combination with CP as treatment. IFNs 
have been used as broad-spectrum antivirals as they have a pivotal role in the innate 
immunity against viral infections. IFNs treatments may be beneficial for the patient 
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1.6. Research aims and objectives 
 
The general aim of this PhD was to give insight into the roles of Ebola virus VP35 and 
L proteins within the host cell. In order to achieve so, label-free proteomics were used 
to elucidate host-virus protein associations. Besides, a minigenome system enabled 
the study of selected protein-protein interaction functionalities on EBOV RNA 
synthesis in BSL-2 facilities. The work comprised in this thesis was organised in three 
chapters.  
 
The first part aimed to elucidate the EBOV VP35 cellular interactome by using a co-
immunoprecipitation approach coupled to LC-MS/MS. Several novel and potential 
VP35-host protein-protein interactions were identified. Two of the most significant 
hits were DYNLL1 and CIRBP. The anti-viral activity of the DYNLL1 antagonist 
Ciliobrevin D on EBOV RNA synthesis were evaluated in this chapter.  
 
The second chapter of results focused on the investigation of relevant EBOV L-host 
protein interactions by also using a co-immunoprecipitation approach coupled to LC-
MS/MS. To overcome the hindrance that a relatively big protein entails in terms of 
cellular stability and levels of expression in cell culture, a cell-free rabbit reticulocyte 
coupled transcription and translation system was used to express L and investigate 
potential host interactions. The observed interaction between EBOV L and the host 
protein CALM and also the role of free intracellular calcium ions on the viral RNA 
synthesis were further investigated in this chapter. 
 
The third part of this thesis studied the potential significance on the viral RNA 
synthesis and IFN-β antagonism performance of three EBOV VP35 non-synonymous 
mutations observed to occur in the start of the 2013-2016 West African outbreak. 
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2.1. Recombinant protein constructs 
 
2.1.1. Fluorescent fusion vector cloning 
 
2.1.1.1. EBOV EGFP-VP35 and VP35-EGFP, mutated VP35-
encoding vectors and pL-mCherry 
 
A codon-optimised for human cell expression cDNA sequence encoding viral protein 
VP35 was cloned into pEGFP-C1 (Figure 2.1A) and pEGFP-N1 (Figure 2.1B) vectors for 
the expression of Zaire ebolavirus Makona strain VP35 [NCBI sequence reference 
number KJ660347.2] with either a C-terminal EGFP tag and an N-terminal EGFP tag, 
respectively. The same codon-optimised for human cell expression EBOV VP35 
sequence was used for the introduction of non-synonymous mutations. The mutated 
genes were inserted in a pUC57 vector (Figure 2.1C) and under the control of a T7-
Pol promoter. Three constructs encoding mutated Makona strain EBOV VP35 
proteins were pVP35M68T, pVP35L249F and pVP35L330F, encoding residue substitutions 
M68T, L249F and L330F, respectively.  
 
A codon-optimised for human cell expression cDNA sequence encoding the reporter 
protein mCherry [NCBI sequence reference number AY678264] was introduced in the 
second hinge (H2) region of the EBOV RNA-dependant RNA polymerase of Zaire 
ebolavirus Makona strain [NCBI sequence reference number KJ660347.2], between 
nucleotides 5527 and 5528 (amino acids G162 and S163). The insert was cloned in a 
pUC57 vector (Figure 2.1C), under the control of a T7 polymerase promoter.  
 
The Invitrogen GenArt Gene Synthesis (Thermo Fisher Scientific) service was used for 
plasmid design, cloning and codon optimisation of the coding sequences.
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Figure 2.1. Map of the expression vectors used in this thesis. (A) pEGFP-C1 and (B) pEGFP-N1 for the expression of EBOV VP35 with an 
EGFP tag at either the C-terminal or the N-terminal end. (C) A pUC57 vector was used for the expression of the minigenome system 
proteins, the EBOV minigenome, the mutated VP35 protein variants and the recombinant protein L-mCherry. 
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2.2. Analysis of 2014-2015 EBOV VP35 sequences  
 
On the 6th of March 2017, 968 Zaire ebolavirus (EBOV) VP35 protein sequences were 
downloaded from GenBank (NCBI). Sequences that were not completed had been 
withdrawn from the analysis previously. All of the analysed sequences were 340 
amino acids in length. The sequences were aligned, and the analysis of the non-
synonymous amino acid mutations was performed through MEGA (Version 6.06). All 
sequences were compared to a Makona strain reference sequence from 2014 
[KJ660347.2] and to a Zaire ebolavirus Mayinga strain [ NCBI ref. num. AGB56837.1] 
sampled in 1976 in the Democratic Republic of Congo during the first known outbreak 
ever.  
 
2.3. DNA methods 
 
2.3.1. Transformation of cells 
 
2.3.1.1. DH5α competent cells  
 
Subcloning Efficiency DH5α Competent Cells (Invitrogen) were used for transforming 
pEGFP C1, pEGFP-VP35 C1 and pVP35-EGFP N1. Aliquots of 50μl of competent cells 
were used for each plasmid DNA and transformations were performed according to 
the manufacturer’s instructions. For each transformation, 10ng of plasmid DNA were 
used. LB-Kanamicin agar dishes were used to plate transformed cells, with a 
kanamycin concentration of 50μg/ml.  
 
2.3.1.2. SURE competent cells 
 
SURE competent cells (Agilent) were used for the production of pMG, pL, pVP30, 
pVP35, pNP, pL-mCherry, pIFNb_GL3, pRLTK, pVP35M68T, VP35L249F, pVP35L330F and 
pT7-Pol stocks. Each plasmid transformation was performed in 100μl of competent 
cells and according the manufacturer’s instructions. 10ng of plasmid were used per 
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transformations. LB-Ampicillin agar dishes were used to plate transformed cells, with 
an ampicillin concentration of 50μg/ml.  
 
2.3.2. Preparation of plasmid DNA: Minipreps and Maxipreps 
 
For the preparation of plasmids, a QIAGEN® Plasmid Mini and Maxi kits (QIAGEN) 
were used according to the manufacturer’s instructions. For each Miniprep and 
Maxiprep, 12ml or 0.5L, respectively, of turbid overnight culture of plasmid DNA-
containing bacteria with the correspondent selective antibiotic were used as input 
and 20μl and 300μl of nuclease-free water, respectively, were added to each eluted 
DNA pellet, left overnight at 4°C and resuspended and stored at 80°C the following 
day.  
 
2.3.3. Measurement of DNA concentration and purity 
 
DNA plasmid stock concentrations were measured by using a NanoDrop ONE 
spectrophotometer (Thermo Scientific) according to the manufacturer’s instructions. 
To blank, 1μl of nuclease-free water was used and for each measurement, 1μl of 
sample. Measurements of each sample were taken twice.  
 
2.3.4. Restriction endonuclease digestion 
 
Endonuclease digestion was performed on plasmid DNA to obtain linear fragments 
and determine their size by electrophoresis for screening purposes. The 
endonucleases used in this study were SacI-HF, SalI-HF, and BsgII-HF, from New 
England Biolabs. The amount of restriction endonuclease was 1 unit/50μl reaction, 
and time, temperature of incubation and buffer used for each enzyme was in 
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2.3.5. Agarose gel electrophoresis 
 
Agarose gel electrophoresis (0.5-1% w/v) was used to achieve visualisation, 
separation and size determination of DNA. HI-Res standard agarose (AGCT 
Bioproducts) was added to the appropriate volume of TBE 1X (Tris-borate-EDTA) 
buffer (89mM Tris, 89mM boric acid, and 2mM EDTA, pH 8.3) and heated until 
molten. To prepare warm agarose solution, 0.1μl/ml of SYBR Safe DNA Gel stain 
(Thermo Scientific) was added. The molten agarose was mixed, poured into a gel-
casting tray, left to cool down and submerged in TBE 1X buffer. DNA samples were 
mixed with DNA loading buffer (5% glycerol, 1mM EDTA, 0.2% bromophenol blue 
(w/v)) in a ratio 4:1 and loaded into the gel. HyperladderTM 1kb (Bioline) or Quick-
Load 1kb Extend DNA Ladder (New England Biolabs) were used according to 
manufacturer’s instructions to determine the DNA fragments size. Electrophoresis 
was then carried out at 90-100v until dye migrated 80% of the gel approximately.  
 
2.4. Tissue culture methods 
 
In this thesis, two cell lines were used. Human Embryonic Kidney 293T cells 
(HEK293T), obtained from the European Collection of Authenticated Cell Cultures 
(ECACC), and BHK-21, a cell line stably expressing T7 polymerase (BRS-T7 cells). BSR-
T7 cells were kindly provided by John Barr’s group, from the University of Leeds. 
 
2.4.1. Cell culture 
 
293T cells were grown with Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma-
Aldrich) supplemented with 10% foetal bovine serum (FBS; Sigma-Aldrich), 1% 
Glutamax (Thermo Fisher Scientific) and 1% Penicillin-Streptomycin (Sigma-Aldrich) 
at 37°C with 5% CO2. BRS-T7 cells were cultured in Dulbecco’s Modified Eagle’s 
Medium supplemented with 10% FBS, 1% Glutamax, 1% Penicillin-Streptomycin and 
0.6% Geneticin® G418 (Thermo Fisher) (100μg/ml stock) at 37°C with 5% CO2. For cell 
passage, cells were washed with phosphate buffered saline (PBS; Sigma-Aldrich), 
trypsinised with Trypsin solution 1X (Sigma-Aldrich) and mixed with fresh pre-warm 
supplemented DMEM with the appropriate antibiotic.  
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2.4.2. Freezing and thawing cells 
 
To freeze cells, media was removed from T-175 flasks containing grown cells. 
Monolayers were washed with 10ml PBS, decanted, and washed again with 3ml of 
pre-warmed trypsin, following trypsination with 3ml of pre-warmed trypsin at 37°C 
for 5 minutes. Flasks were tapped for the cell monolayer detachment and 10ml of the 
appropriate pre-warmed media were added and mixed with cells to neutralise 
trypsin. Cells were trespassed into a 15ml Falcon tube and centrifuged for 5 minutes 
at 400rfc. Supernatant was discarded, following resuspension of pellet in 10ml of ice-
cold freezing medium (DMEM 80%, FBS 10%, 10% dimethyl sulfoxide (DMSO; Sigma-
Aldrich)). Cell suspension was aliquoted in cryovials, left at -80°C for 24 hours and 
stored into liquid nitrogen until requested.  
 
To thaw cells, frozen cell cryovial aliquots were warmed up at 37°C and trespassed 
into 15ml Falcon tubes containing 9ml of cold PBS. Suspended cells were centrifuged 
for 5 minutes at 1000rpm. Supernatant was discarded, and cell pellets were washed 
two more times with PBS followed by spinning down and supernatant removal. Cell 
pellets were resuspended with 10ml of pre-warm media, transferred into T-25 cell 
culture flasks and incubated at 37°C with 5% CO2 for 24 to 48 hours for the correct 
cell attachment to the flask surface. 
 
2.4.3. Transfection of cells 
 
2.4.3.1. LipofectamineTM 2000 and LipofectamineTM 3000  
 
The minigenome system plasmids in BSR-T7 cells were transfected with 
LipofectamineTM 2000 (Invitrogen). For transfections in a 24-well dish format, cells 
were seeded at 105 cells/well and plasmid transfections were carried out according 
to the manufacturer’s instructions. For transfection of IFN-β assay plasmids in 293T 
cells, they were seeded at 1.6x105 cells/well in a 24-well dish and transfection were 
performed with Lipofectamine 3000® (Invitrogen) according to the manufacturer’s 
instructions. 
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2.4.3.2. Calcium phosphate 
 
Calcium phosphate co-precipitation was used as the transfection method in chapter 
3 for the expression of recombinant proteins EGFP-VP35 C1 and VP35-EGFP N1 in 
293T cells. Filtered double distilled H2O (ddH2O) was used to resuspend CaCl2. 
Plasmid DNA was added in a tube containing 2M CaCl2 and ddH2O was used to 
complete the volume. The mix was added into another tube containing 2X HEPES 
buffered saline (HBS) in a drop wise manner and left incubating for 30 minutes at 
room temperature. The solution was then added onto cells. Number of cells seeded, 
quantity of chemical compounds, plasmid DNA amount and transfection media 
volume depended on the dish format used (Table 2.1.). 
 
Table 2.1. Calcium phosphate transfection solution recipes for 293T cells.  
Format 24-well 12-well 6-well 10-cm2 50-cm2 
Relative area 0.25x 0.5x 1.2x 7x 60x 
Cell number 6x104 1x105 2x105 1.25x106 8x106 
Culture media 500μl 1ml 2ml 10ml 100ml 
Transfection media 280μl 570μl 1.4ml 8ml 68ml 
2X HBS 18μl 36μl 86μl 500μl 4.28ml 
2M CaCl2 2.18μl 4.36μl 10.5μl 61μl 523μl 
DNA 0.36μg 0.71μg 1.71μg 10μg 86μg 
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2.5. Protein techniques 
 
2.5.1. Cell-free protein expression 
 
TnT® Quick Coupled Transcription/Translation System (Promega) was used to express 
the fused protein EBOV L-mCherry in vitro. 2μg of the plasmid encoding L-mCherry 
were incubated together with 40μl of TnT® T7 Quick Master Mix, 1μl of methionine 
1mM, 1μl of T7 TnT Enhancer and 4μl of nuclease-free water (Table 2.2). A positive 
and a negative control for the protein expression reaction were also included. The 
total volume per reaction was 50μl. Reactions were incubated at 30°C for 90 minutes.  
 








TnT® Quick Master Mix 40μl 40μl 40μl 
Methionine, 1mM 1μl 1μl 1μl 
T7 TnT® PCR Enhancer - - 1μl 
L-mCherry plasmid - - 2μg  
Firefly luciferase plasmid 0.5μg - - 
Nuclease-free Water 8μl 9μl 4μl 
 
 
2.5.2. GFP and RFP co-immunoprecipitation of proteins 
 
2.5.2.1. RNAse A treatment 
 
For each ml of diluted cell lysate, 2μl (15 units) of RNase A (Qiagen) were added and 
the mix was incubated in a rotor for 1 hour at 4°C. 
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2.5.2.2. Forward co-Immunoprecipitations  
 
EGFP, VP35-EGFP and EGFP-VP35 proteins co-immunoprecipitations (coIPs) were 
performed with GFP-Trap (Chromotech). Harvested cell pellets were lysed in 200μl of 
lysis buffer (10mM Tris/HCl pH 7.5, 150mM NaCl, 0.5mM EDTA, 0.5% NP-40 
supplemented with 1X Halt protease Inhibitor Cocktail EDTA-Free (Thermo 
Scientific)). After an incubation of 30 minutes on ice, cell lysates were cleared by 
centrifugation at 14,000G and the supernatants were diluted five-fold with 
dilution/wash buffer (10mM Tris/Cl pH 7.5; 150mM NaCl; 0.5mM EDTA 
supplemented with 1X Halt protease Inhibitor Cocktail EDTA-Free (Thermo 
Scientific)). The GFP agarose beads were equilibrated with ice-cold dilution/wash 
buffer and incubated with the diluted cell lysates on a rotary mixer at 4°C overnight, 
and then centrifuged at 2500G for 2 minutes. The pellet was washed two times with 
dilution/wash buffer. After removal of the dilution/wash buffer, the beads were 
resuspended with 25μl of glycine-elution buffer (200mM glycine pH 2.5), incubated 
for 10 minutes at 300rpm at room temperature, collected by centrifugation at 2,500G 
for 2 minutes at 4°C and transferred to another Eppendorf tube together with 2.5μl 
of 1M tris-base (pH 10.4) to neutralise the eluted bound-proteins. This step was 
repeated 4 times. Samples were then analysed by mass spectrometry.  
 
2.5.2.3. Reverse co-Immunoprecipitations 
 
Reverse coIPs was performed utilising the immobilised recombinant protein G resin 
(Generon). Harvested cell pellets previously lysed with 200μl of lysis buffer were 
clarified by centrifugation and diluted five-fold with dilution/wash buffer. Diluted cell 
lysates were incubated with 3μg of specific antibodies against host proteins of 
interest for 2 hours at 4°C on a rotor. Recombinant protein G sepharose beads were 
equilibrated as previously described in the forward co-immunoprecipitations section 
(section 2.5.2.2). Cell lysates containing the antibody were incubated with the protein 
G sepharose beads overnight at 4°C on a rotor.  
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2.5.3. Harvest and lysis of culture cells  
 
Cell lysis for western blot was performed with RIPA buffer (50mM Tris-HCl (pH 7.4), 
1% (v/v) NP40, 0.55 (w/v) sodium deoxycholate, 150mM NaCl, 100mM sodium 
dodecyl-sulphate, 1x EDTA-free complete protease inhibitor (Roche)). Media from 
the wells containing the grown and transfected cells was removed. For a 24-well dish 
format, wells were washed with 1ml of PBS and following its removal, 50μl of ice-cold 
RIPA buffer were added in each well. Dishes were incubated on ice for 30 minutes 
and cell monolayers were scrapped and transferred into Eppendorf tubes. Cell lysates 
were centrifuged for 10 minutes at 14000rfc at 4°C. Supernatants were put into 
Eppendorf tubes and stored at -80°C until required for western blot.  
 
2.5.4. Protein concentration determination  
 
The PierceTM BCA Protein Assay Kit (Thermo Scientific) was used for the colorimetric 
detection and quantification of total protein in cell lysates to equal the protein 
concentration loaded in the SDS-PAGE gels for immunoblotting. The microplate (96-
well dish format) procedure was used according to the manufacturer’s instructions. 
The calibration curve was constructed by using bovine serum albumin (BSA) 
standards. The diluent for the standards was the same as used for the samples, 
ddH2O. For each sample, 10μl were pipetted into a well together with 200μl of 
Working Reagent (WR). Plates were incubated at 37°C for 30 minutes, and 
subsequently read on an Infinite® F50 absorbance microplate reader (Tecan Trading 
AG) at 560nm. 
 
2.5.5. SDS-PAGE (Sodium-dodecyl sulphate polyacrylamide gel 
electrophoresis) 
 
Protein samples were resolved by using a Mini-PROTEAN tetra cell (Bio-Rad). Gel 
recipes are described in Table 2.3. Throughout this thesis, 10% resolving gels are used 
unless otherwise indicated. Two ethanol-cleaned glass plates were held in a stand 
and resolving gel solution was poured in between. To provide a flat and air bubble-
free surface, 1ml of water-saturated butanol was added at the top of the resolving 
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gel. Following the polymerisation of the gel and water-saturated butanol removal, 
the stacking gel solution was poured on top of the resolving gel and a comb of either 
10 or 15 wells was added. Upon polymerisation of the stacking gel, the comb was 
removed, and the gels were inserted in an electrophoresis tank with 1X SDS-PAGE 
running buffer (25mM Tris-HCl [pH 8.3], 250mM glycine, o.1% [w/v] SDS). Protein 
samples were boiled and denaturalised for 10 min at 95°C with 5X SDS loading buffer 
(120 mM Tris-Cl, pH 6.8, 20% glycerol, 4% SDS, 0.04% bromophenol blue, 10% β-
mercaptoethanol). As a reference marker for molecular weight, 7.5μl of ColorPlus™ 
pre-stained protein ladder, broad range (10-230 kDa) (New England Biolabs) or 
Spectra™ MultiColor High Range Protein Ladder (40-300kDa) (Thermo Scientific) 
were loaded. SDS-PAGE gels were run at 100-120v, 400mA for approximately 1 hour 
or until optimum resolution of the protein ladder was achieved.  
 
Table 2.3. SDS-PAGE resolving and stacking gels recipes. Amounts and volumes given 
to make 2 mini gels. APS refers to ammonium persulphate. SDS refers to sodium 
dodecyl sulphate. TEMED refers to tetraacetylethylenediamine. 
Resolving Gel (10ml) Stacking Gel (5ml) 
% Gel 15% 12% 10% 7.5% % Gel 5% 
30% Acrylamide 5ml 4ml 3.3ml 2.5ml 30% Acrylamide 0.83ml 
1.5M tris-HCl pH 
8.8 
2.5ml 2.5ml 2.5ml 2.5ml 
1M Tris-HCl pH 
6.8 
0.63ml 
dH2O 2.3ml 3.3ml 4ml 4.8ml dH2O 3.4ml 
10% (w/v) SDS 100μl 100μl 100μl 100μl 10% (w/v) SDS 50μl 
10%(w/v) APS 100μl 100μl 100μl 100μl 10%(w/v) APS 50μl 
TEMED 10μl 10μl 10μl 10μl TEMED 5μl 
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2.5.6. Western blot analysis 
 
Poly-vinylidene fluoride (PVDF) membranes (Millipore) were activated in 100% 
methanol and equilibrated by immersion in Towbin buffer (25mM Tris-base [pH8.1-
8.5], 192mM Glycine, 20% v/v methanol). SDS-PAGE gels were placed on over PVDF 
membranes and sandwiches between sheets of thick filter paper previously soaked 
in Towbin buffer. Transfer was performed using a Bio-Rad semi-dry apparatus at 25V 
for 45 minutes. After transfer, membranes were blocked in 10% (w/v) skimmed milk 
powder (Marvel) made up in Tris-buffered saline (0.25M Tris-base [pH 7.4], 1.5M 
NaCl) containing 10% (v/v) Tween-20 (TBS-T) and incubated on a rocker for one hour 
at room temperature. Blocking solution was then discarded and the membrane 
washed three times in TBS-T. Primary antibody in TBS-T or 5% (w/v) skimmer milk 
powder TBS-T was added to the membrane and incubated overnight (ON) at 4°C on 
a rocker. Antibodies used for the primary incubation are listed in Table 2.4. Following 
the incubation, unbound antibody was removed by washing the membrane three 
times with TBS-T. Horse radish peroxidase-conjugated secondary antibody in TBS-T 
5% (w/v) skimmed milk was added to the membrane and incubated for one hour at 
room temperature on a rocker. Unbound secondary antibody was washed off as for 
primary antibody. The antibodies used for the protein detection are listed in Table 
2.5. Protein-antibody complexes were visualized using the ClarityTM Western ECL 
Blotting Substrates (Bio-Rad) according to the manufacturer’s instructions. A 
ChemiDoc touch gel imaging system (Bio-Rad) was utilised to obtain pictures of the 
developed membranes. PVDF membranes could be restored and reused by stripping 
them off with a Blot restore and rejuvenation kit (Millipore) according to the 
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2.5.7. Functional assays  
 
2.5.7.1. Cell viability assay  
 
Cell viability was determined by using a colorimetric (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) MTT assay. BSR-T7 cells were seeded in triplicate in 
96-well plates at a density of 7.5×103 cells/well to ensure 70-90% confluence at 24 h. 
Ciliobrevin D (Merck) BAPTA-AM (Abcam) or W-7 (N-(6-Aminohexyl)-5-chloro-1-
naphthalenesulfonamide hydrochloride; Sigma-Aldrich) were then added to wells at 
different concentrations (low to high) and incubated for 24h at 37°C. Dimethyl 
sulfoxide (DMSO; Sigma-Aldrich) was used as the vehicle control. After the small 
molecule inhibitor incubations, wells were washed once with 1X PBS. 0.024g MTT 
(Sigma) were dissolved in 10 ml of pre-warmed medium (DMEM 10% FBS, 1% 
Glutamax). The MTT was filtered and a volume of 100μl was added to each well. 
Plates were incubated for 45 minutes at 37°C, MTT was removed. 100μl of DMSO 
were added and mixed by pipetting. Absorbance was measured at 450nm by using 
an Infinite® F50 absorbance microplate reader (Tecan Trading AG). 
 
2.5.7.2. Small molecule inhibitors 
 
Ciliobrevin D (C₁₇H₈Cl₃N₃O₂) (Merck) is an inhibitor of dynein ATPase activity, which 
prevents the retrograde and anterograde transport of organelles and vesicles by 
disrupting spindle pole focusing and kinetochore-microtubule attachment. For the 
functional assays, 10mg of Ciliobrevin D were dissolved in 5ml of DMSO (2.5mg/ml) 
according to the manufacturer’s instructions.  
 
W-7 (N-(6-Aminohexyl)-5-chloro-1-naphthalenesulfonamide hydrochloride; 
C16H21ClN2O2S×HCl) (Santa Cruz), a Ca2+-calmodulin dependent phosphodiesterase 
and myosin light chain kinase inhibitor, was used to antagonise calmodulin in BSR-T7. 
For the functional assays, 25mg of W-7 were dissolved in 1ml of DMSO according to 
manufacturer’s instructions. 
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BAPTA-AM (1,2-Bis(2-aminophenoxy)ethane-N,N,Nʹ,Nʹ-tetraacetic acid 
(acetoxymethyl ester); C34H40N2O18) (Abcam), a membrane permeable selective 
chelator of intracellular calcium, was used to reduce the levels of free Ca2+ ions in 
BSR-T7 cells. For the functional assays, 25mg of BAPTA-AM were dissolved in 327µl 
of DMSO according to the manufacturer’s instructions.  
 
2.5.7.3. EBOV Minigenome system 
 
The EBOV minigenome system used in this thesis was the same used by García-
Dorival et al. in our lab (García-Dorival et al., 2016) (Figure 2.2). BSR-T7 cells were 
seeded at a cell number for 105 cells/well in 24-well plates for an 80-90% confluence 
the next day. The minigenome system was transfected with LipofectamineTM 2000 24 
hours after seeding with the following plasmid amounts per well; 500ng pMG, 250ng 
pNP, 125ng pVP30, 125ng pVP35 and 125ng pL or pUC57, together with 50ng of the 
control plasmid pRLTK, encoding Renilla luciferase. 24 hours post-transfection, cells 
were washed with PBS and lysed with 100µl of passive lysis buffer (PLB; Promega) 
five-fold diluted with H2O. After a 15-minute incubation, cells were harvested into 












Figure 2.2. Map of the EBOV minigenome insert used for the minigenome system. 
The minigenome insert and the RNP genes are encoded individually in the backbone 
pUC57, and their transcription is under the control of a phage T7 RNA polymerase 
promoter. For the construction of the EBOV minigenome plasmid, 5’ end trailer 
(nucleotides 18220 to 18959 of the EBOV genome) and 3’ end leader (the first 469 
nucleotides of the 3’ end of the EBOV genome including the translational NP gene 
START codon) sequences were placed flanking the reporter Firefly luciferase gene in 
the negative direction (3’ to 5’). A non-viral GG motif was introduced between the T7 
polymerase promoter and the 5’ end trailer EBOV sequence for a higher efficient 
transcription by the T7 polymerase. Attached to the 3’end of the minigenome there is 
a hepatitis delta virus (HDV) ribozyme, which self-cleavage activity provides a precise 
3’end, a prerequisite for the replication activity of the minigenome system. SalI and 
SacI restriction sites flanked the minigenome insert, as well as the RNP genes 
individually inserted in pUC57. The EBOV strain used for the construction of the 
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2.5.7.4. IFN-β assay  
 
293T cells were seeded on a 24-well plate format at a density of 1.6x105 cells per well.  
After 24 hours, pIFN-β_GL3 (Figure 2.3), pVP35 (or mutated variants pVP35M68T, 
pVP35L249F, pVP35L330F), pUC57, pT7 Pol and pRLTK were transfected with 
LipofectamineTM 3000 according to the manufacturer’s instructions and left 
incubating for 24 hours. DMEM media was replaced by fresh warmed media and low 
molecular polynosinic-polycytidylic acid (Poly(I:C), InvivoGen) was transfected with 
LipofectamineTM 2000 according to the manufacturer’s instructions. After 24 hours, 
cells were washed once with PBS, lysed with 1X PLB and extracted proteins were 




Figure 2.3. Map of the luciferase reporter plasmid under the control of an IFN-β 
promoter. IFN-β promoter drives the expression of Firefly luciferase. The plasmid was 
used in the IFN-β assay. IFN-Beta_pGL3 was a gift from Nicolas Manel (Addgene 
plasmid # 102597) (Gentili et al., 2015). 
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2.5.7.5. Dual luciferase assay  
 
Cells transfected in a 24-well dish format were washed once with PBS 24 hours post- 
transfection. Passive Lysis 5X Buffer (PBL) (Promega) was diluted 5-fold with 
nuclease-free water and 100μl of PLB 1X were dispensed in each well. Plates were 
incubated at room temperature for 15 minutes with agitation and cell lysates were 
transferred to Eppendorf tubes. 100μl of Luciferase Assay Reagent II (LARII) and 100μl 
of Stop&Glo® reagent (Promega) were used per 20μl of supernatant of cell lysate in 
a 96-well white plate. Firefly luciferase and Renilla luciferase activities were read in a 
GloMax Explorer plate reader (Promega) with a Dual-Luciferase® Reporter Assay 
System (Promega) according to the manufacturer’s instructions. The Renilla 
luciferase activity measurements were used to normalise the firefly luciferase activity 
of the samples. Each condition was done in triplicate for the statistical analysis.  
 
2.6. Imaging techniques 
 
2.6.1. Preparation of the coverslips and cell fixation 
 
Coverslips (19mm Ø) were soaked into ethanol 70% and let dry before soaking them 
again with phosphate buffered saline (PBS; Sigma-Aldrich) and put in wells in a 12-
well dish format. Wells with coverslips in were washed twice with PBS and once with 
Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma-Aldrich) supplemented with 
10% Foetal Bovine Serum (FBS; Sigma-Aldrich). 293T cells were seeded at 1x105 cells 
per well and incubated at 37°C with 5% CO2. After 24 hours, they were transfected 
with pGFP C1, pVP35-EGFP, pEGFP-VP35, pmCherry or pL-mCherry together with 
pT7-Pol by using the calcium phosphate transfection (section 2.4.3.2.). After 24 
hours, cell monolayers were fixed with 4% paraformaldehyde (PFA) diluted in 1x 
phosphate-buffered saline (PBS) for 10 minutes at room temperature and washed 
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2.6.2. Cell permeabilization and immunofluorescence staining 
 
Cells were permeabilised with a 10-minute incubation of PBS with 0.1% Triton X-100 
at room temperature. Following aspiration of the fixation solution, cells were washed 
3 times with PBS with 0.5% Tween-20. Primary and secondary antibodies were 
prepared in PBS containing 2% FBS and 0.5% Tween with the indicated dilution in 
Table 2.4. and Table 2.6. A final volume of 100μl of primary antibody master mix was 
added to each well and left for 1 hour at room temperature in darkness, followed by 
three washes with PBS with 0.5% Tween. A final volume of 100μl of master mix with 
the appropriate secondary antibody was added to each well and incubated for one 
hour at room temperature in darkness. Wells were washed three times with PBS with 
0.5% Tween to remove unbound antibodies.   
 
2.6.3. Mounting of fixed cell samples 
 
Coverslips with fixed cells were picked up from wells with forceps, inverted and put 
on glass microscope slides spotted with ProLong® Gold Antifade Reagent with DAPI 
(4’,6-diamidino-2-phenylindole) (Invitrogen).  
  
2.6.4. Fluorescent imaging 
 
Slides were imaged on a Zeiss Axio Imager M2 fluorescence microscope (Carl Zeiss 
Microscopy). All images were captured by using a 63x/1.4 oil objective lens with the 
Zen 2 Pro software.  
 
2.7. Mass Spectrometry 
 
Sample preparation and LC-MS/MS analyses (sections 2.7.1. to 2.7.2.) were 
performed by Dr. Stuart Armstrong (Infection Biology, Institute of Infection and 
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2.7.1. Proteomics analysis 
 
Eluted samples were diluted two-fold with 25mM ammonium bicarbonate. Proteins 
were reduced with 3 mM dithiothreitol (Sigma) at 60°C for 10 minutes then alkylated 
with 9 mM iodoacetimide (Sigma) at room temperature for 30 minutes in the dark. 
Proteomic grade trypsin (Sigma) was added (0.2 µg) and samples were incubated at 
37°C overnight. The resulting peptide samples were then acidified with 
trifluoroacetic acid (1% (v/v) final). Peptides were concentrated and desalted using 
C18 Stage tips (Thermo Fisher Scientific) and then samples dried using a centrifugal 
vacuum concentrator (Eppendorf). Peptides were re-suspended in 0.1% (v/v) 
trifluoroacetic acid and 5% (v/v) acetonitrile. 
 
Mass spectrometry analysis was essentially as described in Dong et al. (Dong et al., 
2017). Peptides were analysed by on-line nanoflow LC using the Thermo EASY-nLC 
1000 LC system (Thermo Fisher Scientific) coupled with Q-Exactive mass 
spectrometer (Thermo Fisher Scientific). Samples were loaded on a 50cm Easy-Spray 
column with an internal diameter of 75 µm, packed with 2 µm C18 particles, fused to 
a silica nano-electrospray emitter (Thermo Fisher Scientific). The column was 
operated at a constant temperature of 35°C. Chromatography was performed with a 
buffer system consisting of 0.1 % formic acid (buffer A) and 80 % acetonitrile in 0.1 % 
formic acid (buffer B). The peptides were separated by a linear gradient of 3.8 – 50 % 
buffer B over 30 min at a flow rate of 300 nl/min. The Q-Exactive was operated in 
data-dependent mode with survey scans acquired at a resolution of 70,000. Up to 
the top 10 most abundant isotope patterns with charge states +2, +3 and/or +4 from 
the survey scan were selected with an isolation window of 2.0 Th and fragmented by 
higher energy collisional dissociation with normalised collision energies of 30. The 
maximum ion injection times for the survey scan and the MS/MS scans were 250 and 
100ms, respectively, and the ion target value was set to 1E6 for survey scans and 1E4 
for the MS/MS scans. Repetitive sequencing of peptides was minimised through 
dynamic exclusion of the sequenced peptides for 20s. 
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2.7.2. Label-free analysis 
 
Label-free quantitation was performed using MaxQuant (MQ) software (version 
1.6.1.0) with its internal search engine Andromeda as described in García-Dorival et 
al. (García-Dorival et al., 2014). Precursor mass and fragment mass were searched 
with mass tolerance of 4.5 and 20 ppm respectively (default settings). All other 
settings were default. The search included variable modifications of methionine 
oxidation and N-terminal acetylation, and fixed modification of carbamidomethyl 
cysteine. Enzyme specificity was set to trypsin, minimal peptide length was set to 7 
amino acids and a maximum of two mis-cleavages were permitted. The false 
discovery rate (FDR) was set to 0.01 for peptide and protein identifications. The 
Andromeda search engine was configured for a database containing human proteins 
(Uniprot release-2017_11). The MQ software further includes a decoy database as 
well as common contaminants database to determine the false discovery rate and to 
exclude false positive hits due to contamination by proteins from different species. 
For LFQ analysis, “multiplicity” was set to one. Feature matching between raw files 
was enabled; using a retention time window of 2 min. “Discard unmodified 
counterpart peptides” was unchecked. Only unmodified and unique peptides were 
utilised. Averaged LFQ intensity values were used to calculate protein ratios. 
 
2.7.3. Bioinformatics analysis 
 
Label-free mass spectrometry results were processed and analysed using the Perseus 
software (version 1.6.1.1); this software was used to perform statistical analysis and 
to help differentiate background proteins (e.g. those cellular proteins that interacted 
with EGFP alone) from interacting proteins (those cellular proteins that interacted 
with viral protein bait). LFQ intensity value differences were compared using a t-test. 
A volcano plot graphic and table were generated showing the statistically significant 









The antibodies used for western blotting, immunostaining and ci-
immunoprecipitation of proteins of interest in this piece of work are the following.  
 
2.8.1. Primary antibodies  
 
Table 2.4. Primary antibodies used for western blotting (Wb), 
immunofluorescence (IF) and co-immunoprecipitation (co-IP) experiments. 







RPS21 Abcam ab90874 1/1000 1/1000 N/A 
ATP5I Abcam ab122241 1/1000 1/400 3μg 
DYNLL1 Abcam ab51603 1/1000 1/200 3μg 
PAI1 Abcam ab187263 1/1000 1/500 N/A 
CIRBP Abcam ab191885 1/1000 1/1000 N/A 
GFP Santa Cruz  sc-8334 1/2000 N/A N/A 
GAPDH Abcam ab8245 1/5000 N/A N/A 
Firefly Luc Abcam ab185923 1/1000 N/A N/A 
Renilla Luc Abcam ab185926 1/10000 N/A N/A 
EBOV NP IBT Bioservices 0301-012 1/3000 N/A N/A 
EBOV L IBT Bioservices 0301-045 1/1000 N/A N/A 
EBOV VP35 IBT Bioservices 0301-040 1/1000 N/A N/A 
mCherry Abcam ab167453 1/2000 N/A 4μg 
BAG2 Abcam ab47106 1/1000 N/A 3μg 
YBX1 Abcam  ab225706 1/2000 1/200 4μg 
CALM Millipore 05-173 1/2000 1/400 3μg 
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2.8.2. Secondary antibodies 
 
2.8.2.1. For western blot 
 
Table 2.5. Secondary antibodies used for western blotting.  
Target Vendor Cat. Number Dilution 
Goat anti-Rabbit IgG Sigma A6154 1/2000 
Goat anti-Mouse Sigma A4416 1/2000 
 
 
2.8.2.2. For immunofluorescence 
 
Table 2.6. Secondary antibodies used for immunofluorescence.  
Target Vendor Cat. Number Dilution 
Donkey anti-Rabbit IgG Alexa 
Fluor® 488 Life technologies A-21206 1/50 
Donkey anti-Rabbit IgG Alexa 
Fluor® 546 Life technologies A-100040 1/50 
Rabbit anti-Mouse IgG Alexa 
Fluor® 488 Life technologies A-11059 1/50 
Rabbit anti-Mouse IgG Alexa 
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Ebolavirus is a highly contagious and virulent pathogen with no FDA-licensed 
therapeutic available yet. The case-fatality rates and magnitude of the 2013-2016 
West African outbreak and the open-ended Democratic Republic of Congo EBOV 
outbreak highlight the need for effective therapeutics against Ebola virus disease 
(EVD) (Espeland et al., 2018). Huge efforts are currently being made in the 
development and implementation of an EBOV preventive vaccine (Henao-Restrepo 
et al., 2017; Lévy et al., 2018). However, equally important is the investigation of 
antiviral treatments to diminish the viral load in EBOV infected patients, thus 
increasing the chance of survival and prevent EVD spread among population. The 
elucidation of specific host-oriented molecules instead of viral-target drug candidates 
has arisen as an alternative to be investigated as antiviral treatment because (i) 
viruses are obligate parasites of the host cell machinery and (ii) RNA viruses have a 
high mutation rate due to the error-prone viral RNA-dependent RNA polymerase 
(Rdrp or L) and its low fidelity (Hoenen et al., 2015; Sanjuán and Domingo-Calap, 
2016). Small molecule inhibitors directed against cellular proteins or signalling 
pathways potentially have a much broader spectrum of antiviral activity, as different 
viruses may need similar cellular factors for transcription and replication and host 
proteins are less likely to mutate and acquire drug resistance (Ma-Lauer et al., 2012; 
Baillie and Digard, 2013). For instance, the host protein viperin (virus inhibitory 
protein endoplasmic reticulum-associated, interferon-inducible) can interact and 
inhibit replication of many RNA viruses such as Influenza virus, dengue virus, hepatitis 
C virus, HIV-I and Chikungunya (Reviewed in Ng and Hiscox, 2018). Therefore, the 
better understanding of all the viral processes involved in EBOV replication inside 
cells will improve the guidance towards the finding of a therapy to treat EVD. The 
interactome is the totality of protein-protein interactions that take place in an 
organism, in a cell or in a specific biological context. Finding the interaction partners 
for a protein can reveal its function and its relevance in a certain condition and period 
of time.  
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EBOV has a 19Kb genome that encodes at least nine proteins encoded in seven genes 
(Cantoni and Rossman, 2018). EBOV viral proteins carry out several functions but still 
require the interaction, modulation or hijacking of the host cell machinery in order 
to accomplish each stage of the viral life cycle. As observed in the 2013-2016 West 
African outbreak, the lower the viral load in patients infected with EBOV, the higher 
the chance they will survive (de La Vega et al., 2015; Fitzpatrick et al., 2015; Kerber 
et al., 2016), making the viral RNA synthesis process an antiviral target to be taken 
into account. Some host proteins have already been recognised as having a role in 
these processes. For instance, the down-regulation of TOP1, a nuclear protein that 
unwinds the dsDNA helices for transcription and replication in the host cell 
(Takahashi et al., 2013), the inhibition of Hsp90, a cytosolic chaperone (Smith et al., 
2010), or the disruption of ATP1A1 and HSP70 (García-Dorival et al., 2016, 2014) have 
been proven to diminish EBOV replication as well. The viral component that sustains 
EBOV transcription and replication is the ribonucleoprotein (RNP), a macromolecular 
complex composed of viral RNA, the viral RNA-dependent RNA polymerase, the 
nucleoprotein (NP) the non-catalytic phosphoprotein (VP30) and the viral 
polymerase co-factor (VP35). Viral transcription and replication of EBOV RNA takes 
place in the cytoplasm of infected cells, and is dependent on VP35 (Mühlberger et al., 
1999).  
 
VP35 is a multifunctional protein with diverse roles in the viral lifecycle and essential 
for the viral transcription and replication processes (Mühlberger et al., 1999; 
Mühlberger, 2007). The protein also plays an important role in the ribonucleocapsid 
assembly by its interaction with NP and VP30 (Huang et al., 2002), functions as a type-
I interferon (IFN) antagonist by blocking both the activation of IFN regulatory factor 
3 (IRF-3) and the detection of the dsRNA stage of viral transcription/replication and 
by upregulating the SUMOylation of IRF-7 (Basler et al., 2003; Elshabrawy et al., 2015; 
Chang et al., 2009; Binning et al., 2013). Together with VP24, VP35 ensures the poor 
production of IFN and therefore the infected cell is unable to produce a sufficient 
response to counteract the virus activity (Audet and Kobinger, 2015). VP35 can also 
inhibit antiviral effects by blocking protein kinase R and impairs the dendritic cell 
maturation (Schumann et al., 2009; Yenet al., 2014). It regulates the RNA synthesis 
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by modulating NP-RNA interactions (Groseth et al., 2009) and by associating with 
other cellular factors, such as the cytoplasmic dynein light chain 1 (LC8/DYNLL1) and 
the double stranded RNA binding protein 76 (DRBP76/NFAR-1/NF90) (Luthra et al., 
2015; Shabman et al., 2011). These cellular factors could only represent a small part 
of all the cellular associations that take place between VP35 and the infected host 
cell, and these cellular factors could also be potential candidates for antiviral-directed 
targets.  
 
In this chapter, a label-free liquid chromatography coupled with tandem mass 
spectrometry (LC-MS/MS) based approach was used to elucidate protein-protein 
interactions between EBOV VP35 and the host cell in human embryonic kidney 293T 
cells. Novel interactions with the viral protein were discovered and validated with 
forward and reverse pulldowns followed by the detection of these associations with 
specific antibodies by western blotting. An EBOV minigenome system was utilised to 
measure the effect on viral RNA synthesis that the small molecule inhibitor 
Ciliobrevin D has when antagonising the VP35 cellular partner DYNLL1 and the 




















Since viruses require the host protein machinery to accomplish their life cycle, this 
study aims to elucidate novel cellular partners of EBOV VP35 by using high-affinity 
purification coupled to a label-free mass spectrometry approach to give further 
insight into virus biology. By determining the viral RNA polymerase co-factor cellular 
interactome, novel host partners of EBOV VP35 could be further examined as anti-
viral targets and their functional roles in the virus life cycle.  
 
One of the top hits identified was the cytoplasmic dynein light chain 1 (DYNLL1), a 
host factor previously observed to interact with VP35 and to have a role in EBOV 
genome synthesis (Kubota et al., 2009; Luthra et al., 2015). The second aim of this 
chapter was to test the antiviral effect of the repurposed drug Ciliobrevin D, a cell 
permeable small molecule inhibitor that reversely and specifically blocks the 















NOTE: The sample preparation for LC-MS/MS and the raw data analyses obtained 
were performed by Dr. Stuart Armstrong (Infection Biology, Institute of infection and 
Global Health, University of Liverpool).  




3.2.1. Construction of EGFP, EGFP-VP35 and VP35-EGFP in 293T cells 
 
In order to determine the cellular associations between Makona EBOV VP35 and the 
host, an enhanced green fluorescent protein (EGFP)-tagged co-immunoprecipitation 
strategy coupled to a label-free proteomic approach was used in HEK293T (293T) 
cells. Therefore, a codon-optimised complementary DNA (cDNA) sequence encoding 
EBOV VP35 was cloned into either the pEGFP-C1 or the pEGFP-N1 vectors for the 
expression of the viral protein together with an EGFP tag at either the N-terminal or 
C-terminal ends. The sequence used belonged to a Zaire ebolavirus Makona strain 
[NCBI sequence reference number KJ660347.2]. The constructs were designed by 
using the online tool GeneArt Gene Synthesis Services 
(https://www.thermofisher.com/order/geneartgenes/projectmgmt) and production 
and validation of the cloned insertions inside backbone vectors were performed by 
Invitrogen (Figure 3.1A and 3.1B). The vector EGFP-C1, referred in this chapter as 
pEGFP, was used for the expression of EGFP. pEGFP-V35 C1, pVP35-EGFP N1 and 
pEGFP were transformed into competent cells and grown for plasmid production. 
After plasmid extraction and purification, plasmids were digested once and twice, 
and size was checked by electrophoresis agarose gels (Figure 3.1C).  
 
In order to confirm cellular expression of the above-mentioned fusion proteins, 
0.36µg of either pEGFP, pEGFP-VP35 C1 or pVP35-EGFP N1 were calcium phosphate-
transfected into 293T cells in a 24-well format at a density of 6x104 cells per well. 
Cells were examined 24 hours after transfection by fluorescence microscopy to 
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Figure 3.1. Construction, design and expression of the vectors encoding EGFP and 
recombinant proteins EGFP-VP35 C1 and VP35-EGFP N1. Maps of the vectors 
encoding cDNA of EBOV VP35 tagged to the reporter gene EGFP. (A) cDNA of EBOV 
VP35 with EGFP tagged at the N-terminal end of the gene; (B) cDNA of EBOV VP35 
with EGFP tagged at the C-terminal end of the gene. (C) Endonuclease digestion of 
pEGFP, pEGFP-VP35 C1 and pVP35-EGFP N1. Vectors were cut once by BglII, and twice 
by BglII and SalI. Uncut plasmid and digestion products were run in a 1% agarose gel 
electrophoresis to confirm product lengths. (D) Fluorescence microscope visualisation 
of transfected 293T cells expressing EGFP, EGFP-VP35 C1 and VP35-EGFP N1 24 hours 
post-transfection. Scale bar, 10µm.  
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3.2.2. Co-immunoprecipitation of EGFP-VP35 C1 and VP35-EGFP N1 and 
determination of VP35-host protein interactions by label-free LC-
MS/MS  
 
Following visual confirmation of EGFP-fused VP35, the viral recombinant proteins 
were overexpressed in 293T cells to obtain enough amounts for their co-
immunoprecipitation (coIP) wiith GFP-Trap® beads for further analyses on virus-host 
protein interactions (Figure 3.2A).  
 
Cells were seeded in triplicate in two 145cm2 dishes per condition and calcium 
phosphate-transfected either with pEGFP, pEGFP-VP35 C1 or pVP35-EGFP N1. Cells 
were harvested, lysed and EGFP-tagged VP35 proteins and host protein interactors 
were co-immunoprecipitated with GFP-Trap®. To assess the abundance and presence 
of the recombinant proteins in the pulled-down protein complexes, co-IP products 
were run in SDS-PAGE and a blotting was performed with a specific antibody anti-
EGFP (Figure 3.2B). EGFP (27 kDa) was detected in the input and eluted samples of 
HEK293T transfected with pEGFP. EGFP-VP35 C1 and VP35-EGFP N1 (62 kDa) were 
detected in the input and eluted samples of 293T transfected with the vectors 
encoding either of the two fused viral proteins, confirming that the recombinant viral 
proteins had been pulled-down for the following analysis on their host interactors by 
mass spectrometry.  
 
A label-free proteomics approach was used to identify and quantify cellular proteins 
that potentially associate with EBOV VP35. Co-immunoprecipitation of each 
condition was done in triplicate to maximise the identification of positive interactions 
and help identify non-specific interactions between the cellular factors and the 
binding matrix. LC-MS/MS was used to determine VP35-host PPIs and the data 
obtained was statistically analysed by Perseus software (1.5.6.0. version). 
Contaminants and proteins identified by only one unique peptide were removed 
from the list. The false discovery rate (FDR) was set at 1% or below, meaning that 
theoretically 99% of the proteins would be identified correctly. LFQ intensity values 
of the identified proteins were analysed using a t-test for statistical significance. In 
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order to identify changes in the replicate data set, volcano plots were generated, 
showing the logarithmic p-values for confidence in peptide identification vs. fold 
change difference in binding protein between VP35 fusion proteins and EGFP. 
Therefore, data points appearing at the top right side of the plot represent identified 
proteins that have lower p-values and larger fold change between conditions. 
Between the EGFP-VP35 C1 and the VP35-EGFP N1 cellular interactor data sets, 28 
significant proteins with a fold change difference equal or higher than 2 were 
identified (Figure 3.3A and Figure 3.3B, Table 3.1 and Table 3.2).  
 
In order to have a further insight into the relation among the potential EBOV VP35 
cellular interactions, the 28 proteins potentially interacting with EBOV VP35 were 
uploaded into the STRING software (version 10.5). Clusters of cellular proteins 
predicted to interact with each other were identified as ribosomal proteins (in green), 
motility and structural proteins (in blue), TIMM family proteins (in red). Proteins 
shown in yellow were not associated to a cluster (Figure 3.3A). To identify the 
potential functionality of the data set of proteins in Table 3.1 and Table 3.2, the 28 
significant proteins found between the two data sets were uploaded to the PANTHER 
bioinformatics algorithm (version 12.0), resulting in 26 protein function hits. Data was 
displayed as a pie chart, showing the category of protein and the number of proteins 
in each group. Four main groups of proteins were separated according to their 
molecular function, indicating that the identified EBOV VP35 potential interactors 
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Figure 3.2. Co-immunoprecipitation of EGFP/VP35 and EGFP in 293T cells. (A) 
Schematic representation of the method used for the transfection, co-IP and LC-
MS/MS analysis of EGFP/VP35 transfected cells. (B) Identification by western blot of 
the co-immunoprecipitated EGFP-fused EBOV VP35 proteins. Cell lysates were diluted 
and incubated overnight with GFP-Trap® beads. Beads and protein complexes 
attached were washed and eluted by boiling with 2X SDS buffer. Input [I] and eluted 
[E] samples were run in an SDS-PAGE, proteins were transferred onto a PVDF 
membrane and blocked. Monoclonal mouse anti-EGFP was used as the primary 
antibody, and goat anti-mouse was used as the secondary antibody.  
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Figure 3.3.1. Analysis of the potentially significant cellular proteins that interact 
with EBOV VP35. Statistical analysis of the cellular proteins found to potentially 
interact with (A) EGFP VP35 C1 and (B) VP35-EGFP N1 using a volcano plot, with the 
names of the proteins of interest. The logarithmic p-value for confidence in peptide 
identification is plotted against the fold change difference in binding protein between 
EBOV VP35/EGFP and EGFP (≥ 2 FC). The isolated dot on both upper right corners 
represents EBOV VP35. 
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Figure 3.3. Potential host protein interactors of EBOV VP35 and their molecular 
function classification. (A) The significant cellular proteins potentially interacting 
with EBOV VP35 from the LC-MS/MS data sets were submitted to the STRING 
software (version 10.5) to show the currently known PPI networks. Associations are 
meant to be specific and meaningful, but they are not necessarily physically binding 
to each other. Clusters of cellular proteins were identified as ribosomal proteins 
(green), motility and structural proteins (blue), TIMM family proteins (red). Proteins 
in yellow were not associated in a cluster. (B) Molecular function classification of 
proteins identified with cut-off ratio of change ≥2 in abundance in both EGFP-VP35 C1 
and VP35-EGFP N1 sets of data compared to the EGFP data set protein abundance. 
Twenty eight cellular proteins were submitted to the PANTHER online software 
(www.pantherdb.org). 
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Table 3.1. List of statistically significant and potentially EBOV EGFP-VP35 C1 cellular interacting partners. Contaminants and proteins 
identified by only one unique peptide were removed. The false discovery rate (FDR) was set at 1% or below, meaning that theoretically 
99% of the proteins would be identified correctly. LFQ intensity values of the identified proteins were analysed using a t-test. The proteins 
that interact specifically with VP35 would be expected to show a higher binding ratio that the ones that interact with the control, which 
show a FC close to 1. The threshold was set to 2.  
Protein 











P63167 Dynein light chain 1, cytoplasmic DYNLL1 12 8 75.3 1.131 4.8 
Cytoplasmic dynein 1 acts as a motor for 
the intracellular retrograde motility of 
vesicles and organelles along 
microtubules. 
P62263 40S ribosomal protein S14 RPS14 9 9 43 1.929 4.7 
Structural constituent of ribosome. It 
has a translation regulator activity. 
P42677 40S ribosomal protein S27 RPS27 5 5 44 1.907 4.2 
Structural constituent of ribosome. It 
has a translation regulator activity. 
P18124 60S ribosomal protein L7 RPL7 4 4 21.4 1.251 3.5 
Binds to G-rich structures in 28S rRNA 
and in mRNAs. Plays a regulatory role in 
the translation apparatus; inhibits cell-






HNRNPU 13 13 22.7 1.189 3.5 
Component of the CRD-mediated 
complex that promotes MYC mRNA 
stabilization. Binds to pre-mRNA. Has 
high affinity for scaffold-attached region 
(SAR) DNA. Binds to double- and single-
stranded DNA and RNA. Plays a role in 
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the circadian regulation of the core 
clock component ARNTL/BMAL1 





TUBB4B 23 4 64.3 0.942 3.5 Major constituent of microtubules. It binds two molecules of GTP. 





CIRBP 6 6 50 1.636 3.3 
Protective role in the genotoxic stress 
response by stabilizing transcripts of 
genes involved in cell survival. 
Translational activator and repressor. 
Seems to play an essential role in cold-
induced suppression of cell 
proliferation. Binds to the 3-UTRs of 
stress-responsive transcripts RPA2 and 
TXN. Promotes assembly of stress 




like protein 1 






SERBP1 6 6 13.7 1.311 2.9 
May play a role in the regulation of 
mRNA stability. Binds to the 3-most 134 
nt of the SERPINE1/PAI1 mRNA, a region 
which confers cyclic nucleotide 
regulation of message decay. 
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P61313 60S ribosomal protein L15 RPL15 2 2 7.8 1.291 2.8 Structural constituent of ribosome.  
P62241 40S ribosomal protein S8 RPS8 7 7 33.2 2.596 2.8 
Structural constituent of ribosome. It 
has a translation regulator activity. 
Q9BRP8 Partner of Y14 and mago WIBG 4 4 27.9 1.214 2.8 
Key regulator of the exon junction 
complex (EJC). 
P98179 RNA-binding protein 3 RBM3 2 2 15.9 1.889 2.8 
Cold-inducible mRNA binding protein 
that enhances global protein synthesis 
at both physiological and mild 
hypothermic temperatures. Reduces the 
relative abundance of microRNAs, when 
overexpressed. Enhances 
phosphorylation of translation initiation 
factors and active polysome formation. 
P37108 
Signal recognition 
particle 14 kDa 
protein 
SRP14 5 5 40.4 1.521 2.8 
Crucial role in targeting secretory 
proteins to the rough endoplasmic 
reticulum membrane. 
P62244 40S ribosomal protein S15a RPS15A 4 4 20 1.664 2.6 Structural constituent of ribosome. 
P49207 60S ribosomal protein L34 RPL34 10 10 44.4 1.209 2.6 Structural constituent of ribosome. 
P39019 40S ribosomal protein S19 RPS19 15 15 69.7 1.387 2.6 
Required for pre-rRNA processing and 
maturation of 40S ribosomal subunits. 
P62917 60S ribosomal protein L8 RPL8 6 6 19.5 2.328 2.5 Structural constituent of ribosome. 






CNBP 5 5 31.6 1.896 2.4 
Single-stranded DNA-binding protein, 
with specificity to the sterol regulatory 
element (SRE). Involved in sterol-
mediated repression. 
P62857 40S ribosomal protein S28 RPS28 9 9 79.7 1.909 2.3 Structural constituent of ribosome. 





ATP5I 2 2 18.8 1.927 2.2 
Produces ATP from ADP in the presence 








TIMM10 2 2 31.1 1.818 2.1 
Mitochondrial intermembrane 
chaperone that participates in the 
import and insertion of multi-pass 
transmembrane proteins into the 
mitochondrial inner membrane. 
P36578 60S ribosomal protein L4 RPL4 8 8 16.2 1.724 2.1 Structural constituent of ribosome. 
P15880 40S ribosomal protein S2 RPS2 9 9 25.3 2.200 2.0 
Structural constituent of ribosome and 
fibroblast growth factor. 
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Table 3.2. List of statistically significant and potentially EBOV VP35-EGFP N1 cellular interacting partners. Contaminants and proteins 
identified by only one unique peptide were removed. The false discovery rate (FDR) was set at 1% or below, meaning that theoretically 
99% of the proteins would be identified correctly. LFQ intensity values of the identified proteins were analysed using a t-test. The proteins 
that interact specifically with VP35 would be expected to show a higher binding ratio that the ones that interact with the control, which 
show a FC close to 1. The threshold was set to 2.  
Protein 














like protein 1 
SDF2L1 4 4 23.5 1.325 3 Dolichyl-phosphate-mannose-protein mannosyltransferase activity. 
P63167 Dynein light chain 1, cytoplasmic DYNLL1 12 8 75.3 2.058 2.9 
Cytoplasmic dynein 1 acts as a motor for 
the intracellular retrograde motility of 







subunit Tim8 B 
TIMM8B 3 3 37.3 1.490 2.8 
Probable mitochondrial intermembrane 
chaperone that participates in the import 
and insertion of multi-pass 
transmembrane proteins into the 
mitochondrial inner membrane. Required 
for the transfer of beta-barrel precursors 
from the TOM complex to the sorting and 
assembly machinery or the outer 
membrane. 






ATP5I 2 2 18.8 2.932 2.4 
Produces ATP from ADP in the presence 
of a proton gradient across the 
membrane. 






subunit Tim10 B 
TIMM10
B 3 3 37.9 2.516 2.2 
Component of the TIM22 complex, which 
mediates the import and insertion of 
multi-pass transmembrane proteins into 







TIMM10 2 2 31.1 3.215 2.2 
Mitochondrial intermembrane chaperone 
that participates in the import and 
insertion of multi-pass transmembrane 
proteins into the mitochondrial inner 
membrane. 
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3.2.3. Validation of cellular interactions with EBOV VP35  
  
To validate the interactions observed in the LC-MS/MS analysis GFP-Trap®, co-
immunoprecipitations were performed again in cells expressing EGFP, EGFP-VP35 C1 
or VP35-EGFP N1. The validated PPIs were selected according to their presence in 
both EGFP-VP35 C1 and VP35-EGFP N1 data sets, the relative high fold change 
difference on interaction intensity between the mock eluate and the EGFP/VP35 
eluate, or to antibody availability. These were the dynein light chain 1 (DYNLL1/LC8), 
the ATP synthase subunit e (ATP5I), the 40S ribosomal protein S21 (RPS21), the cold 
inducible RNA-binding protein (CIRBP) and the plasminogen activator inhibitor 1 
(PAI1/SERBP1). PPI detection by western blot showed consistency with LC-MS/MS 
analyses, as selected proteins were detected by specific antibodies in at least one of 
the EGFP-VP35 C1 or VP35-EGFP N1 eluates (Figure 3.4A). Among the identified 
protein-protein associations, detection of DYNLL1 in the eluate fraction of the pull-
down was enriched compared to the input in both EGFP-VP35 C1 and VP35-EGFP N1 
coIP sets of samples. The enrichment suggested that there is either a strong 
interaction between this cellular protein and VP35 or that their interaction is 
favoured by a high expression of this cellular protein. According to the “PaxDb: 
Protein Abundance Database”, DYNLL1 is one of the top 5-25% most abundant 
proteins in human cell lines (https://pax-db.org/protein/1843632#). DYNLL1 had 
been previously described, strengthening the confidence in the VP35-host interactors 
identified by LC-MS/MS (Kubota et al., 2009). DYNLL1 is a subunit of the large 
cytoplasmic dynein complex, involved in intracellular transport and motility. CIRBP is 
a cold-induced RNA chaperone that influences transcription and translation under 
hypothermic conditions. ATP5I is a minor subunit in the mitochondrial membrane 
ATP synthase, which is involved in the production of ATP from ADP. RPS21 is a 
component of the 40S subunit of ribosomes. PAI1 is a serine protease that inhibits 
the tissue plasminogen activator, disrupting fibrinolysis. ATP5I and CIRBP were also 
detected in the eluate fractions of both EGFP-tagged VP35 proteins, while RPS21 and 
PAI1 were only present in enough amounts for detection in the eluate fractions of 
the pulled-down EGFP-VP35 C1 recombinant protein. This observation may suggest 
that the EGFP tag at the C-terminal end of VP35 affected the recombinant protein 
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configuration or disrupted the interactions between the viral protein and RSP21 or 
PAI1 (Snapp, 2005), perhaps via a mechanism of steric hindrance. GAPDH was used 
as a negative control as it was not expected to interact with EBOV VP35, according to 
the data generated by LC-MS/MS.  
 
EBOV VP35 is known to interact with dsRNA, for instance, when the protein interferes 
in the cellular expression of type-I IFN (Cardenas et al., 2006; Prins et al., 2010; Zinzula 
et al., 2012). To assess whether the observed interactions between EBOV VP35 and 
cellular factors were potentially direct or due to an RNA intermediate, 293T cells 
where EGFP, EGFP-VP35 C1 or VP35-EGFP N1 had been expressed were treated with 
RNase A prior to co-immunoprecipitation. RNA presence in the lysates was then 
assessed by electrophoresis in an agarose gel (Figure 3.4B). VP35-host protein 
interactions in the RNase A treated lysates were validated again by western blot 
(Figure 3.4C). DYNLL1, ATP5I and RSP21 were detected in the eluted samples of 
RNase A treated VP35/EGFP transfected cell lysates, confirming that their interaction 
was not mediated by RNA. On the other hand, the detection of CIRBP and PAI1 in the 
RNAse A non-treated cell lysates was due only to binding to RNA. Reverse pull-downs 
of DYNLL1 and ATP5I were performed to further validate the PPI seen in the LC-
MS/MS analysis (Figure 3.4D). 
 
As an alternative way to gain confidence on protein-protein interactions, 
immunofluorescence staining and fluorescence visualisation were performed on 
EGFP-VP35 C1 and VP35-EGFP N1 transfected 293T cells to assess potential co-
localisation of the expressed recombinant proteins with either DYNLL1 or CIRBP. 
Specific rabbit primary antibodies and a secondary antibody against rabbit (Alexa 
Fluor® 546) were used for the detection of DYNLL1 and CIRBP in pVP35/EGFP-
transfected cells. As seen in Figure 3.5, recombinant proteins and selected cellular 
proteins were expressed in the same cell compartment, the cytoplasm, making it 
more likely to establish an interaction between them. 
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Figure 3.4. Validation of PPIs between 293T cellular proteins and VP35 by western 
blot. (A) Detection of DYNLL1, ATP5I, RPS21, CIRBP and PAI1 in the cell lysates [input, 
I] and in the eluted fractions [eluate, E] of the pull-downs of the three constructs. (B) 
Agarose gel showing RNA presence in 293T cell lysates treated (+) and non-treated (-
) with RNase A. (C) EGFP and EGFP-tagged VP35 expressing cell lysates were pre-
treated with RNase A and co-immunoprecipitated by GFP-trap beads. A western blot 
was performed to assess the presence of selected host proteins potentially interacting 
with VP35 in the eluted fraction of the RNase A treated lysates. (D) Reverse co-
immunoprecipitations for DYNLL1 and ATP5I and detection of EGFP-VP35 C1 and 
VP35-EGFP N1 with a specific antibody anti-EGFP. Cell lysates were incubated for 2 
hours with specific antibodies against either DYNLL1 or ATP5I. Co-
immunoprecipitations were performed by using protein G sepharose beads. Samples 
were eluted. A western blot assessed the presence of the EGFP-tagged VP35 proteins 
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Figure 3.5. Immunofluorescent microscopy showing potential cytoplasmic co-
localisation of expressed EGFP-VP35 C1 or VP35-EGFP N1 with host proteins. (A) 
DYNLL1 and (B) CIRBP in red (Alexa Fluor® 546), auto-immunofluorescence of EGFP or 
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3.2.4. Functionality of EGFP-tagged EBOV VP35 proteins 
 
To assess EGFP-VP35 C1 and VP35-EGFP N1 functionalities, an EBOV minigenome 
system optimised in BSR-T7 cells was used. BSR-T7 cells are a widely used baby 
hamster kidney (BHK)-derived cell line that stably expresses the T7 RNA polymerase, 
allowing the expression of viral proteins required for RNA synthesis, whose 
transcription from corresponding genes was under the control of a T7 RNA 
polymerase promoter upstream (Mühlberger et al., 1998; García-Dorival et al., 2016; 
Jasenosky et al., 2010). Minigenome systems mimic viral transcription and replication 
of viruses in BSL-2 facilities by delivering the RNP complex proteins together with a 
minigenome plasmid in mammalian cells. They have been established for a number 
of negative strand RNA viruses, such as Marburg virus, Rift Valley fever virus and 
Nipah virus, for instance (Freiberg et al., 2008; Ikegami et al., 2005; Mühlberger et 
al., 1998). The minigenome plasmid encodes the EBOV genomic leader and trailer 
sequences flanking a reporter Firefly luciferase gene. L, NP, VP30 and VP35 conform 
the RNP complex, which recognises the viral genome leader and trailer sequences 
and transcribe the reporter gene. The reporter gene expression is an indicator of the 
transcription and replication activities of the system (Mühlberger et al., 1998). 
 
The plasmids forming the EBOV minigenome system were pNP, pVP30, pVP35, pL and 
pMG, with a length of 5469 pb, 4116 pb, 4272 pb, 9888 pb and 5750 pb, respectively. 
The vector used to encode each of the viral proteins and also the EBOV minigenome 
was pUC57, and the inserts with the viral gene sequences were introduced between 
the restriction sites SalI and SacI. An agarose gel was run with the digested products 
of each plasmid to confirm their size (Figure 3.6). After plasmid size confirmation, 
BSR-T7 cells were seeded at a density of 105 cells/well in 24-well plate. After 24 hours, 
500ng of pMG, 250ng of pNP, 125ng of pVP30, pVP35/pEGFP-VP35/pVP35-EGFP and 
pL/pUC57, and 50ng of pRLTK were transfected per well by using LipofectamineTM 
2000. Each condition was performed in triplicate for statistical significance. Cells were 
lysed 24 hours post-transfection. Firefly luciferase activities of the EGFP-tagged VP35-
transfected minigenome system were measured and compared to the wild-type 
VP35 one by using a dual luciferase assay (DLA). Luciferase measurements of the 
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system were normalised with Renilla luciferase expression from the same lysates and 
significance was assessed by performing a t-test between groups (Table 3.3). 
Functionality of EGFP-VP35 C1 and VP35-EGFP N1 was 30.4% and 56.7%, respectively, 
compared to the reporter activity of the minigenome system. The EGFP tags may 
have affected somehow either the protein configuration and/or the interactions that 
VP35 stablishes with the RNP-RNA. Nevertheless, VP35 recombinant proteins still 
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Figure 3.6. Endonuclease digestion of the EBOV minigenome system supportive 
plasmids pNP, pVP30, pVP35, pL and pMG. Vector constructions were digested once 
using SalI, and twice using SalI and SacI. Uncut plasmid and digestion products were 
run in a 1% agarose gel electrophoresis to confirm product lengths.  
 
Table 3.3. Statistical analysis of luciferase activities in BSR-T7 cells transfected with 
EBOV minigenome system plasmids with either VP35, EGFP-VP35 C1 or VP35-EGFP 
N1. A DLA was performed on BSR-T7 cell lysates. Each condition was carried out and 
measured in triplicate. Measurements of Firefly luciferase were normalised with 
Renilla luciferase values. A t-test between -L and the other conditions assessed 
significance. FC, fold change.  
Condition 
Normalised FC 









+ L 924.995 100 0.19 0.001 
- L 1 1.08 0.00 1 
EGFP-VP35 C1 280.9893 30.38 0.03 0.000 
VP35-EGFP N1 524.476 56.70 0.15 0.003 
 




Figure 3.7. Relative functionality of recombinant EBOV EGFP-VP35 and VP35-EGFP 
proteins. (A) An EBOV minigenome system assay assessed the functionality of the 
EGFP-tagged VP35 proteins compared to the wtVP35 in BSR-T7 cells. Firefly luciferase 
activities were normalised with Renilla luciferase values. A minigenome system 
lacking the support plasmid encoding L was used as the negative control. Each 
condition was performed in triplicate. A t-test between +L and the other conditions 
assessed significance (**p-value<0.01, ***p-value>0.001). A botting with 2.5μg of 
total protein per loaded sample, assessed by a bicinchonic acid protein (BCA) assay, 
was performed to confirm Firefly luciferase (Luc) expression. Detection of the 
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3.2.5. Determining the potential antiviral activity of the DYNLL1 antagonist 
Ciliobrevin D in an EBOV minigenome system 
 
DYNLL1/LC8, the cytoplasmic dynein light chain 1, has been observed to be 
implicated in the biological cycle of many viruses, such as rabies virus, human 
immunodeficiency virus 1, the African swine fever virus, hepatitis B virus or herpes 
simplex 1 virus, for instance (Bauer et al., 2015; Dodding and Way, 2011; García-
Mayoral et al., 2011; Osseman et al., 2018). DYNLL1 was demonstrated to interact 
with EBOV VP35 (Kubota et al., 2009) and to enhance minigenome activity when the 
host protein is overexpressed in a dose-dependent manner (Luthra et al., 2015). 
These findings supported the LC-MS/MS analysis performed in this study as DYNLL1 
was one of the top hits as an EBOV VP35 interactor. Nevertheless, in this piece of 
work the potential of DYNLL1 as an antiviral target and the effect of its antagonism 
on the EBOV genome RNA synthesis were assessed. The small molecule Ciliobrevin D 
is a cell permeable small molecule inhibitor that acutely, specifically and reversely 
blocks the AAA+ ATPase motor cytoplasmic dynein 1 and 2 in cells (Firestone et al., 
2012). Ciliobrevin D affects the ATP function of the complex, disrupting the spindle 
pole focusing and kinetochore-microtubule attachments (Roossien et al., 2015).  
 
A cell viability assay on BSR-T7 cells was performed to obtain the half maximal 
inhibitory concentration (IC50) of Ciliobrevin D. Ciliobrevin D was dissolved in DMSO 
and a concentration range of 5 μM to 160 μM in DMEM was tested. Cells were seeded 
at 1.6x104 in a 96-well dish format and incubated for 24 hours with the different 
Ciliobrevin D concentrations in triplicate. Following, an MTT ((3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium reduction) assay was performed. 
IC50 of Ciliobrevin D in BSR-T7 cells was 40μM (Figure 3.8). 
 
Cells were then seeded at 1x105/well in a 24-well format to achieve ≥90% confluence 
the day after. Cells were transfected with the minigenome system plasmids by using 
LipofectamineTM 2000. After 4 hours, media was replaced with fresh DMEM 
containing Ciliobrevin D at a concentration of 2.5 μM, 5 μM and 10 μM. Cells were 
harvested and lysed 24 hours post-transfection. In order to measure the Firefly 
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luciferase activity of the minigenome system under the different inhibitor 
concentrations, a DLA was performed on cell lysates. Firefly luciferase values were 
normalised by the Renilla luciferase activity of the transfected cells. Each condition 
was done in triplicate for statistical significance. Results indicated that 24 post-
transfection and with a treatment period of 20 hours with Ciliobrevin D, minigenome 
system-transfected BSR-T7 cells presented an inverse dose-dependent response on 
Firefly luciferase expression. As seen in Figure 3.9 and Table 3.4, the reporter activity 
of the EBOV minigenome system significantly decreased to 27% relative expression 
when cells were treated with a concentration of 10 μM of Ciliobrevin D, being it not 
toxic to BSR-T7 cells according to the cytotoxicity assay. A dose-dependent manner 
decrease in Firefly luciferase expression was further confirmed by SDS-PAGE and 
western blot, whereas the detection of the housekeeping GAPDH did not show 


















Chapter 3: Results  
 106 
 
Figure 3.8. Cell viability assay (MTT) of BSR-T7 cells treated with the small molecule 
inhibitor Ciliobrevin D, a DYNLL1 antagonist. A concentration range between 5 μM 
and 160 μM of Ciliobrevin D was diluted in DMEM and BSR-T7 cells were incubated 
for 24 hours. DMSO was used as vehicle control; Etoposide 10nM was used as a 
positive control for the induction of apoptosis. Dashed red line indicates the IC50. A t-
test between conditions assessed significance compared to non-treated cells (*p-
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Figure 3.9. Effect of Ciliobrevin D 24 hours post-transfection on EBOV minigenome 
system transfected BSR-T7 cells. Relative luciferase activity of EBOV minigenome 
system-transfected BSR-T7 cells treated with Ciliobrevin D for 20 hours and western 
blot of cell lysates. DMSO-treated cells were included as a vehicle control. Each 
condition was performed in triplicate. A t-test between conditions assessed 
significance (ns non-significant, *p-value > 0.05, **p-value < 0.01). +L as the positive 
control; - L as the negative control and DMSO as the vehicle control. Western blot 
showing abundance of Firefly luciferase (LUC), DYNLL1, NP (*actual protein size = 84 
kDa; seen at 115 kDa due to protein phosphorylation). GAPDH abundance was used 
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Table 3.4. Statistical analysis of luciferase activities in BSR-T7 cells transfected with 
EBOV minigenome system plasmids and treated with different concentrations of 
the DYNLL1 antagonist Ciliobrevin D. A DLA was performed on BSR-T7 cell lysates 
treated with different concentrations of Ciliobrevin D. Each condition was performed 
in triplicate. Measurements of Firefly luciferase were normalised with Renilla 
luciferase values. A t-test between +L and the other conditions assessed significance. 













+ L 1358.41 100 0.1324 1 
- L 1 0.74 0.0001 0.00019 
Ciliobrevin D 2.5μM 803.34 55.64 0.0997 0.01293 
Ciliobrevin D 5μM 573.31 42.23 0.1255 0.00536 
Ciliobrevin D 10μM 803.34 27.00 0.1897 0.00805 
DMSO 1067.71 88.22 0.1047 0.40621 




Proteins are essential components for most biological processes in a cell, such as cell 
growth, nutrient uptake, motility or intracellular communication among others. 
Viruses are characterised as obligate intracellular parasites since they do not possess 
the minimal protein machinery to ensure completing their replicative cycle and 
making viral progeny. Due to the low encoding capacity of its genome, Ebola virus 
proteins carry out diverse functions and bind to cellular partners or modify their 
function for their own benefit (reviewed in Yu et al., 2017). Several studies have used 
mass spectrometry to elucidate the cellular interactome of each viral protein, but the 
functional implications of these interactions within the virus biology remains little 
understood (Batra et al., 2018; García-Dorival et al., 2016, 2014; Shah et al., 2015; 
Takahashi et al., 2013).  
 
This study presented the cellular interactome of Makona EBOV VP35 in 293T cells 
investigated by using GFP-Trap co-immunoprecipitation in combination with label-
free LC-MS/MS. Results provided a comprehensive view on the interplay between 
EBOV VP35 and its specific host by giving insight into potential cellular partners of 
VP35. Findings suggested, for instance, that this viral protein may have a major role 
in modulating the translational machinery of the cell as at least 15 ribosomal 
constituent proteins showed to have a significant interaction with the viral protein. 
VP35 also has a potential interaction with RNA-binding proteins. CIRBP, a novel 
observed interactor, plays a protective role in the genotoxic stress response, 
stabilises transcripts of genes that are involved in cell survival and acts as a 
translational activator (Lleonart, 2010). According to the data obtained, the VP35-
CIRBP interaction occurred through an RNA intermediate. Nevertheless, further work 
would need to be conducted to assess the importance of this interaction in viral RNA 
synthesis and the possible regulation of translation. PAI1/SERBP1, another novel 
VP35-host partner, is a serine protease inhibitor of tissue-type plasminogen activator 
responsible for the controlled degradation of blood clots and regulation of cell 
migration (Cesariet al., 2010). Cilloniz et al. observed that the upregulation of this 
acute phase signalling gene was associated with lethality in EBOV-infected mice 
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(Cilloniz et al., 2011). Whether VP35 modulates the function or hijacks PAI1 remains 
unknown but the study of its functionality could help understand the late clotting 
disorder symptoms observed in EVD patients and EBOV-infected animal models 
(Geisbert et al., 2003; Chang, 2017). VP35 also established a putative interaction with 
a small cluster of cellular proteins involved in motility and transport. These were 
TUBB4B, a major constituent of microtubules, and DYNLL1/LC8 a subunit of the 
cytoplasmic dynein 1 motor complex. Kubota et al. had previously discovered the 
VP35-DYNLL1 interaction, giving confidence to the protein-protein interactions (PPIs) 
elucidated by the label-free proteomic analysis performed in this study. Other 
significant and novel VP35 cellular partners with a greater than two-fold change 
abundance elucidated in this study were mitochondrial transmembrane chaperones 
TIMM8B, TIMM10 and TIMM10B; proteins with catalytic activity like ATP5I; and 
SDF2L1. Curiously, SDF2L1, a dolichyl-phosphate-mannose-protein with 
mannosyltransferase activity, had been observed to also associate with EBOV NP, 
suggesting it may have a role in the stabilisation of the viral RNP complex (García-
Dorival et al., 2016). Nevertheless, interactomes do not only identify relevant cellular 
targets and functional validation of viral partners is often required (Meyniel-Schicklin 
et al., 2012). One of the main goals of this piece of work was to provide evidence that 
the cellular interactome of a viral protein can be used to examine the role of each 
cellular protein in the virus life cycle as well as to study the potential they have as 
targets of antiviral therapeutics.  
 
Cytoplasmic dynein 1 motor is a multimeric complex responsible for the minus-end 
directed intracellular movement of various cargos and organelles along the 
microtubules. It is composed of two heavy chains, two intermediate chains, two light 
intermediate chains and several light chains (Hook and Vallee, 2006). Many different 
viruses use dyneins as facilitators of their direct movement across cells during the 
initial establishment of infection, including herpesvirus 1 (HSV1) (Dohner et al., 2002; 
Sodeiket al., 1997), papillomavirus (HPV) (Schneider et al., 2011) and the human 
immunodeficiency virus type 1 (HIV-1) (Jayappa et al., 2015). The cytoplasmic dynein 
light chain 1 (DYNLL1) is one of the several light chains that form part of the complex. 
DYNLL1 is the smallest light chain of the molecular motor dynein, being 10 kDa in 
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molecular weight (Mohan et al., 2006). It is involved in retrograde vesicular 
trafficking, ciliary/flagellar motility and cell division. DYNLL1 is the human homolog 
of LC8 and forms a dimer in a phosphorylation-dependent manner. DYNLL1 promotes 
dimerization of several enzymes, also including myosin V and apoptotic factors (King, 
2008). Several studies have demonstrated this particular subunit to be an interactor 
partner and play a specific and essential role in the virus replication. For instance, 
hepatitis B capsids require binding to the cytoplasmic dynein light chain 1 for its 
translocation through the cytoplasm (Osseman et al., 2018). Rabies virus (RABV) L 
protein has a DYNLL1 motif that potentially mediates microtubules binding through 
the cytoplasmic dynein motors. DYNLL1, binding to both RABV L an P proteins, 
constitutes a viral primary transcription enhancer (Bauer et al., 2015; Jacob et al., 
2000). African swine fever virus (ASFV) interacts with DYNLL1 through the viral 
protein p54, constituting a molecular mechanism for the virus transport along 
microtubules (Alonso et al., 2001). DYNLL1 also plays an important role in HIV-I 
proper uncoating process and efficient reverse transcription by interacting with the 
viral integrase (Jayappa et al., 2015). Luthra et al. demonstrated that the 
overexpression of DYNLL1 enhances the stability of the N-terminal domain of EBOV 
VP35 and also the reporter activity of an EBOV minigenome, suggesting that the 
cellular protein is involved in the viral genomic synthesis (Luthra et al., 2015).  
 
The classification of EBOV as a biosafety level 4 (BSL-4) pathogen constitutes a huge 
limitation for the study of its biology. In order to overcome this hindrance, an EBOV 
minigenome system (García-Dorival et al., 2016) was used to allow the importance of 
selected host proteins in the viral RNA synthesis of the Makona variant of Ebola virus 
in a BSL-2 setting. This technology permitted the performance of functional assays on 
DYNLL1 with the dynein motor antagonist Ciliobrevin D to determine the use of it as 
a drug-target and its effect on viral transcription and replication. Results in this piece 
of work demonstrated that non-cytotoxic concentrations of Ciliobrevin D are able to 
significantly disrupt the reporter activity of an EBOV minigenome system. According 
to the blotting performed on cells transfected with the minigenome system and 
treated with Ciliobrevin D, abundance of VP35, NP and DYNLL1 did not differ from 
the non-treated cells. Therefore, these findings suggest that the mechanism of action 
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of Ciliobrevin D does not destabilise the RNP complex but focuses on the disruption 
of the ATPase activity of the dynein motor complex (Firestone et al., 2012), maybe 
making DYNLL1 less available for VP35 and having a negative effect on the viral 
transcription and replication.  
 
One limitation of this study was the fact that the LC-MS/MS analysis was not 
performed with virus-infected cell lysates. Therefore, some of the interactions that 
possibly would be seen in a real infection were missed. For instance, Shabman et al. 
discovered that the interleukin enhancer binding factor 3 (ILF3) isoform DRBP76 
associated with the interferon inhibitory domain (IID) of EBOV VP35 in the presence 
of the dsRNA analog and IFN-I inducer poly(I:C). Having VP35 a role as the RNA-
dependent RNA polymerase co-factor, DRBP76 can inhibit the viral polymerase 
activity as well as disrupt the VP35-NP interaction, knocking down the EBOV 
replication (Shabman et al., 2011). Depending on the proteomic approach used, the 
type of cells transfected/infected and the treatment induced to them, the cellular 
interactomes of a viral protein can differ and give insight on the virus cellular partners 
in different environment conditions. 
 
To conclude, every stage of the viral lifecycle is assumed to be dependent on the host 
proteins, which can be examined as potential antiviral targets. Traditionally, efforts 
to develop antiviral drugs are focused on viral enzymes because they are perceived 
as specific targets. Although host targets have been hampered by their potential on-
target toxicity, there is a growing interest on exploring them because this strategy 
can provide broad coverage for different strains and possibly different viruses (Lin 
and Gallay, 2013). Furthermore, the current therapeutic arsenal against viral 
infections remains extremely limited, often with incomplete coverage and poor 
efficacy (Ma-Lauer et al., 2012). In this study, the cellular interactome of VP35 was 
provided, with multiple host-derived drug targeting candidates that were potential 
partners of the viral protein, and also demonstrated the efficacy of targeting DYNLL1 
with the cytoplasmic antagonist Ciliobrevin D, which reduced the transcription and 
replication activities of EBOV in cellular culture. 





Chapter 4: Characterisation of EBOV L – 
calmodulin interaction and influence of 
calmodulin/calcium on the synthesis of viral RNA 
  




Viruses are obligate intracellular parasites and utilise many aspects of host cell 
components and processes in order to accomplish their life cycle. For viral RNA 
synthesis, which occurs in the cell cytoplasm, Ebola virus must interact with host 
proteins. EBOV transcription and replication rely on the activity of the viral 
ribonucleoprotein (RNP) complex, composed of viral RNA and viral proteins NP, VP30, 
VP35 and L (Mühlberger et al., 1999). Nevertheless, EBOV transcription and 
replication remain still not completely understood, or the role of host factors that are 
involved in these two viral processes.  
 
The viral RNA-dependent RNA polymerase (L for large) is the main player in EBOV 
transcription and replication. L is a multifunctional protein with a molecular weight 
of ~250 kDa and composed of 2210 amino acids. It is the catalytic subunit of the 
ribonucleoprotein RNP complex, and together with its co-factor, VP35, responsible 
for EBOV genome transcription and replication (Mühlberger et al., 1999). To date, 
non-segmented negative sense (nsNS) viruses are thought to encode conserved RNA 
dependent RNA polymerases believed to perform all of the RNA catalytic functions 
such as nucleotide polymerisation, mRNA capping, polyadenylation and cap 
methylation processes (Poch et al., 1990). Poch et al. and Volchkov et al. observed six 
conserved blocks shared among the amino acid sequence of the viral RNA 
polymerase of Mononegavirales, which were separated by more variable regions. 
Three polymerase motifs (A-C) were also identified for nsNS virus L proteins. Amino 
acid region 553 to 571 constitutes motif A, an RNA binding element. Motif B, which 
corresponds to amino acids 738 to 744, is a putative phosphodiester bond formation 
region and/or an RNA template recognition domain. Motif C is comprised between 
residues 1815 to 1841 and is an ATP and/or purine ribonucleotidetriphosphate 
binding domain (Figure 4.1) (Poch et al., 1990; Volchkov et al., 1999). 
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Figure 4.1. Schematic representation of Ebola virus L protein. Conserved domains 
based on a model by Poch et al. (Poch et al., 1990). 
 
In nsNS RNA viruses, primary transcription is the first viral step after entry to the 
infected cell and uncoating. It originates from the 3’ terminal end of the viral genomic 
RNA and polyadenylated, monocistronic mRNA of each gene is produced sequentially 
due to the presence of a single polymerase entry site (reviewed in Whelan et al., 
2004). Attenuation of transcription occurs at every gene junction, triggering a 
progressive reduction in the production of mRNA of the genes proximal to the 
genomic 5’ end. Therefore, viral genes whose products are needed in large amounts 
are located closer to the leader region, while those that are not, are more distal to 
the 3’ terminus and proximal to the 5’ end (Brauburger et al., 2016; Albariño et al., 
2018). Members of the order Mononegaviridae have a highly conserved gene order, 
with core genes N (NP for EBOV), P (VP35 for EBOV) and M (VP40 for EBOV) always 
close to the 3’ terminus and the viral RNA-dependent RNA polymerase (L for EBOV) 
being the most promoter distant and the lowest abundant in expression, reflecting a 
putative way for gene expression control (reviewed in Whelan et al., 2004). The host 
cellular machinery translates the viral mRNA and viral proteins accumulate in 
perinuclear regions before being transported to the budding sites at the plasma 
membrane. Phosphorylation of VP30 is thought to be related to the viral RNA 
C-TermN-Term I
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polymerase switch from transcription to replication mode, leading to the synthesis 
and encapsidation of genomic vRNA and its complementary sequence, the 
antigenome (Biedenkopf et al., 2016). Newly synthesised RNP complex proteins 
participate in what is called secondary transcription.  
 
Levels of the viral RNA polymerase modulate the RNA synthesis activity. Shabman et 
al. demonstrated in an EBOV minigenome system where pL was added in increasing 
amounts that an excess of viral polymerase was detrimental for the virus replication. 
In their experiment, the replication of the system was barely functional when L 
amounts exceeded four times the optimal amount (Shabman et al., 2013). The large 
size of L and its complexity makes it the less studied of the EBOV proteins. 
Nevertheless, the RNP complex in general, and L in particular, represent very 
attractive antiviral targets due to the importance of the viral processes they carry out 
during Ebola virus infection. Although studies made on host protein associations with 
EBOV L are scarce, some host factors have been found to have a role in the EBOV 
transcription and replication. For instance, knockdown of DNA topoisomerase 1 
(TOP1), a host protein that unwinds the helical structures of dsDNA to allow 
transcription and replication, has been seen to associate to L and reduce its viral 
replicase activity (Takahashi et al., 2013). Smith et al. also observed that heat-shock 
protein 90 (hsp90) is an important host factor for the replication of Ebola virus and 
its inhibition also affects negatively viral transcription and replication of EBOV (Smith 
et al., 2010), as well as its disruption impairs the RNA synthesis of other negative-
stranded RNA viruses (Geller et al., 2012).  
 
In this chapter, a label-free liquid chromatography coupled with tandem mass 
spectrometry (LC-MS/MS) was used to elucidate novel protein association between 
EBOV L and transcription, replication and translation host factors by using a cell-free 
transcription/translation system. Novel potential protein-protein interactions (PPIs) 
with the viral protein were discovered and validated. The role of the potential Ebola 
virus L cellular partner calmodulin (CALM) and the influence of calcium on viral 
replication were further investigated by using a minigenome system in cell culture 
where the CALM small molecule inhibitor W-7 or the calcium chelator BAPTA-AM 
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were added in non-cytotoxic amounts. Overall, this study examined the importance 
of free intracellular Ca2+ on viral biology and the potential of the host protein CALM 








The first aim of this piece of work is to examine novel interactions between the EBOV 
RNA-dependent RNA polymerase (EBOV L) and cellular factors to further test the 
hypothesis that cellular proteins play a putative role in the transcription and 
replication activity of the virus. Due to the large size and complexity of L, its 
expression in high amounts required for further analyses and stability was hindered 
in cell culture. Thus, a transcription/translation cell-free system was utilised instead 
for the production of the protein and examination of protein-protein interactions 
(PPIs). A liquid chromatography tandem-mass spectrometry approach was used for 
the analysis of the co-immunoprecipitated protein complexes and to identify 
potential cellular binding patterns. Finally, western blotting was used to further 
validate any interactions.  
 
The second objective of the study was the investigation of potential EBOV L host 
partners as antiviral targets for the disruption of the viral RNA polymerase 
functionality. The importance of the host protein CALM and its substrate, calcium, on 
the viral transcription and replication was further studied in cell culture by using an 
EBOV minigenome system, and the CALM small molecule inhibitor W-7 and calcium 










NOTE: The sample preparation for LC-MS/MS and the raw data analyses obtained 
were performed by Dr. Stuart Armstrong (Infection Biology, Institute of infection and 
Global Health, University of Liverpool).  




4.2.1. Construction and expression of a recombinant protein L-mCherry  
 
In order to study potential cellular binding partners of EBOV L, label-free proteomics 
coupled to a co-immunoprecipitation strategy was used. An mCherry tag was 
inserted in EBOV L to selectively precipitate the viral protein and the cellular binding 
partners by utilising RFP-Trap® beads.  
 
A pUC57 vector encoding a human codon-optimised cDNA sequence of the viral 
protein Zaire ebolavirus Makona strain RNA-dependent RNA polymerase (EBOV L) 
[NCBI sequence reference number KJ660347.2] was designed using the online tool 
Invitrogen GeneArt Gene Synthesis Plasmid Construction 
(https://www.thermofisher.com/uk/en/home/life-science/cloning/gene-
synthesis/geneart-gene-synthesis.html) and constructed by Invitrogen (Thermo 
Fisher Scientific). The sequence coding for the reporter protein mCherry [NCBI ref. 
num. AY678264] was introduced between nucleotides 5555 and 5556 (amino acids 
M1852 and G1853) into the EBOV L sequence open reading frame (ORF) (Figure 4.2A). 
This variable region is located between conserved domains V and VI (Fix et al., 2011), 
a region called second hinge (H2), which constitutes a variable and non-conserved 
sequence between functional domain 2 and 3 of the L protein of Mononegavirales 
and has been widely used for the insertion of fluorescent tags (Ruedas and Perrault, 
2009; Duprex et al., 2002; Fix et al., 2011; Hoenen et al., 2012). The construction 
contained an ampicillin resistance gene for specific selection of competent cells 
containing the plasmid (Figure 4.2B). The recombinant L sequence was under the 
control of the T7 bacteriophage polymerase promoter. An electrophoresis gel run 
with the digested products of the construction confirmed both size of the insert and 
the backbone (Figure 4.2C).  
 
To assess the proper expression of the recombinant L-mCherry protein in cell culture, 
BSR-T7 cells were transfected with LipofectamineTM 2000 with different amounts of 
pL-mCherry ranging from 0.5µg to 2µg per well. The highest expression of the 
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recombinant viral protein was observed by western blot at the highest transfected 
amount. In order to investigate whether the recombinant L-mCherry required the 
other RNP complex proteins to enhance its transcription and translation in cell 
culture, pNP, pVP35 and pVP30 were also transfected at pL-mCherry amounts 0.5µg 
and 1µg. L-mCherry did not require the co-expression of the other RNP complex 
proteins for its appropriate expression and stability (Figure 4.3). 
 
In order to prove the tolerance of the insertion of the reporter gene mCherry into the 
viral RNA polymerase gene and whether it compromised the RNP complex 
functionality, and EBOV minigenome system was used to characterise the 
recombinant L protein transcription and replication activities. BSR-T7 cells were 
transfected with the minigenome system plasmids (500ng pMG, 250ng pNP, 125ng 
pVP30, 125ng pVP35 and 125ng pL or pUC57) together with 50ng of the control 
plasmid pRLTK, encoding Renilla luciferase, in a 24 well format. In one of the 
conditions, the support plasmid encoding EBOV L was replaced with the plasmid 
encoding the recombinant protein L-mCherry at a concentration of 125ng/well, the 
same plasmid amount that was used for L in the MG control. The relative luciferase 
activity of L-mCherry compared to L was 78%, confirming a reduction but not the loss 
of the total replicase and transcriptase activities of the viral RNA polymerase (Table 
4.1 and Figure 4.4A). The detection of Firefly luciferase and GAPDH expression with 
specific antibodies by western blotting confirmed the reduced but still functional 
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Figure 4.2. Recombinant EBOV L-mCherry construct design. (A) A reporter mCherry 
tag was inserted between amino acids 1852 and 1853 for the Makona strain Zaire 
ebolavirus RNA-dependent RNA polymerase, L. Conserved domains based on a model 
by Poch et al. (Poch et al., 1990). (B) Map of pUC57 vector encoding the recombinant 
viral protein with the inserted reporter gene mCherry. An ampicillin resistance gene 
allowed the selection of the growth of the competent cells when growing the plasmid 
for production. (C) Endonuclease digestion of plasmid L-mCherry. The vector was cut 
once by SacI, and twice by SacI and SalI. A 1% agarose gel was loaded with the uncut 
plasmid and digestion products and an electrophoresis was run to confirm product 
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Figure 4.3. Expression of L-mCherry in BSR-T7 cells. Different amounts of the plasmid 
encoding the recombinant viral protein were mixed with LipofectamineTM 2000 and 
transfected into BSR-T7 cells alone or with vectors encoding the other RNP complex 
proteins. Into each well of the SDS-PAGE, 2.5µg of total protein was run. Specific 
antibodies against mCherry and GAPDH assessed protein expression. Detection or 
GAPDH was used as loading control.  
 
 
Table 4.1. Statistical analysis of luciferase activities in BSR-T7 cells transfected with 
EBOV minigenome system plasmids with either wt L or L-mCherry. A Dual Luciferase 
assay (DLA) was performed on BSR-T7 cell lysates. Each condition was performed and 
measured in triplicate. Measurements of Firefly luciferase were normalised with 
Renilla luciferase values. A t-test between –L and the other conditions assessed 











+ L 1534.72 100 0.09 0.00004 
L-mCherry 1198.42 78.09 0.10 0.0002 






















































































































Figure 4.4. Functionality of the recombinant EBOV L-mCherry in BSR-T7 cells. (A) An 
EBOV minigenome system assay assessed the functionality of the L-mCherry protein 
compared to the wt L in BSR-T7 cells. Firefly luciferase activities were normalised with 
Renilla luciferase values. Each condition was performed in triplicate. A t-test between 
conditions assessed significance (* p-value < 0.05, ***p-value < 0.001). (B) A western 
blot was performed to detect and compare the expression of Firefly luciferase in an 
EBOV minigenome system where either wt L or L-mCherry expressing plasmids were 
transfected. Assessed by BCA, 2.5μg of total protein was loaded into each well. 
Specific antibodies against Firefly luciferase were used in BSR-T7 lysates. +L indicates 
the expression of the minigenome system with the wt L. –L indicates the expression 
of the minigenome system without the viral polymerase as a negative control for 
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4.2.2. Expression of EBOV L-mCherry in rabbit reticulocytes and coIP  
 
The recombinant L-mCherry protein has a size of 281 kDa, which complicated its 
expression for co-immunoprecipitation and sufficient amounts could not be obtained 
in mammalian cells (data not shown). Also, as a common feature of Mononegavirales, 
EBOV genes are transcribed in a gradient where the transcripts of genes proximal to 
the genomic 3’ terminus are more abundant than the transcripts of the genes 
proximal to the 5’ end. This characteristic makes the L gene the least transcribed of 
the EBOV genome (Albariño et al., 2018) and high concentrations of this protein in 
cells result detrimental to virus replication (Shabman et al., 2013).  
 
In order to obtain sufficient amounts of translated L-mCherry for the co-
immunoprecipitation (coIP) assays by an RFP-Trap® approach and subsequent LC-
MS/MS analyses, a cell-free TnT® Quick Coupled Transcription/Translation System 
(TnT) was used to study potential EBOV L-interactors (Figure 4.5A). This transcription 
and translation system is based on cell-free rabbit reticulocytes expressing the 
protein of interest in vitro by using a T7 RNA polymerase. Reticulocytes are immature 
red blood cells that contain all the translational machinery but lack the nucleus. Cell-
free systems allow the expression of toxic proteins and allow fast production in a 
simple format. They contain all the macromolecules and components needed for 
transcription, translation and post-translational modification. These components 
include transcription factors, regulatory protein factors, ribosomes and transporter 
RNA (tRNA). TnT systems have been widely used to examine and study protein-
protein interactions (PPIs), protein-DNA/RNA interactions, and post-translational 
modifications (PTMs) among others (Arduengo et al., 2007). Although not ideal for 
the study of cellular interactomes, TnT systems can alternatively help elucidate PPIs 
as they contain eukaryote and mammalian transcription and translation elements, 
which can show interaction with the EBOV RNA-dependent RNA polymerase.  
 
Within the in vitro TnT system, 2 μg of pL-mCherry were incubated. As a negative 
control for the LC-MS/MS, distilled water was added to the TnT systems in triplicate. 
As a positive control for expression, Firefly luciferase under the control of a T7 
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polymerase promoter was added in one of the in vitro systems set. Cell lysates from 
BSR-T7 cells expressing mCherry were run together with the rest of the samples to 
assess the detection of the reporter protein by specific antibodies in all the samples. 
The expressed L-mCherry was co-immunoprecipitated by RFP-Trap® beads and 
protein-protein complexes were eluted. A western blot was conducted to confirm 
the presence of L-mCherry in the eluted fraction of the co-immunoprecipitations 









Figure 4.5. Co-immunoprecipitation (coIP) of L-mCherry expressed in a cell-free 
rabbit reticulocyte transcription and translation (TnT) system. (A) Methodology used 
for the analysis of L-mCherry-host protein-protein interactions (PPIs). The vector 
encoding L-mCherry was added to rabbit reticulocytes, whereas distilled water was 
used as mock. Conditions were performed in triplicate. The expressed recombinant 
protein with their host interactors were pulled-down with RFP-Trap® beads and 
analyzed by LC-MS/MS. PPIs were validated by western blot with specific antibodies 
and further validated by reverse coIP. Functional assays for specific PPIs were 
performed with small molecule inhibitors. (B) Western blot assessing the confirmation 
of L-mCherry expression and coIP. In cell-free rabbit reticulocytes, 2μg of pL-mCherry 
were transcribed and transfected under the control of the T7 promoter. Co-
immunoprecipitation (coIP) with RFP-Trap beads of L-mCherry and detection of the 
pull-down product by western blot with a specific antibody against mCherry 
confirmed L-mCherry presence. A vector encoding Firefly luciferase was used as a 
transcription/translation control of the expression system. mCherry-transfected BSR-
T7 lysates were used as a positive control for the specificity of the antibody against 
mCherry in the whole rabbit reticulocyte (I, input), the coIP product (E, eluate) and the 
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4.2.3. Label-free LC-MS/MS results 
 
A peptide coverage of the pulled-down L-mCherry identified by mass spectrometry 
was assessed to confirm that the recombinant protein was expressed and identified 
along its whole length. Peptides from both the reporter mCherry insert and from 
EBOV L (N-terminal and C-terminal ends) were identified (Figure 4.6). RFP-Trap® co-
IP were performed in triplicate on EBOV L-mCherry-expressing TnT systems and on 
non-protein expressing TnT systems as negative controls to distinguish any non-
specific binding to the bead matrix. The eluted fractions were digested and analysed 
by label-free mass spectrometry in triplicate to investigate host proteins that were 
susceptible of associating with L in the eluted fraction of the pulled down TnT 
systems. Label-free quantitation was performed using MaxQuant (MQ) software 
(version 1.6.1.0) with its internal search engine Andromeda. The significance of the 
identified proteins LFQ intensity values were analysed using a t-test to distinguish 
between significant and specific, and non-specific L partners. A volcano plot was 
generated, showing the logarithmic p-values for confidence in peptide identification 
(y-axis) vs. fold change difference in binding proteins (x-axis) between L-mCherry and 
the mock (Figure 4.7A). Dots in the top right side of the volcano plots represent the 
statistically significant identified cellular partners of L. The proteins that interacted 
specifically with L-mCherry were expected to show a higher binding ratio that the 
ones that interacted with the control. Proteins that bound equally to the control and 
test samples were predicted to have a fold change of 1. Therefore, interacting 
partners with a binding ratio equal or less than 1.9 were removed. Using these 
criteria, 4 TnT system proteins were found to potentially interact with L-mCherry 
(Table 4.2). A novel significant interaction, the nuclease-sensitive element-binding 
protein 1 (YBX1) was found to potentially associate with L-mCherry. YBX1 is a splicing 
regulator that binds to splice-sites in pre-mRNA, contributing to the regulation of 
translation. It also binds and stabilises cytoplasmic mRNA (Eliseeva et al., 2011). 
 
Presence of most of the cellular partners in the L-mCherry pull-downs were not found 
to be statistically significant. Nevertheless, bearing in mind the limitations of the 
expression system, a heatmap was generated in order to have a further insight into 
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the potential L-host PPIs, even though they were not statistically significant. Several 
potential interactions were observed to occur in each biological replicate, differing 
between them. However, as shown in the heatmap in Figure 4.7B, EBOV L was 
present at high intensity in all the TnT systems that expressed the recombinant 
protein and in none of the negative TnT ones. The database, configured for human 
proteins (Uniprot release-2017_11), identified all the rabbit proteins that had 
homologous human proteins showing potential association with L-mCherry. Of 
particular interest were those host proteins that were detected and identified in L-
mCherry but not in negative TnT pulldowns, meaning that they potentially associated 
with the recombinant viral protein and not with the RFP-bead instead. For instance, 
one of them is the heat shock cognate 71 protein (HSPA8), a constitutive chaperone 
that belongs to the HSC70 family, is critical for cell surviving during stress situations 
and assists mis-folded polypeptide chains to become functional proteins (Stricher et 
al., 2013). A co-chaperone of the HSC70 family, BAG family molecular chaperone 
regulator 2 (BAG2), was also only present in the 3 pull-downs of L-mCherry. It acts as 
a nucleotide-exchange factor promoting the release of ADP from the HSC70 family 
proteins (Rauch et al., 2014). Peroxiredoxin-1 (PRDX1), calmodulin-1 (CALM) and 
calmodulin-like protein 5 (CALML5), were other host associations found only in the 
co-immunoprecipitation eluates of the TnT that expressed the recombinant L-
mCherry. Interestingly, BAG2 and PRDX1 were also seen to interact with EBOV L 
previously, giving more confidence in the observed interactions by using a cell-free 
system to express the recombinant viral protein (Takahashi et al., 2013). Keratins 
were considered contaminants, as they are found in the outer layer of human skin, 
epithelial cells or hair and are due to human contamination by manipulation of the 
samples.  
 
Nevertheless, the potential association between EBOV L and CALM in one of the 
three replicates was of interest. Besides, the protein sequence homology between 
rabbit (Uniprot entry num. P0DP23) and human (Uniprot entry num. P62160) 
calmodulin is 100%, giving confidence that the interaction observed between L and 
CALM in rabbit reticulocytes can be extrapolated to occur between the viral protein 
and the human protein homolog. CALM has a 149 amino acid length and is a calcium-
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modulated protein that is found in the cytoplasm of all eukaryotic cells. CALM gets 
activated by sensing Ca2+ and acts as an intermediary protein that regulates and 
modulates the function of other enzymes, like a number of phosphatases and 




Figure 4.6. Peptide coverage of L-mCherry identified by label-free mass 
spectrometry. Amino acid sequence of the recombinant protein L-mCherry. 
Highlighted in red, the reporter mCherry insertion. Highlighted in grey, peptides that 





































KLILHH à EBOV L amino acid sequence 
LRGTN à inserted mCherry amino acid sequence 
Lqmshe à Peptides identified by MS 
 


















Difference (L-mCherry – Neg)
L-mCherry














1 2 3 Acc. Description
Chapter 4: Results  
 133 
Figure 4.7. Protein-protein interactors between EBOV L-mCherry and rabbit 
reticulocytes protein components identified by LC-MS/MS. (A) Analysis of the 
potentially significant cellular proteins that interact with EBOV VP35. A volcano plot 
shows the cellular proteins found to potentially interact with L-mCherry in a cell-free 
rabbit reticulocyte transcription and translation (TnT) system. The logarithmic p-value 
for confidence in peptide identification is plotted against the fold change difference 
in binding protein between L-mCherry and a negative (≥ 2 FC). (B) Triplicates of rabbit 
reticulocytes-expressed L-mCherry were co-immunoprecipitated and protein-protein 
complexes were quantified and identified by label-free LC-MS/MS and compared with 
mock rabbit reticulocyte triplicates. A heatmap was generated showing the LFQ 
intensities of the proteins identified in each replicate.  
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Table 4.2. Significant protein-protein interactions between EBOV L and rabbit reticulocytes TnT system proteins elucidated by LC-
MS/MS. Contaminants and proteins identified by only one unique peptide were removed. The false discovery rate (FDR) was set at 1% or 
below. LFQ intensity values of the identified proteins were analysed using a t-test. The proteins that interact specifically with L-mCherry 
would be expected to show a higher binding ratio that the ones that interact with the control, which show a FC close to 1. The binding 
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4.2.4. Validation of cellular interactions with EBOV L-mCherry  
 
To validate the potential EBOV L partners observed by LC-MS/MS, the co-IP products 
were separated by SDS-PAGE and western blotting assessed the presence of selected 
host proteins by using specific antibodies to CALM, to BAG2 and to YBX1 (Figure 
4.8A). The observed statistically significant L interactor YBX1 and also CALM were 
selected to be further validated by reverse coIP. The negative and the L-mCherry 
expressing TnT products were incubated with 3 μg/ml of specific antibody against 
either YBX1 or CALM. Protein-antibody complexes were reverse pulled-down with 
protein G sepharose beads and an SDS-PAGE and western blotting were carried out 
with reverse co-IP products to detect L-mCherry with a specific antibody against 
mCherry. L-mCherry was detected in the eluates, confirming the interaction of L with 
CALM and YBX1 (Figure 4.8B). The L protein is part of the RNP complex and can bind 
RNA with different affinities. Therefore, to investigate whether the PPIs observed 
were either direct between proteins or due to an RNA intermediate, TnT products 
were treated with RNase A followed by forward co-IP. Detection of the selected 
proteins in the co-IP products only showed presence of BAG2 in the co-IP eluate 
sample, suggesting that CALM and YBX1 require RNA to interact with L (Figure 4.8C 
and Figure 4.8D).  
 
To investigate if the L-CALM interaction also take place in human cells, 12-well dishes 
seeded with 293T cells at a cell density of 105 cells were transfected with 720ng of 
pL-mCherry and 360ng of pT7-Pol. Presence and expression of L-mCherry and CALM 
were confirmed by immunofluorescence microscopy. The merged expression of L-
CALM (Figure 4.9A) suggested co-localisation of the viral and the host factor and 
reinforced their potential interaction.  
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Figure 4.8. Validation of PPIs between L-mCherry and TnT cellular proteins. (A) 
Western blot showing the presence of CALM, BAG2 and YBX1 in the negative TnT and 
the L-mCherry expressed TnT systems. (B) Western blot performed for the detection 
of CALM and YBX1 in the reverse co-IP products of TnT systems. Rabbit reticulocytes 
were incubated with 3µg of a specific antibody against mCherry for 2 hours and 
incubated again with protein G sepharose beads overnight. Specific antibodies 
against L-mCherry confirmed its interaction with both CALM and YBX1. (C) 
Determination of the RNA intermediate dependency on PPIs between L-mCherry and 
host proteins. Western blotting assessed the presence of CALM, BAG2 and YBX1 in 
RNase A treated negative TnT and the L-mCherry expressed TnT systems. (D) 
Confirmation of RNA absence in the RNase A treated input samples for co-
immunoprecipitation. I, input; E, eluate; RNase A treated (+) and non-treated (-). 
 





Figure 4.9. Potential co-localisation of CALM with EBOV L-mCherry in 293T cells. 
Immunofluorescence microscopy image of 293T cells transfected with EBOV L-
mCherry and mock cells. In blue, DAPI-stained nuclei; in red, EBOV L-mCherry; in 
green, CALM. Scale bars indicate 10μm. 
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4.2.5. The antagonism of CALM negatively affects the transcription and 
replication of EBOV  
 
CALM is an intermediary protein that senses calcium levels and relays signals to 
various calcium-sensitive enzymes. CALM is abundant in the cytoplasm, a critical 
component in eukaryotic cells and transduces Ca2+ signals into biological responses 
through its modulation of the structure and function of aquaporins, ion channels, and 
enzymes like kinases and phosphatases (Walsh, 1983). CALM has been observed to 
functionally associate with other viruses proteins (Chattopadhyay et al., 2013; 
Bautista-Carbajal et al., 2017) and also with the EBOV matrix protein VP40 (Han et 
al., 2007). Although its interaction with EBOV L in the performed label-free mass 
spectrometry analysis did not show significance, its association with L-mCherry was 
confirmed by forward and reverse pulldowns in the cell-free system followed by 
western botting, so its hypothesised role on EBOV transcription and replication was 
addressed.  
 
To gain confidence in the L-CALM interaction, the protein sequence L-mCherry was 
uploaded to the web-based database “Calmodulin Target Database” 
(http://calcium.uhnres.utoronto.ca/ctdb) to predict putative CALM-binding motifs 
within the viral protein. Potential calmodulin recruitment signalling (CRS) motifs on 
the protein of interest were predicted by searching for homology to the database and 
by numerous criteria such as distribution of hydrophobicity and basic charge, 
presence of proline residues and similarity to typical database parameters (Yap et al., 
2000). According to the results obtained, a putative CALM-binding motif close to the 
N-terminal end of the L-mCherry protein sequence was found to have a high score in 
consonance with the database algorithm criteria (Figure 4.10). The putative motif, 
AKGRITKLVNDY, did not overlap with the mCherry insert sequence an it was found 
close to the C-terminal end of the viral protein. As reported in Chapter 3, the LC-
MS/MS analysis did not identify CALM as a potential interactor of VP35. Therefore, 
the amino acid sequence of EBOV VP35 was also uploaded to the database as a 
negative control and the scoring for a potential CALM-binding domain in this viral 
protein was zero.   
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The repurposed drug W-7 (N-(6-aminohexyl)-5-chloro-1- naphthalenesulfonamide 
hydrochloride) antagonises CALM by binding to its calcium-binding domains and 
blocks the interaction of calmodulin with its target proteins. The cytotoxicity of W-7 
on BSR-T7 cells treated for 24 hours was assessed with an MTT assay. Concentrations 
ranging up to 40μM did not result significantly cytotoxic to cells, but concentrations 
of 50μM and above resulted in cell death, showing >90% reduction on cell viability 
(Figure 4.11A). Therefore, BSR-T7 cells were treated with W-7 concentrations of 
10μM and below to ensure optimal cell viability and that any observed effects on 
virus biology were down to specific virus effects and not off target effects. To 
investigate the repercussion of the CALM antagonism with W-7 on EBOV 
transcription and replication, an EBOV minigenome system was used. BSR-T7 cells 
were seeded at 105 cells/well in a 24-well dish format 24 hours prior to transfection. 
500ng of pMG, 250ng of pNP, 125ng of pVP30, 125ng of pVP35, 125ng of pL or empty 
vector pUC57 and 50ng of pRLTK were transfected with Lipofectamine® 2000 and cell 
media was replaced with fresh media with non-cytotoxic concentrations of W-7 four 
hours post-transfection. After 24 hours, BSR-T7 cells were harvested and lysed. Each 
condition was performed in triplicate for statistical significance. Results indicated 
that BSR-T7 cells treated with 2.5μM, 5μM and 10μM of W-7 had their minigenome 
normalised luciferase abundance reduced up to 55.6%, 42.3% and 27%, respectively. 
Reporter activity of minigenome system-transfected BSR-T7 cells was significantly 
decreased in a dose-dependent manner when treated with the CALM antagonist W-
7 (Figure 4.11B and Table 4.3). An SDS-PAGE was performed on cell lysates to further 
confirm the drop of reporter activity of the minigenome system, where a decrease of 
EBOV L detection in W-7-treated cells was also seen, suggesting that the viral RNA 
polymerase may lose stability in the host cell when CALM is antagonised. The 
abundance of NP remained stable even if cells were treated with W-7, indicating that 
the effect of the drug on the viral RNA synthesis was not due to a disruption in the 
expression or stability of the support proteins (Figure 4.11B). The observed reduction 
of the minigenome system activity was not due to non-specific cytotoxicity effects, 
as the W-7 concentrations selected for the functional assay had no significant effect 
on cell viability according to the cell viability assay previously performed.  




Figure 4.10. EBOV L has a putative CALM-binding motif at the C-terminal end. 
Putative CALM-binding site was predicted by “CaM Target Database” 
(http://calcium.uhnres.utoronto.ca/ctdb/ctdb/home.html) by using the protein 
sequence of EBOV L-mCherry. Normalised scores (0-9) are shown below the amino 
acid sequence. A consecutive string of high values indicates a putative CALM-binding 
site, 0 representing null chance and 9 representing high chance of CALM interaction. 
In this case, AKGRITKLVNDY (in blue) at amino acid positions 2356-2367, constitute a 
putative CALM-binding motif. In red, sequence of the inserted mCherry. Only the C-
terminal end of the protein sequence is shown in the figure, from amino acid 1651 to 
2449. 
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Figure 4.11. Effect of the calmodulin inhibitor W-7 on the reporter activity of an 
EBOV minigenome system in BRS-T7 cells. (A) Cell viability assay (MTT) of BSR-T7 
cells treated for 24 hours with the small molecule inhibitor W-7, a calmodulin (CALM) 
antagonist. A concentration range between 5μM and 100μM of W-7 was used to treat 
BSR-T7 cells for 24h. DMSO as vehicle control. Etoposide 10nM was used as a positive 
control for the induction of apoptosis. (B) DLA to assess the effect of W-7 on the viral 
RNA synthesis of an EBOV minigenome system in BSR-T7 cells. Each condition was 
performed in triplicate. Firefly luciferase activities were normalised with Renilla 
luciferase measurements. Each condition was performed in triplicate. A t-test 
between conditions assessed significance (ns non-significant, **p-value<0.01, ***p-
value<0.001). Western blot showing levels of Firefly luciferase (LUC), CALM, NP 
(*actual protein size = 84 kDa; seen at 115 kDa due to protein phosphorylation) and 
EBOV L in the cell lysates 24 hours post-transfection and 20 hours post-treatment with 
W-7. GAPDH used as loading control. Assessed by a BCA assay, 2.5μg of total protein 
were loaded in each well. – L indicates the expression of the minigenome system 
without the vector expressing the viral polymerase. DMSO-treated cells were used as 
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Table 4.3. Statistical analysis of luciferase activities in BSR-T7 cells transfected with 
EBOV minigenome system plasmids and treated with different concentrations of 
the CALM antagonist W-7. A dual luciferase assay (DLA) was performed on BSR-T7 
cell lysates treated with different concentrations of W-7. Each condition was 
performed and measured in triplicate. Measurements of Firefly luciferase were 
normalised with Renilla luciferase values. A t-test between –L and the other conditions 
assessed significance. Significance of the DMSO condition was compared to +L. FC, 












+ L 1358.4147 100 0.13 0.0002 
- L 1 0.07 0.00 1 
W-7 2.5μM 755.7764 55.64 0.07 0.0069 
W-7 5μM 573.6931 42.23 0.16 0.0087 
W-7 10μM 366.7664 27.00 0.01 0.0007 
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4.2.6. Depletion of intracellular free calcium ions is detrimental for EBOV 
replication 
 
Viral infection alters calcium homeostasis within the infected cell. Several viruses 
have been shown to induce calcium release with a subsequent enhanced intracellular 
calcium concentration during their infection cycle (reviewed in Zhou et al., 2009). 
Free calcium ions promote Ebola virus virion egress. Han and Harty demonstrated 
that calcium chelation affects the amount of VP40 released from transfected cells, 
resulting in a reduction of viral-like particles (VLP) budding (Han and Harty, 2007). In 
order to investigate whether the disruption of free intracellular calcium levels affects 
EBOV replication independently of the L-CALM interaction, BSR-T7 cells transfected 
with the minigenome system were treated with the calcium chelator acetoxymethyl 
ester (BAPTA-AM) and its activity was examined.  
 
To assess if the cell permeable Ca2+ chelator BAPTA-AM caused non-specific cytotoxic 
effects on BSR-T7, an MTT assay was performed with concentrations of the drug 
ranging from 5 µM to 200µM (Figure 4.12A). No significant cell viability reduction was 
observed. In cells transfected with the EBOV minigenome system, Ca2+ chelation 
resulted in significant reduction of EBOV replication activity in a dose-dependent 
manner, with concentration 50 µM showing 47% reporter activity and going down to 
30% when treated with a BAPTA-AM concentration ³100µM (Figure 4.12B and Table 
4.4). Treatment with BAPTA-AM resulted in an alteration of the stable expression of 
EBOV L (Figure 4.12B). However, it did not affect the abundance of another RNP 
complex protein, EBOV NP, suggesting that the reduced activity of the minigenome 
system was not due to a disruption of the viral ribonucleoprotein complex. Protein 
abundance of CALM also resulted intact, according to the western blotting performed 
with cell lysates. These results suggest that the disruption of intracellular calcium 
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Figure 4.12. Effect of the depletion of intracellular Ca2+ on the replication of the 
EBOV minigenome system in BSR-T7 cells. (A) An MTT assay was performed on BSR-
T7 cells treated with BAPTA-AM, a membrane permeable intracellular Ca2+ chelator. 
A concentration range between 5μM and 200μM of BAPTA-AM was used to treat BSR-
T7 cells for 2 hours, followed by a replacement of fresh media. DMSO was used as 
vehicle control and Etoposide 10nM was used as a control for the induction of 
apoptosis. (B) DLA to assess the effect of calcium chelation on viral RNA synthesis in 
BSR-T7 cells transfected with an EBOV minigenome system plasmids. Each condition 
was performed in triplicate. Firefly luciferase activities were normalised with Renilla 
luciferase measurements. Each condition was performed in triplicate. A t-test 
between conditions assessed significance (ns non-significant, **p-value<0.01, ***p-
value<0.001). Western blot showing abundance of Firefly luciferase (LUC), CALM, NP 
(*actual protein size = 84 kDa; seen at 115 kDa due to protein phosphorylation) and 
EBOV L in the cell lysates 24 hours post-transfection and treated with BAPTA-AM. 
GAPDH used as loading control. Assessed by BCA, 2.5μg of total protein was loaded 
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Table 4.4. Statistical analysis of luciferase activities in BSR-T7 cells transfected with 
EBOV minigenome system plasmids and treated with different concentrations of 
BAPTA-AM. A DLA was performed on BSR-T7 cell lysates treated with different 
concentrations of Ca2+ chelator. Each condition was performed and measured in 
triplicate. Measurements of Firefly luciferase were normalised with Renilla luciferase 
values. A t-test between –L and the other conditions assessed significance. 












+ L 364.56 100 0.11 0.0001 
- L 1 0.27 0.00 1 
BAPTA-AM 10μM 274.12 75.21 0.17 0.1083 
BAPTA-AM 50μM 171.52 47.06 0.07 0.0023 
BAPTA-AM 100μM 115.36 31.65 0.07 0.0009 
BAPTA-AM 150μM 112.38 30.84 0.10 0.0013 
BAPTA-AM 200μM 120.80 33.14 0.11 0.0018 








Since Ebola virus RNA-dependent RNA protein (L) is the catalytic subunit of the RNP 
complex, and transcription and replication processes are an interesting alternative 
target for antiviral exploitation, the main aim of this study was the investigation of 
novel interactions between L and host proteins to characterise their functionality in 
the EBOV biological cycle. To our knowledge, only a few studies have investigated 
EBOV L due to its complexity (Tchesnokov et al., 2018). Nevertheless, only one study 
has been able to determine EBOV L host partners in cell culture by co-
immunoprecipitating the viral protein and analysing protein-protein associations by 
mass spectrometry. Takahashi et al. developed a Flag-EBOV L. By pulling-down and 
analysing the protein complexes by LC-MS/MS, DNA topoisomerase 1 (TOP1) was 
identified as a significant L partner with an important role in the transcription and 
replication of the virus (Takahashi et al., 2013). As tags can affect the viral protein 
conformation and, therefore, the interactions that it can stablish with cellular factors, 
in this study an EBOV L protein was engineered with the reporter gene mCherry 
inserted at the second hinge, which constitutes a variable region located between 
conserved domains V and VI. The insertion of a reporter gene in this region has been 
previously demonstrated not to disrupt the viral RNA polymerase activity of Ebola 
virus and other members of the order Mononegavirales, like human respiratory 
syncytial virus (HRSV), vesicular stomatitis virus (VSV) and rabies virus (RABV) 
(Hoenen et al., 2012; Fix et al., 2011; Ruedas et al., 2014; Duprex et al., 2002). Hence, 
by changing the location of the EBOV L tag, the observation of both similar and 
different PPIs to the ones observed by Takahashi et al. was expected. In the work 
performed in this chapter, cellular factors BAG2 and PRDX-1 were found to 
potentially interact with EBOV L, and they coincide with the mass spectrometry 
results obtained by Takahashi et al., giving confidence in the outcome of the study 
described in this chapter.  
 
The reason why L-mCherry could not be detected by LC-MS/MS when expressed in 
cell culture in this study is not clear. At first glance, it was hypothesised that 
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recombinant L-mCherry might have not been functional or stable in cell culture but a 
western blotting with minigenome and L-mCherry expressing cell lysates proved that 
was not the case. Little amounts of the recombinant protein could be detected by 
western blot in coIP eluates from cell lysates expressing L-mCherry (data not shown), 
but the required amounts for LC-MS/MS analysis could never be obtained in cellular 
culture. To overcome this hindrance, a TnT system was used instead to overexpress 
the recombinant viral protein. Although TnT systems cannot be employed to 
elucidate cellular interactomes, they can help investigate virus-host protein-protein 
interactions related to the transcription and translation processes, and these can 
later be extrapolated and validated in mammalian cells (reviwed in Arduengo et al., 
2007). Potential novel interactions between the host and EBOV L proteins were found 
out in this piece of work, such as YBX1 and CALM. Giving more confidence to mass 
spectrometry analysis on rabbit reticulocytes expressing L-mCherry, CALM and YBX1 
had been previously elucidated by mass spectrometry as components of human 
reticulocytes (Chu et al., 2018). 
 
YBX1 is a nuclear/cytoplasmic protein involved in the regulation of cellular 
transcription and translation in the cytoplasm. It regulates the translation of mRNA 
(Matsumoto et al., 1998) and has been observed to interact with other viruses and 
to have a role in their biological cycle. YBX1 translocates to the nucleus of Influenza-
infected cells and facilitates the association of the RNP complex to the cellular 
microtubules, facilitating the egress of the virus to the vesicular trafficking system. 
Overexpression of YBX1 has been seen to stimulate the production of influenza virus 
virions progeny (Kawaguchi et al., 2012). In hepatitis C virus (HCV), phosphorylated 
YBX1 stabilises viral non-structural protein 5A (NS5A) and regulates HCV propagation 
(Chatel-Caix et al., 2013; Wang et al., 2015). Another example of viral YBX1 
interaction occurs with Dengue virus (DENV), where the cellular protein binds to the 
viral 3’ untranslated region (UTR) and represses translation, suggesting that in this 
case YBX1 may have an antiviral role within the viral infection (Paranjape et al., 2007). 
Further work on the role of YBX1 in the biological cycle of Ebola virus will need to be 
addressed, but these preliminary results could shed light on a new and exploitable 
host-directed antiviral target.  
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Other interesting potential EBOV L associations elucidated by mass spectrometry 
were chaperones HSPA8 and BAG2. Chaperones are thought to be needed for the 
stability and for the RNP complex formation (Noton et al., 2012; Tchesnokov et al., 
2018). A mutational analysis performed by Sztuba-Solinska et al. proved that the first 
50 nucleotides of the Ebola virus trailer region constitute an interacting HSPA8 motif 
that conforms a small-stem loop, which is essential for sustaining viral replication. 
Mutational analysis on this region showed that the HSPA8 interaction is key for EBOV 
minigenome system replication (Sztuba-Solinska et al., 2016). HSPA8 co-chaperone, 
BAG2, shows to be enriched in the elute fraction of the pull-downs performed in this 
piece of work and has also been previously revealed to interact with EBOV L and NP 
(Takahashi et al., 2013; García-Dorival et al., 2016), suggesting that this cellular factor 
may play a role in the stability of the RNP complex and its functionality on the viral 
transcription and replication.  
 
CALM was the chosen host factor for further functional analysis on the Ebola virus 
RNA synthesis. CALM is a calcium-modulated protein that is found in the cytoplasm 
of all eukaryotic cells. It gets activated by sensing Ca2+ and acts as an intermediary 
protein that regulates and modulates the function of other enzymes, like a number 
of phosphatases and kinases, ion channels and structural proteins (Villalobo et al., 
2018). Homeostasis of intracellular calcium gets compromised during viral infections 
as viruses can create a tailored environment for their own demands (Zhou et al., 
2009). A previous study in our lab conducted by Wu et al. (data not published) 
showed that CALM interacted with porcine reproductive and respiratory syndrome 
virus (PRRSV) RNA-dependent RNA polymerase (RdRp or nsp9) and had a role in the 
transcription and replication of the RNA virus. Moreover, the importance of CALM 
and calcium free ions has been previously reported to play a pivotal role in EBOV 
budding process by interacting with VP40 (Han and Harty, 2007). Therefore, in this 
study it is hypothesised that CALM and intracellular Ca2+, indirectly, may also have a 
role in the transcription and replication of EBOV and CALM was present in one of the 
three TnT system replicas expressing L-mCherry pulldowns.  
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In this study, the interaction EBOV L-CALM and the performance of EBOV replication 
when free intracellular Ca2+ levels are decreased, were addressed. Evidence was 
provided regarding the role of the host protein and the importance of calcium on 
viral transcription and replication in an Ebola virus minigenome system. When 
minigenome-transfected BSR-T7 cells are treated with either the CALM antagonist 
small molecule W-7 or the Ca2+ chelator BAPTA-AM at non-cytotoxic concentrations, 
the system’s reporter activity diminished down to 27% and 30% relative luciferase 
abundance, respectively. Both effects on the minigenome RNA synthesis were dose-
dependent. Detection by specific antibodies in a western blot of Firefly luciferase 
proved the reduction on its expression in CALM antagonist and BAPTA-AM drug-
treated cells. Abundance of EBOV L was also affected by the presence of both drugs, 
suggesting that the viral polymerase requires available and functional CALM not only 
to carry out viral transcription and replication but also to stabilise its expression in 
cellular culture. As W-7 binds to the calcium domains of calmodulin in a competitive 
manner and disrupts its interaction with other enzymes (Osawa et al., 1998), it was 
expected that CALM abundance in treated and non-treated cells remained the same. 
EBOV NP expression and stability in treated and non-treated cell lysates was also 
assessed by western blot, showing no difference in its abundance along all the 
conditions tested and indicating that the disruption on CALM activity or the free 
intracellular Ca2+ levels may not affect the support proteins abundance, thus having 
an antiviral effect due to the loss of Ebola virus L stability. W-7 had also been used in 
other studies to antagonise CALM, showing to have an antiviral effect against dengue 
virus, rotavirus and human immunodeficiency virus type 1 (HIV-1), for instance 
(Bautista-Carbajal et al., 2017; Chattopadhyay et al., 2013; Taylor et al., 2012). 
Moreover, CALM is implicated in the virion budding process of Ebola virus by 
interacting with VP40, and W-7 had been observed to inhibit this process in a dose-
dependent manner (Han et al., 2007). These studies all together, suggested that 
CALM and calcium, indirectly, may be involved in the biological cycle of RNA viruses 
at different stages of their biological cycle and that the host protein and the calcium 
pathway could represent attractive host-directed antiviral targets for a broad range 
of viral infections.  
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This piece of work provides evidence that cell-free systems can be considered to help 
elucidate protein-protein interactions in those cases where the protein under study 
results difficult to be expressed in cell culture. The novel interactions between CALM, 
YBX1 and BAG2 and L-mCherry observed to occur in rabbit reticulocytes by LC-MS/MS 
were further validated by co-immunoprecipitation. Replication of an EBOV 
minigenome system was shown to be reduced in a dose-dependent manner when 
cells were treated with the CALM antagonist W-7 and calcium chelator BAPTA-AM, 
demonstrating that CALM/Ca2+ played a pivotal role in these viral processes.  





Chapter 5: Functional characterisation of non-
synonymous mutations in EBOV VP35 that 
occurred at the start of the 2013-2016 West 
Africa Ebola virus outbreak 
  




Ebola virus was first identified in 1976 and, since then, small outbreaks have been 
occurring in rural areas of the Central African belt countries. The largest EBOV 
outbreak until now occurred in West Africa between 2013 to 2016. This resulted in 
more than 28,000 cases and 11,000 deaths (Mendoza et al., 2016). Nevertheless, the 
rapid response of the international community helped with diagnostics, spreading 
prevention measures and supportive care of patients in order to control 
transmission. The 2013-2016 EBOV outbreak surpassed both cases and fatalities of 
all the previous Ebola virus outbreaks combined (Kaner and Schaack, 2016). This 
unprecedented magnitude together with the fact that, to date, there are no licensed 
therapeutics for human use against Ebola virus disease (EVD), speeded up the 
investigation of human, environmental and host factors that might have played a role 
in the scale and impact of the outbreak. Due to the high error rate of the EBOV RNA-
dependent RNA polymerase replicase (Hanada et al., 2004; Hoenen et al., 2015; 
Sanjuan et al., 2010), non-synonymous variations in the amino acid sequence of EBOV 
proteins can be frequently found (Deng et al., 2015; Tong et al., 2015; Pappalardo et 
al., 2017), with the potential to enhance viral fitness or adaptation to new hosts 
(Dowall et al., 2014; Wong et al., 2019). Deep sequencing approaches helped gain 
insight into the evolution of EBOV and identified several mutations in all of the viral 
proteins during the outbreak (Carroll et al., 2015; Dietzel et al., 2017a; Wong et al., 
2019). The importance of studying non-synonymous mutations lay in the fact that 
these can have an impact on viral virulence, host tropism and the design of antiviral 
approaches (Alfson et al., 2016; Pappalardo et al., 2017; Ueda et al., 2017; Wong et 
al., 2019).  
 
This study was focused on VP35 and the importance of observed naturally occurring 
mutations in this protein during the largest EBOV outbreak to date. VP35 is a 
multifunctional protein essential for viral transcription and replication as it is one of 
the constituents of the viral ribonucleoprotein (RNP) complex. VP35 has several 
known functions. The viral protein is a structural element required for viral genome 
packaging (Johnson et al., 2006), assembly (Kirchdoerfer et al., 2015), and the viral 
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RNA polymerase co-factor. VP35 is also an RNAi silencing suppressor (Haasnoot et al., 
2007) and facilitates the immune evasion by antagonising the type-I interferon (IFN-
α/β) responses by binding to dsRNA and supressing the retinoic acid-inducible gene 
1 (RIG-1) helicase signalling cascade (Cardenas et al., 2006; Chang et al., 2009; Prins 
et al., 2010). The structure of VP35 comprises two main domains; a coiled-coil domain 
(CCD) is located at the N-terminal end of the protein. This region is required for the 
oligomerisation of the protein (Reid et al., 2005). The oligomerisation domain has a 
critical role in the nucleoprotein (NP) and VP40 binding as well as RNP complex 
formation (Johnson et al., 2006; Kirchdoerfer et al., 2015). At the C-terminal end 
there is the IFN inhibitory domain (IID), which binds to dsRNA and blocks several 
signalling components that trigger the type-I IFN response of the host (Edwards et 
al., 2016; Leung et al., 2009). The VP35 IID has been demonstrated to be critical for 
full virulence of EBOV (Leung et al., 2009; Schumann et al., 2009). Mutations in any 
of these domains or close to them could represent a change on the protein 
configuration and/or the way it interacts with other viral and host proteins (Binning, 
et al., 2010).  
 
In the present study, the effect of naturally occurring substitutions in the EBOV VP35 
from Makona gene sequence analysis and whether they affect function in terms of 
viral RNA synthesis and interferon antagonism was investigated.   
 




In this study, the available VP35 sequence data from EBOV Makona strain genomes 
sampled during years 2014-2015 in West Africa were compared between them and 
to a Mayinga sequence sampled in 1976 to elucidate non-synonymous mutations in 
the viral RNA dependent RNA polymerase co-factor. The goal of the study was the 
characterisation of the most frequent residue substitutions in VP35 early during the 
West African outbreak. For that, the effect of the selected mutations in VP35 on EBOV 
viral RNA synthesis function was assessed by using an EBOV minigenome system that 
faithfully recapitulated viral RNA synthesis. Moreover, the effect of those mutations 
on the IFN-b response suppression was investigated by using an IFN-b reporter assay 
in cell culture.  
 




5.2.1. Analysis of EBOV VP35 sequences 
 
In order to investigate whether non-synonymous mutations had occurred in VP35 
during the West African Outbreak, all the available Zaire ebolavirus (EBOV) Makona 
strain VP35 sequences from samples taken in 2014-15 that had a complete protein 
sequence were identified in the GenBank database on the date 6th of March 2017 
(http://www.ncbi. nlm.nih.gov/GenBank/).  
 
A total of 950 EBOV VP35 sequences were included in the alignment (see Appendix). 
From them, 947 of the downloaded sequences were sampled in 2014 in Liberia, 
Guinea, Nigeria, Sierra Leone, Switzerland, Great Britain, Mali and Democratic 
Republic of Congo. Three of the 950 sequences were sampled in 2015 in Liberia. To 
examine the year of appearance of the observed mutations, 18 sequences from 
outbreaks that occurred prior 2013 were also included in the analysis. Those were 
sampled in 1976, 1977, 1995, 1996, 2002 and 2007 and were from Gabon and 
Democratic Republic of Congo (Table 5.1). The 950 sequences of VP35 protein 
sampled during 2014 and 2015 were aligned and compared to a reference EBOV 
Makona strain from 2014 [KJ660347.2], the same VP35 sequence used in the EBOV 
minigenome in this thesis, in search for non-synonymous mutations.  
 
In total, 45 non-synonymous mutations were detected. From these, five mutations 
had an occurrence frequency higher than 1.5%. These were V12A (1.68% of the 
sequences), N41S (2.53%), L144F (2%), L249F (4.75%) and L330F (2.83%). From the 
950 VP35 amino acid sequences analysed,  46 contained the non-synonymous 
mutation L249F; 45 of them belonged to strains sampled in Liberia in 2014, and 1 
belonged to a strain sampled in Sierra Leone in 2014. The non-synonymous mutation 
L330F was present in 25 out of the 950 VP35 amino acid sequences analysed, all of 
them belonging to viral genomes sampled in Guinea in 2014 (Table 5.1). Interestingly, 
the reference sequence (AGB56837.1, 1976, Democratic Republic of Congo) had a 
threonine (T) at the position 68, whereas all except for 6 of the sequences from the 
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samples taken in 2014-15 had a methionine (M). According to the alignment of the 
18 VP35 sequences sampled prior 2014, the residue change T > M at position 68 
occurred in 2002 in Gabon and was maintained through the viral progeny onwards. 
Therefore, the reverse mutation M68T on VP35 was included in this study. L249F and 
L330F are located in the interferon inhibitory domain (IID, position 221-340). L249F 
is between residues K248 and K251, which are amino acids with polymerase cofactor 
activity in VP35 together with positions 240, 282-3, 298 and 300. M68T is located at 
the N-terminal of the protein sequence, close to the coiled-coil domain (CCD) 
(Dunham et al., 2015). This region is thought to interact with the viral RNA 
polymerase L (Cardenas et al., 2006) and to be responsible for the oligomerisation of 
the region (St Patrick Reid et al., 2005) (Figure 5.2). No combination of any of these 





Figure 5.1. Occurrence frequency and amino acid position of non-synonymous 
mutations in EBOV VP35 sequences. Alignments were performed by using the 
software MEGA6 (Version 6.06). Compared to the reference sequence [GenBank acc. 
num. KJ660347.2], 45 non-synonymous mutations were found in the EBOV VP35 






























































































































































Non-synonymous mutations position in the amino acid VP35 sequence
2014-15 EBOV VP35 non-synonymous mutations
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Table 5.1. Non-synonymous mutations at amino acid positions 68, 249 and 330 of 
the EBOV VP35. Rows indicate year of first appearance of these mutations in VP35, 
frequency of occurrence during years 2014-2015 and countries where they were 





Frequency of occurrence 
in 2014-15 



















Figure 5.2. Schematic representation of the protein structure of EBOV VP35. VP35 is 
340 amino acids in length and has two functional domains. CCD, coiled-coil domain 
(aa 82-118) at the N-terminus of the protein sequence. IID, interferon inhibitory 
domain (aa 221-340) at the C-terminal end of the protein. The numbers indicate the 
amino acid position. In red, selected residue substitutions to be further studied. VP35 
functional domains are based on models by Kimberlin et al., 2010, Reid et al., 2005 
and Dunham et al., 2015.  
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5.3.2. Construction of mutated EBOV VP35 and expression in 293T cells 
 
In order to characterise the functional effect of M68T and the observed L249F and 
L330F mutations found in EBOV VP35 sequences during 2014-2015 in the West 
African outbreak, 3 plasmids were designed. Each vector encoded EBOV VP35 with 
each of these single non-synonymous mutations. Being VP35 a multifunctional viral 
protein, their effect on transcription and replication, and their IFN-b antagonism 
functions were studied by using an EBOV minigenome system and an IFN-b reporter 
assay, respectively (Figure 5.3). The synthetic genes encoding EBOV VP35 with the 
specific mutations were designed by using the online tool GeneArt 
(https://www.thermofisher.com/uk/en/home/life-science/cloning/gene-
synthesis/geneart-gene-synthesis.html). The inserts had a size of 1624 bp and were 
cloned into pUC57 vectors between restriction enzymes SacI and SalI. Initial mRNA 
transcription was under the control of a phage T7 polymerase promoter. An 
encephalomyocarditis virus internal ribosome entry site (EMCV IRES) was located 
downstream to facilitate translation. Like the pVP35 support plasmid of the mini-
genome system, called “pwtVP35” in this chapter, the mutated EBOV VP35 inserts 
(Figure 5.4) were codon-optimised for human translation. Three different EBOV VP35 
genes with single non-synonymous mutations were constructed. One of them 
encoded EBOV VP35 with a leucine (L) to phenylalanine (F) replacement at the amino 
acid position 249 (pVP35L249F). A second vector was designed to encode EBOV VP35 
with an F instead of an L at the amino acid position 330 (pVP35L330F). A third vector 
was constructed to encode VP35 with the amino acid change methionine (M) to 
threonine (T) at position 68 (pVP35M68T).  
 
To assess the presence of the inserts in the backbone after plasmid transformation, 
production and purification, an agarose gel loaded with undigested, digested once 
and digested twice mutated VP35 cDNA constructions confirmed both insert and 
backbone vector lengths (Figure 5.5).  
 




Figure 5.3. Diagram of the methodology used in this study.  
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Figure 5.4. Insert construct utilised for the study of the mutated Ebola virus VP35. 
Graphic representation of the insert encoding the Ebola virus Makona VP35 protein 
where non-synonymous mutations were introduced. The insert comprises a T7 
polymerase promoter, followed by an EMCV IRES, the EBOV VP35 open reading frame 
(ORF) and the T7 polymerase terminator. The backbone used was pUC57. Nucleotide 
changes that led to single amino acid changes were inserted at the positions 





Figure 5.5. Endonuclease digestion of vectors encoding mutated EBOV VP35. 
Vectors were cut once by SacI, and twice by SacI and SalI. Digestion products were run 
in a 1% agarose gel electrophoresis to confirm product lengths. The insert lengths 
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5.3.3. Effect of VP35 mutations on the EBOV viral RNA synthesis 
 
In order to characterise the potential effect of the observed non-synonymous VP35 
mutations on the viral transcription and replication, an EBOV Makona minigenome 
system was used in BSR-T7 cells. Each mutated VP35 was used individually and the 
amount of luciferase was compared to the one obtained by a minigenome system 
with the wtVP35. The minigenome plasmid of the system encodes Firefly luciferase, 
under the control of EBOV transcription/replication signals and therefore is 
dependent on the viral RNP complex proteins. BSR-T7 cells were harvested and lysed 
24 hours post-transfection of the minigenome and support plasmids and a dual 
luciferase assay (DLA) was performed for each condition. Firefly luciferase values 
were normalised with measurements of Renilla luciferase, encoded in the co-
transfected plasmid pRLTK in the system. No significant differences in the reporter 
activity of the system were observed between wtVP35 and VP35M68T, suggesting that 
the change that occurred in 2002 onwards from T to M at the position 68 constituted 
a neutral mutation and results suggested that this mutation did not constitute an 
advantage to the virus fitness/adaptation in terms of transcription and replication 
(Table 5.2 and Figure 5.6A). However, to our knowledge, the substitution at position 
68 was conserved through time. In contrast, VP35 mutations L to F at positions 249 
and 330 individually conferred a replication advantage with a significantly higher fold 
change difference of 1.64 (p-value = 0.003) and 1.33 (p-value = 0.05), respectively, 
compared to the wtVP35 functionality. Each condition was performed in triplicate, 
assuring the minimum number of replicas to have a robust statistical test for 
significance.  
 
Western blotting was performed to confirm the protein abundance of the reporter 
protein Firefly luciferase, EBOV VP35 and the housekeeping protein GAPDH, which 
was used as loading control. Specific antibodies against EBOV NP were used in order 
to see if the mutations studied on VP35 affected somehow the structure of the RNP 
complex. Abundance of NP was enriched in cells expressing the minigenome system 
proteins with VP35L330F. Although further studies would need to be addressed, these 
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results suggest that the interaction between VP35 and NP could be affected by 
residue changes at position 330 in VP35 (Figure 5.6B).  
 
 
Table 5.2. Statistical analysis of luciferase activities in BSR-T7 cells transfected with 
EBOV minigenome system plasmids with either wt VP35, VP35M68T, VP35L249F or 
VP35L330F. A Dual Luciferase assay (DLA) was performed on BSR-T7 cell lysates. Each 
condition was performed and measured in triplicate. Measurements of Firefly 
luciferase were normalised with Renilla luciferase values. A T-test between wt VP35 
and the other conditions assessed significance on the luciferase activity differences 










wt VP35 1534.72 100 0.09 0.00004 
- L 1 0.065 0.00 1 
VP35M68T 1660.53 108.18 0.28 0.66 
VP35L249F 2514.95  163.87 0.15 0.003 
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Figure 5.6. Functionality of mutated VP35. (A) An EBOV minigenome system assay 
assessed the reporter gene activity of VP35M68T, VP35L249F and VP35L330 proteins 
compared to wt VP35 in BSR-T7 cells. Firefly luciferase activities were normalised with 
Renilla luciferase values. A minigenome system lacking the support plasmid encoding 
L was used as a negative control. Each condition was performed in triplicate. A t-test 
between conditions assessed significance (n/s non-significant, *p-value<0.05, **p-
value<0.01, ***p-value>0.001). (B) Firefly luciferase (LUC), EBOV VP35, EBOV NP and 
GAPDH proteins expression and stability were confirmed by western blotting. 
Assessed by BCA, 2.5 μg of total protein from the lysed cells were loaded in each well. 
*EBOV NP has a predicted molecular weight of 85 kDa, but an actual weight of 115 
kDa when run through an SDS-PAGE (Shi et al., 2008).  
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5.3.4. Effect of VP35 mutations on the IFN-β antagonism  
 
5.3.4.1. Standardisation of IFN-β reporter assay in 293T cells  
 
EBOV VP35 is a multifunctional protein (Leung et al., 2010). Apart from being a 
component of the RNP complex and the viral RNA polymerase co-factor, it also plays 
a key role in shutting down the induction of the anti-viral immune response of the 
host by inactivating the RIG-I signalling pathway by recognition of dsRNA (Basler et 
al., 2000; Cardenas et al., 2006) (Figure 5.7A). In order to measure the IFN-β response 
of the host in cell culture, an IFN-β reporter assay was established in 293T cells. 
Primary transfection of plasmids encoding EBOV VP35 were co-transfected with pT7-
Pol for the transcription of the viral mRNA. pIFN-β_GL3 was a gift from Nicolas Manel 
(Addgene plasmid # 102597) (Gentili et al., 2015) and encoded the Firefly luciferase 
reporter gene under the control of an IFN-β promoter. A pRLTK plasmid, encoding a 
Renilla luciferase protein, was also transfected for the normalisation of the Firefly 
values. 24 hours after primary transfection, a secondary transfection was carried out 
with the low molecular weight synthetic mismatched analog of dsRNA polyinosinic-
polycytidylic acid (poly(I:C)). Poly(I:C) is a pathogen associated molecular pattern 
(PAMP) that is recognised by antiviral receptors TLR-3, RIG-1/MDA5 and PKR. 
Therefore, it induces inflammatory pathways and the expression of type-I 
interferons. EBOV VP35, already expressed in the transfected cell, was expected to 
block the IFN-β induction of the host (Figure 5.7B).  
 
The reporter activity of the system showed a dose-response curve with saturation 
when more than 2.5µg of poly(I:C) was transfected in cells (Figure 5.8A). Therefore, 
the optimal amount of the dsRNA analog IFN-β inducer poly(I:C) was determined to 
be 2.5µg/well in a 24-well plate format. The antagonism effect at different amounts 
of wt VP35 on the IFN-β induced reporter activity of the system was also tested. 
250ng, 1000ng, and 2000ng of pwtVP35 were transfected in BSR-T7 cells in a 24-well 
plate format and then IFN-β was induced by transfecting 2.5µg of poly(I:C) per well. 
As seen in Figure 5.8B, the more the amount of plasmid expressing VP35 transfected, 
the fewer the luciferase reporter activity of the IFN-β assay. The amounts of VP35 
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used and the corresponding suppression of reporter activity were in accordance with 



































Figure 5.7. Schematic representation of IFN-β induction repression by EBOV VP35. 
A) EBOV VP35 blocks the detection of viral RNA by cytosolic helicases RIG-1/MDA5 
and impedes the phosphorylation and nuclear translocation of the transcription 
factor IRF-3/7. B) IFN-β reporter assay in 293T cells. 24 hours after 293T cells are 
plated in 24 well dishes, pwtVP35 or mutated VP35 proteins, pIFN-β_GL3, pT7-Pol and 
pRLTK are transfected with LipofectamineTM 3000 and incubated at 37°C, 5% CO2. 
Media is replaced with fresh DMEM and 2.5µg of poly(I:C) is transfected with 
LipofectamineTM 2000 and incubated for 24 hours before cells are lysed. The synthetic 
double-stranded analog Poly(I:C) is recognised by TRL-3, RIG-1/MDA5 and PKR and 
induces signalling via multiple inflammatory pathways and the expression of IFN-β. 
pIFN-β_GL3 encodes the reporter gene Firefly luciferase, which is transcribed if IFN-β 
is present due to its IFN-β promoter. Therefore, detection of Firefly luciferase (FLuc) in 
cell lysates is indicative of IFN-β expression. pRLTK encodes Renilla luciferase and its 
expression (RLuc) is used as a control for normalisation of the Firefly measurements. 
The expression of VP35 is under the control of a T7 polymerase promoter, and its 






IFN-β promoter Firefly Luc

























Figure 5.8. Standardisation of the IFN-β reporter assay in 293T cells. DLA on 293T 
cells transfected with the IFN-β assay plasmids. (A) Different poly(I:C) concentrations 
were tested to assess the maximum IFN-β expression; and (B) different quantities of 
transfected wild-type EBOV VP35 encoding vectors were tested to assess the amounts 
required to observe increasing levels of IFN-β antagonism. Assays were performed in 
24-well plates and each condition was done in triplicate. To assess significance, a t-
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5.3.4.2. Comparison of the effects on the IFN-β induction inhibition 
between wild-type VP35 and single mutated VP35 proteins.  
 
Once the IFN-β reporter assay was optimised, the effect of each single mutation in 
EBOV VP35 on the IFN-β induction and antagonism in 293T cells was determined. As 
shown in Table 5.3, cells transfected with pIFN-β_GL3, pRLTK, pT7-Pol and the empty 
vector pUC57 were used as negative and positive controls for the IFN-β induction, 
with a secondary transfection with poly(I:C) in the case of the positive one. The 
amounts 250ng, 1000ng and 2000ng of each mutated EBOV VP35-encoding plasmid 
were compared to the same amounts of wt VP35 and its effect on IFN-β antagonism 
when inflammatory pathways were induced with poly(I:C). The empty vector pUC57 
was added to each well to have a 2000ng total amount of pVP35+pUC57. Amounts 
of pT7-Pol were adjusted to amounts of pVP35. Each condition was performed in 
triplicate for statistical analysis, at once and with the same 293T cell passage number 
to reduce experimental variation. A DLA was performed 24 hours after IFN-β induced 
cells were lysed. Firefly luciferase values were normalised with Renilla luciferase 
measurements. The functionality of VP35M68T, VP35F249L and VP35F330L was intact and 
a dose-response curve was observed in all the different expression levels tested. The 
more the VP35 expressed, the higher the suppression of IFN-β and, therefore, the 
less Firefly luciferase activity measured in the system (Figure 5.9A). The only 
exception was VP35F330L, whose antagonism function seemed to be saturated at a 
transfected amount of 1000ng onwards.  
 
If comparisons are made between VP35 variants at the level of 250ng of transfected 
cDNA condition (Figure 5.9B), the three mutated viral proteins seemed to have a 
significantly better performance at blocking the induction of IFN-β compared to wt 
VP35. However, wt VP35 at 1000ng displayed a higher IFN-β antagonism than 
VP35M68T and VP35F249L when 1000ng and 2000ng of viral protein-encoding plasmids 
were transfected. These results may suggest that at low concentrations of VP35, 
variants VP35M68T, VP35F249L and VP35F330L have a faster immune evasion regarding 
the IFN-β cellular induction. Nevertheless, at higher protein amounts, they do not 
display an advantage for the cellular IFN-β expression compared to wt VP35.  
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A western blotting was performed with the cell lysates in order to validate the 
expression of each variant of EBOV VP35. The reporter activity of the system was 
detected by specific antibodies against Firefly luciferase (LUC), and the housekeeping 
protein GAPDH was detected as loading control of the total protein amounts run in 
each well during the SDS-PAGE procedure (Figure 5.9C). At equal total protein 
amounts loaded, western blots showed differences between the abundance of the 
different VP35 protein variants. EBOV wt VP35 and VP35L249F seemed to be more 
efficient at being expressed or more stable, making intrinsic protein processing or 
stability determinants the cause of such differences at their IFN-β antagonism 
function.  
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Table 5.3. Plasmids and amount of cDNA used in the IFN-b reporter assay. Different amounts of wtVP35 and vectors encoding single 
non-synonymous mutations VP35M68T, VP35L249F or VP35L330F were co-transfected with the reporter plasmid pIFN-b_GL3, the Renilla 
luciferase-encoding plasmid pRLTK for normalisation, pT7-Pol and the empty vector pUC57. The amounts in the table are given in 
microliters (µl) from plasmid stocks at 500ng/µl except for pRLTK (*100ng/µl). 24 hours post primary transfection, cells were transfected 
again with the IFN-b inducer poly(I:C). Primary transfection was performed with 1µl of Lipofectamine3000TM and 1.5µl P3000 reagent 
per well. Secondary transfection was performed with 2µl of Lipofectamine2000TM per well. Amounts of plasmids given reflect that each 
condition was performed in triplicate and in a 24-well plate format.  
 IFN-b_Luc wt VP35 VP35M68T VP35L249F VP35F330L 
(µl) - + 250ng 1ug 2ug 250ng 1ug 2ug 250ng 1ug 2ug 250ng 1ug 2ug 
pIFN-b_GL3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
*pRLTK 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
pT7-Pol 6 6 1.5 6 12 1.5 6 12 1.5 6 12 1.5 6 12 
pVP35  - 1.5 6 12 - - - - - - - - - 
pVP35M68T  - - - - 1.5 6 12 - - - - - - 
pVP35L249F  - - - - - - - 1.5 6 12 - - - 
pVP35L330F  - - - - - - - - - - 1.5 6 12 
pUC57 12 12 10.5 6 - 10.5 6 - 10.5 6 - 10.5 6 - 
               
Poly(I:C) - 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 


























































































































































Figure 5.9. IFN-β antagonism at different amounts of transfected plasmids encoding 
EBOV wt VP35, VP35M68T, VP35L249F and VP35L330F encoding plasmids in cells. 293T 
cells were seeded at 1.6x105 cells per well in a 24-well dish format. pVP35, pIFN-
β_GL3, pRLTK, pUC57 and pT7-Pol were transfected with LipofectamineTM3000. 
Poly(I:C) was transfected with LipofectamineTM 2000 and cells were incubated for 24 
hours. Significance between conditions was assessed with a t-test (n/s non-
significant, *p-value<0.05, **p-value<0.01, ***p-value<0.001). A) Comparison 
between different amounts of each EBOV VP35 variant. Significance was assessed 
between each condition and the positive control. B) Comparison between EBOV VP35 
variants at each plasmid amount transfection (250ng, 1000ng and 2000ng). T-tests 
for significance were assessed between wt VP35 and VP35 variants at each 
transfected plasmid amount. C) Detection of Firefly luciferase (LUC), EBOV VP35 and 
GAPDH proteins with specific antibodies on a western blot membrane. For each 


















































































Virulence of a pathogen is multifactorial in nature. The study of viral mutations during 
the course of an epidemic is essential to monitor the evolution of circulating virus 
populations. Non-synonymous mutations can have relevant effects on viral virulence 
(Dietzel et al., 2017b), antiviral therapy efficiency (Kugelman et al., 2015) or virus 
adaptation to novel species (Dowall et al., 2014; Pappalardo et al., 2017). The 2013-
2016 West African EBOV outbreak was the largest on record and unprecedented in 
terms of cases and fatalities (Holmes et al., 2016). Since EBOV discovery in 1976, 
sporadic outbreaks have occurred in Central and West Africa (Breman et al., 2016). 
Due to the shortness and relatively few cases of previous outbreaks, consistent 
changes in the viral genome sequence had been observed but not studied before the 
West African outbreak, to our knowledge (Leroy et al., 2002; Rodriguez et al., 1999). 
Next-generation sequencing of clinical samples from the 2013-2016 West African 
EBOV outbreak allowed the rapid elucidation of naturally occurring single nucleotide 
polymorphisms (SNPs) that led to discover non-synonymous mutations in the viral 
protein sequences of the EBOV Makona strain (Carroll et al., 2015; Dietzel et al., 
2017b; Dowall et al., 2014; Wong et al., 2019). Nevertheless, a complete 
characterisation of the impact of dominant non-synonymous mutations is lacking and 
can help understand the virus enhanced fitness, its mechanisms of virulence across 
its evolution and its adaptation to novel hosts.  
 
Studies made early in the outbreak claim no gain in virulence from a genetic point of 
view of the virus since its discovery in 1976 to 2014 (Dunham et al., 2015; Olabode et 
al., 2015). Nevertheless, later studies proved that naturally occurring mutations like 
NPR111C or LD759G improved viral infectivity and replication during the West African 
outbreak, conferring an advantage to the virus during the epidemic (Bedford and 
Malik, 2016; Wong et al., 2019). For instance, GPA82V is believed to be the cause of 
the rapid spread of EBOV pandemic early in 2014. Located at the interaction interface 
of the viral glycoprotein, it made the mammal cell receptor Niemann Pick C1 (NPC1) 
more susceptible to binding and entry from the endosome to the cytoplasm by EBOV 
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(Carroll et al., 2015; Diehl et al., 2016). Controversially, Marzi et al. found that 
Makona EBOV isolates from late 2014 displayed decreased growth kinetics compared 
to Makona EBOV isolates from early 2014 and to Mayinga EBOV isolates in animal 
models and tissue culture. Therefore, they concluded that the naturally occurring 
mutations observed during the 2013-2016 outbreak did not increase viral 
pathogenicity in animal models (Marzi et al., 2018).  
 
In this study, reverse genetics were used to study the effect of identified naturally 
occurring mutations in VP35 on the protein functionality in isolation. 950 available 
Makona EBOV VP35 sequences on GenBank from genomes sampled in 2014 and 2015 
were analysed. Several amino acid changes were observed compared to a Mayinga 
isolate from 1976. Changes from leucine to phenylalanine (L > F) at positions 249 and 
330, both substitutions located at the functional IID, were the most abundant. This 
functional domain of VP35 carries out at least two different functions, involving 
interaction with binding partners for viral replication and host IFN responses 
suppression. VP35 IID needs to interact with NP for viral RNA polymerase function 
and also requires binding to dsRNA to suppress type-I IFN responses (Leung et al., 
2010). According to the results presented in this chapter, stability of NP in an EBOV 
minigenome system seemed to be slightly compromised when VP35L249F was present 
but enriched when VP35L330F was added instead. Previous studies demonstrated that 
some residues in the IID are essential for the viral RNA polymerase co-factor function 
of VP35 but are not critical for the IFN response suppression, and that not all residues 
involved in viral RNA synthesis require a strong binding to NP. Point mutations R305, 
K309, R312, K319 and R322 in the IID of EBOV VP35 have been demonstrated to be 
critical for type-I IFN response inhibition and dsRNA binding and, curiously, are 
conserved in VP35 of Lloviu virus (LLOV), a member of the Filoviridae family that has 
not been found to infect humans to date (Feagins and Basler, 2015; Hartman et al., 
2004; Leung et al., 2010). Regarding the viral RNA polymerase co-factor function, 
Prins et al. observed that residues R225, K248 and K251 in the CCD are essential for 
transcription and replication of an EBOV minigenome system (Prins et al., 2010). 
None of these punctual residues were found to be substituted in the Makona EBOV 
VP35 sequences from 2014 and 2015 analysed in this study except for R225K, which 
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had only a 0.53% occurrence frequency. These observations reinforce that these 
residues are key for VP35 functionality and any substitution at the above-mentioned 
amino acid positions could have been detrimental for EBOV virulence, as negative 
mutations affecting vital functions tend to be eliminated. 
 
The effect of mutations at protein residues 68, 249 and 330 on different functions of 
VP35 and whether they could have been determinant for the course of the largest 
EBOV outbreak were investigated in this chapter. With the exception of the residue 
substitution at position 68, mutations occurred early during the West African 
outbreak and were not found simultaneously in the same genomes. Therefore, their 
effect on the protein functionality was characterised in isolation. Results proved that 
these naturally occurring amino acid changes individually enhanced the viral genome 
transcription and replication function in vitro in a minigenome system compared to 
a wild type VP35. Moreover, their IFN-b antagonism function was also evaluated, 
showing mutation L330F to heighten this immune response evasion mechanism and 
L249F to do so at lower amounts compared to wild type Makona VP35. These findings 
suggest both mutations could have contributed to disease severity early in the EVD 
epidemic. Amino acid change at position 68, on the contrary, constituted a neutral 
mutation that neither enhanced or suppressed the viral RNA polymerase co-factor 
function, also in accordance with findings by Dunham et al. (Dunham et al., 2015). 
Nevertheless, residue replacement methionine to threonine (M > T) at position 68 
constituted a discrete disadvantage in terms of IFN-b suppression, suggesting that it 
was the reason why T > M substitution observed in 2002 onwards was favoured and 
maintained through time.  
 
This study provides evidence that single mutations in a multifunctional viral protein 
can affect different functions and modulate viral features between virus populations, 
and that outbreaks should be stopped as soon as possible to avoid the emergence of 
naturally occurring mutations that confer more virulence to EBOV. Further work 
should include the characterisation of the combination of these two mutations on 
both viral replicase activity and IFN-b antagonism performances, as in an in vivo EBOV 
infection there are multiple RNA virus populations infecting a host, having either a 
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synergic or an antagonistic effect on the infected cells. Moreover, virus-like particles 
would be an attractive tool to study whether substitutions L249F and L330F get 
neutralised by compensatory mutations in VP35 or other viral genes. Nevertheless, 
EVD severity depends not only on virus genome mutations, but also on other 
parameters like comorbidities, infection dose, patient health state or quality of the 
treatment (Hartley et al., 2017). Another limitation of the study is that mutations 
were studied in cell culture, which is not representative of the complex environment 
an organism constitutes. To better understand the impact of VP35T68M, VP35L249F and 
VP35L330F or any other mutation observed on the viral performance, suitable animal 
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6.1. General discussion 
 
Ebola virus disease caused more than 28,000 cases and 11,000 deaths during the 
2013-2016 West African outbreak and is currently striking again in the Democratic 
Republic of Congo with a total of 1367 confirmed and probable EVD cases, of which 
885 died (case-fatality rate 65%), as of 23rd of April 2019 (“WHO | Ebola virus disease 
– Democratic Republic of the Congo,” 2019). The broad cell tropism the virus has 
(Geisbert et al., 2003), together with the diverse manifestations that EVD presents, 
make Ebola virus pathogenicity not completely unveiled and urges for a better 
understanding of the mechanisms underlying the virus biology in order to guide the 
development of therapeutics against the disease. Although determinants of patient 
survival are poorly understood, viral load has been reported to peak 3 to 7 days after 
the onset of symptoms in patients, being 10 to 100 fold higher in fatal cases than in 
survivors (Lanini et al., 2015). Thus, viral transcription and replication, conducted by 
the viral RNP complex, are very attractive viral stages of the virus life cycle to be 
further studied and targeted by antivirals in order to prevent and revert the outcome 
of patients presenting a high level of viremia (Martin et al., 2017). Since the viral RNA-
dependent polymerase (L) and its co-factor (VP35) are the main players of the above-
mentioned processes, this thesis intended to tackle three main themes. Chapter 3 
and 4 explored novel and essential interactions between VP35, L and the host cell. In 
them, the effect of antagonising with small molecule inhibitors two potential host-
virus interactions with roles in EBOV transcription and replication in cell culture - 
DYNLL1 and CALM/calcium – were also examined. Finally, chapter 5 focused on the 
virus genetics, characterising three non-synonymous mutations in VP35 occurring 
early in the West African EBOV outbreak. Their effect on VP35’s functionality on both 
viral replication and interferon beta suppression in the host cell were assessed in 
order to characterise the consequences of having circulating viral populations 
carrying these mutations.  
 
Co-immunoprecipitation of protein-protein complexes and LC-MS/MS analyses are 
reliable tools for the elucidation of novel cellular factors that play a key role in viral 
processes (Pichlmair et al., 2012). This approach helps gaining knowledge on viral 
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biology and on cellular response to infection, and has been widely used to determine 
protein-protein interactions between viruses and their hosts, leading to the discovery 
of promising antiviral cellular targets (Dong et al., 2016; Emmott et al., 2013; García-
Dorival et al., 2016, 2014; Martinez-Gil et al., 2017; Munday et al., 2015; Wang et al., 
2017; Wu et al., 2011).  
 
6.1.1. Elucidation of the cellular interactome of EBOV VP35 – 
Chapter 3 
 
In the case of EBOV VP35, this thesis presents the first study of the Makona strain 
VP35 cellular interactome. Results showed 28 statistically significant host proteins 
that potentially associate with VP35. Following forward and reverse co-
immunoprecipitations, protein-protein complexes were validated by western blot 
and novel VP35-host interactions were described for the first time. These were CIRBP, 
PAI1, SDF2L1 and ATP5I. EBOV VP35 interactome also showed a cluster of ribosomal 
proteins to potentially associate with VP35, suggesting a putative role on modulation 
of the host translational machinery or the stability of mRNA (Batra et al., 2018). Host 
chaperones from the TIMM family were also observed in the LC-MS/MS analysis, as 
well as proteins involved in intracellular transport and cellular motility. These were 
proteins from the TUBB family and DYNLL1, which had been reported previously to 
interact with VP35 and to have a role in Ebola virus replication (Kubota et al., 2009; 
Luthra et al., 2015). Finding DYNLL1 to be one of the top hits in our analysis gave 
confidence in the outcome of this study. To our knowledge, only Batra et al. did 
previously elucidate the interactome of EBOV VP35 by using a label-free LC-MS/MS 
approach in 293T cells, but they expressed Mayinga strain Zaire ebolavirus VP35 
(GenBank Ref. Number NC_002549.1) (Batra et al., 2018). Although using a very 
similar approach, when the Makona and Mayinga VP35 cellular interactomes in 293T 
cells are compared, the only significant PPI that could found in both was DYNLL1. 
Further studies should be addressed to examine whether the differences observed in 
both interactomes were due to the affinity tags used or whether Mayinga and 
Makona strains do associate with the host proteins dissimilarly, as the protein 
sequences used in the two studies differed in 4 amino acid residues. 
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6.1.2. Using rabbit reticulocytes to determine protein-protein 
interactions between EBOV L and the host - Chapter 4 
 
In chapter 4, expression of L-mCherry was challenging in cell culture and a cell-free 
rabbit reticulocyte system was used alternatively, not making possible to study the 
cellular interactome of the viral RNA polymerase in mammalian cells. Similar issues 
with the expression of steady-state amounts of recombinant protein to further 
proceed with LC-MS/MS were encountered by Batra et al. when they attempted to 
elucidate EBOV L’s cellular interactome (Batra et al., 2018). L-mCherry, being large in 
size and having the reporter gene inserted in a variable region between functional 
domains, proved to be functional at replicating the Ebola minigenome system, as 
expected from similar constructions used previously in other studies for EBOV and 
other members of the order Mononegaviridae (Duprex et al., 2002a; Fix et al., 2011; 
Hoenen et al., 2012; Ruedas and Perrault, 2009a). Takahashi et al. constructed a 
FLAG-tagged EBOV L and elucidated viral-host protein associations by LC-MS/MS. 
They did not validate those interactions but focussed on the functionality of the L 
cellular partner DNA topoisomerase 1 (TOP1) (Takahashi et al., 2013). This particular 
association was not found in the analyses showed in this thesis, but other PPIs found 
by Takahashi et al. were present in our study. These were BAG2 and PRDX1. 
Validation by western blot of the association between EBOV L and BAG2 gave 
confidence in the cell-free-EBOV L protein associations observed by LC-MS/MS in this 
piece of work. Nevertheless, some interactions between the recombinant protein 
and host factors were unrevealed for the first time and further validated, like CALM 
and YBX1. Although not all of them were found statistically significant due to the 
complexity to express EBOV L, they might guide towards future approaches to better 
understand the interactions between the viral RNA polymerase and the host. Further 
optimisation of the cellular expression of L-mCherry should be addressed to better 
understand the cellular associations involved in the viral RNA polymerase 
functionality.  
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6.1.3. Antagonism of host proteins DYNLL1 and CALM by using 
repurposed drugs Ciliobrevin D and W-7, respectively, reduce 
the EBOV viral RNA synthesis in cell culture – Chapter 3 and 4 
 
Huge efforts are currently being made in order to find effective therapeutics against 
Ebola virus disease, being host-directed antivirals arising as an alternative to virus-
specific drugs (Mohr et al., 2015; Wilde et al., 2014; Zeisel et al., 2015). Virus biology 
often requires host factors. For instance, endosomal membrane fusion requires 
cathepsin L and B for GP proteolytic cleavage and Niemann-Pick C1 cholesterol 
transporter for entry; viral protein progeny needs the host translation machinery; 
and virion assembly and budding rely on the host cytoskeleton and ubiquitin ligases 
(Carette et al., 2011; Chandranet al., 2005; Côté et al., 2011; Gordon, et al., 2019). 
Cellular factor-directed targets are often perceived as non-beneficial for the host as 
they are not specific and may lead to target-related cytotoxicity (Lin et al., 2013). 
Knocking-down a host gene or protein expression to basal levels may be sufficient for 
a virus to have their replication affected. Cells, on the contrary, have redundant 
pathways that can make up for the suppression of a specific cellular factor, so such 
risk can be mitigated. Moreover, cellular proteins are less likely to show drug 
resistance within time. Another advantage of using host-directed therapies is that 
they represent an alternative to combat quasispecies populations. In this thesis, host 
factors DYNLL1 (Chapter 3) and CALM (Chapter 4) were antagonised with repurposed 
small molecule drugs in order to assess their potential as antiviral targets. The use of 
an EBOV minigenome system (García-Dorival et al., 2016) allowed the study of the 
effect of Ciliobrevin D and W-7, antagonist drugs targeting DYNLL1 and CALM 
respectively, on the viral RNA synthesis. In this piece of work, the use of the above-
mentioned drugs was demonstrated to be detrimental for EBOV replication in cellular 
culture at non-cytotoxic concentrations. Findings in chapter 3 reinforced the role of 
DYNLL1 in the biological cycle of Ebola virus by associating with VP35 (Luthra et al., 
2015) and demonstrated that the use of the repurposed drug Ciliobrevin D affects 
detrimentally viral replication in a minigenome system. Results in chapter 4 
demonstrated that CALM interacts with the Ebola virus RNA polymerase and that the 
host protein antagonism by W-7 diminishes the reporter activity of the previously 
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mentioned EBOV minigenome. Moreover, cell culture pre-treated with W-7 had 
previously shown ton inhibit budding of EBOV virus-like particles (Han and Harty, 
2007). Additionally, literature shows that both DYNLL1 and CALM are host factors 
widely used by viruses to carry out different stages of their viral lifecycles (Alonso et 
al., 2001; Bauer et al., 2015; Bautista-Carbajal et al., 2017; Chattopadhyay et al., 
2013; Jacobet al., 2000; Jayappa et al., 2015; Osseman et al., 2018). Although further 
experiments should be addressed, these findings suggest that Ciliobrevin D and W-7 
could constitute broad range host-directed antiviral repurposed drugs. 
 
6.1.4. Chelation of free intracellular ions of calcium correlates to a 
decrease in EBOV RNA synthesis – Chapter 4 
 
The dependency of EBOV RNA synthesis on free intracellular calcium levels was also 
demonstrated, potentially through the functionality of Ca2+-dependent enzymes such 
as CALM, which was previously shown to interact with EBOV L in chapter 4.  The 
ability of some viruses to appropriate or interrupt the calcium signalling pathways 
and other calcium-dependent cellular processes to their own benefit has been 
observed in the literature, such as HIV-I, enterovirus, HCV or rotavirus (reviewed in 
Zhou et al., 2009). Cellular pre-treatment with the intracellular calcium chelator 
BAPTA-AM proves that an alteration of the calcium homeostasis in the cytoplasm 
disturbs the EBOV vRNA synthesis. Calcium ions play important roles in the lifecycle 
of many viruses. Some viral proteins such as Tat and gp120 in HIV-I are able to disturb 
calcium homeostasis inside the host cell (Lannuzel et al., 1995), some others bind to 
intracellular calcium ions for structural integrity or functionality, like NSP4 in 
rotavirus (Bowman et al., 2000) and some virus-host interactions depend on cellular 
calcium-regulated proteins such as CALM and the HIV-I protein MA (Taylor et al., 
2012). Whether a drop in the intracellular free calcium ions level causes a weaker 
interaction between EBOV L and CALM or whether it affects other calcium-
dependent enzymes required for viral replication, disrupting EBOV vRNA synthesis, 
needs to be further studied.  
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6.1.5. Naturally occurring mutations in EBOV VP35 during the West 
African outbreak can potentially enhance viral virulence – 
Chapter 5 
Due to the nature of RNA viruses, they encode RNA polymerases lacking 
proofreading, allowing viral populations to rapidly adapt to new environments and 
to develop resistance to antiviral therapeutics. RNA viruses exist as “clouds” of similar 
variants generated by continuous mutations during genomic replication and limit the 
prediction of the outcome of an infection (Lauring and Andino, 2010). The 
examination of the effect of naturally occurring phenotypic changes in EBOV viral 
proteins during the 2013-2016 West African outbreak could help understand the viral 
evolutionary dynamics and its relationship to virulence. Although changes in the 
amino acid sequence of Ebola virus proteins have been reported early during the 
largest west African EBOV outbreak (Carroll et al., 2015; Deng et al., 2015; Gire et al., 
2014; Tong et al., 2015), not many studies have undertaken the investigation of the 
effect of these naturally occurring mutations on the virus biology up to date. In 
harmony with the lack of genetic variation reported in 1995 during the EBOV 
outbreak in Kikwit (Rodriguez et al., 1999), Dunham et al. and Olabode et al. claimed 
no gain in virulence of EBOV at the beginning of the West African outbreak in 2013 
(Dunham et al., 2015; Olabode et al., 2015a). However,  naturally occurring mutations 
in NP, L and GP were found later to enhance viral fitness during the course of the 
epidemic (Dietzel et al., 2017b; Wong et al., 2019). Currently, there is a lack of a 
complete definition of the impact of the observed mutations in the viral proteins and 
their functionality. In chapter 5, it was hypothesised that genomic changes observed 
in VP35 early in the 2013-2016 EBOV outbreak led to an enhanced viral virulence. 
Amino acid variation in the EBOV VP35 protein sequence from 950 samples taken at 
the start of the outbreak, from different countries and available in GenBank, was 
examined. The effect of mutations L249F and L330F on EBOV VP35 functionality in 
cell culture was examined in isolation for the first time, as they represented the most 
occurring non-synonymous amino acid changes among the sequences included in the 
analysis (4.75% and 2.83%, respectively). Mutation T68M was observed for the first 
time in an EBOV genome from Gabon sampled in 2002. Methionine was maintained 
as the major variant from that year on, representing a neutral mutation in viral 
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transcription and replication terms. L249F and L330F, on the contrary, showed 
enhanced activity in an EBOV minigenome system compared to the wild type RNP 
complex proteins. The IFN-β induction antagonism of the mentioned mutations was 
also examined, as residues 249 and 330 are located within the interferon inhibitory 
domain of VP35. Amino acid changes M68T, L249F and L330F keep VP35 functional 
at repressing the IFN-β expression and show significant differences in the IFN-β 
induction compared to the wild type VP35, enhancing the inhibition of the IFN- β 
induction when mutated VP35s were added individually at lower amounts. These 
findings give evidence of the necessity of characterising naturally occurring 
phenotypic changes in the viral protein sequences, as they can modulate their 




Overall, this thesis presents the cellular interactome of EBOV Makona strain VP35 
and the interactome of EBOV Makona strain L in a cell-free expression system for the 
first time. Moreover, it gives insight into novel virus-host interactions and host factors 
with potential to be used as antiviral targets to disrupt the Ebola virus replication. 
DYNLL1 and CALM proved to have a role in the virus replication and repurposed drugs 
Ciliobrevin D and W-7 showed to have detrimental effects for the virus biological 
cycle. Also, it is demonstrated that free intracellular Ca2+ levels are determinant for 
EBOV to carry out replication. The characterisation of naturally occurring mutations 
in VP35 during the largest EBOV outbreak to date in this thesis points out the need 
of isolating dominant amino acid changes for the study of the consequences in the 
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6.3. Future perspectives  
 
Future perspectives regarding the work done in this thesis involve the examination 
of EBOV VP35-CIRBP and EBOV L-YBX1 interactions role on the virus replication. A 
further characterisation of the interaction between EBOV L and CALM may also be of 
interest, since the host protein is a calcium-dependent modulator of a wide range of 
enzymes and has been reported to have diverse roles in the biology of other viruses. 
For instance, the role of the putative CALM-binding domain in EBOV L predicted in 
Chapter 4 could be further studied by site-directed mutagenesis. Ebola virus is 
currently a concern in the Democratic Republic of Congo, and it is in the RNA virus 
nature to present high mutation rates. Continuing with the work done in chapter 5, 
it would certainly be interesting to keep tracking non-synonymous mutations 
occurring in the viral proteins and characterising them to examine the virus evolution 
and implications of such changes on the viral fitness and the effectiveness of antiviral 
therapeutics. Investigating the effect of non-synonymous mutations in VP35 and 
extending the work to L’s mutations between survivor and deceased patients is quite 
attractive since these viral proteins are the main players of the viral transcription and 
replication. Moreover, VP35 in particular, has multiple roles within the virus 
infectious cycle. Also, there is no evidence whether the amino acid changes observed 
in this piece of work translate to differences in protein functionality in vivo and 
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8.1. Sequence reference numbers of EBOV Makona VP35 from 2014-15 
 
AQS26739.1 
AQS26730.1 
AQS26721.1 
AQS26712.1 
AQS26703.1 
APT69713.1 
APT69686.1 
APT69677.1 
APT69646.1 
APT69637.1 
APT69619.1 
APT69561.1 
AND81204.1 
AND81195.1 
AND81186.1 
AMY60352.1 
AMY60343.1 
AMY60334.1 
AMY60325.1 
AMY60316.1 
AMY60307.1 
AMY60298.1 
AMY60289.1 
AMY60280.1 
AMY60271.1 
AMY60262.1 
AMT75753.1 
AMT75744.1 
AMT75735.1 
ALG02051.1 
ALG02042.1 
ALG02033.1 
AMT75726.1 
AMT75717.1 
AMT75708.1 
AMT75699.1 
AMT75690.1 
AMT75681.1 
AMT75672.1 
AMT75663.1 
AMT75654.1 
AMT75645.1 
AMT75636.1 
AMT75627.1 
AMT75618.1 
AMT75609.1 
AMT75600.1 
AMT75591.1 
AMT75582.1 
AMT75573.1 
AMT75564.1 
AMT75555.1 
AMT75546.1 
ALX34556.1 
ALX34480.1 
ALX34420.1 
ALX34414.1 
ALX34389.1 
ALX34348.1 
ALX34337.1 
ALX34122.1 
ALG01745.1 
ALG01736.1 
ALG01727.1 
ALX34108.1 
ALX34096.1 
ALX34068.1 
ALX34014.1 
ALX34009.1 
ALX33855.1 
ALX33838.1 
ALX33785.1 
ALX33732.1 
ALX33724.1 
ALX33676.1 
ALX33650.1 
ALX33561.1 
ALX33451.1 
ALX33370.1 
ALX33145.1 
ALX33133.1 
ALX33088.1 
ALX32988.1 
ALX32655.1 
ALX32633.1 
ALX32589.1 
ALX32350.1 
ALX32271.1 
ALX32171.1 
ALX32150.1 
ALX32064.1 
ALX31986.1 
ALX31954.1 
ALG01412.1 
ALG01403.1 
ALG01394.1 
ALX31874.1 
ALX31724.1 
ALX31681.1 
ALX31630.1 
ALX31500.1 
ALX31465.1 
ALX31430.1 
ALX31241.1 
ALX31215.1 
ALX31197.1 
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ALT66774.1 
ALT66765.1 
ALT66756.1 
ALT66747.1 
ALT66738.1 
ALT66729.1 
ALP30064.1 
ALP30056.1 
ALN12277.1 
ALH21461.1 
ALH21452.1 
ALG02123.1 
ALG02114.1 
ALG02105.1 
ALG02078.1 
ALG02069.1 
ALG02060.1 
ALG01115.1 
ALG01097.1 
ALG01088.1 
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ALG02024.1 
ALG02015.1 
ALG02006.1 
ALG01997.1 
ALG01988.1 
ALG01979.1 
ALG01961.1 
ALG01952.1 
ALG01943.1 
ALG01934.1 
ALG01925.1 
ALG01916.1 
ALG01907.1 
ALG01898.1 
ALG01889.1 
ALG01880.1 
ALG01871.1 
ALG01862.1 
ALG01853.1 
ALG01844.1 
ALG01826.1 
ALG01817.1 
ALG01808.1 
ALG01790.1 
ALG01781.1 
ALG01772.1 
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ALG01520.1 
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ALG01502.1 
ALG01493.1 
ALG01484.1 
ALG01466.1 
ALG01457.1 
ALG01448.1 
ALG01439.1 
ALG01430.1 
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AKI84020.1 
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AKI83993.1 
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ALG01250.1 
ALG01241.1 
ALG01232.1 
ALG01223.1 
ALG01205.1 
ALG01196.1 
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ALG01178.1 
ALG01169.1 
ALG01160.1 
ALG01151.1 
ALG01142.1 
ALG01133.1 
ALG01124.1 
AKI84038.1 
AKI84029.1 
AKI84020.1 
AKI84011.1 
AKI84002.1 
AKI83993.1 
ALG01079.1 
ALG01070.1 
ALG01061.1 
ALG01052.1 
ALG01043.1 
ALG01034.1 
ALG01016.1 
ALG01007.1 
ALG00998.1 
ALG00980.1 
ALG00971.1 
ALG00962.1 
ALG00953.1 
ALG00944.1 
ALG00935.1 
ALG00926.1 
ALG00917.1 
ALG00908.1 
ALG00899.1 
ALG00890.1 
ALG00881.1 
ALG00872.1 
ALF04599.1 
ALF04590.1 
ALF04581.1 
ALF04549.1 
ALF04540.1 
ALB07142.1 
AKI83759.1 
AKI83750.1 
AKI83741.1 
AKI83732.1 
AKI83723.1 
AKI83714.1 
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AKL91086.1 
AKI84254.1 
AKI84251.1 
AKI84236.1 
AKI84227.1 
AKI84218.1 
AKI84209.1 
AKI84200.1 
AKI84191.1 
AKI84182.1 
AKI84173.1 
AKI84164.1 
AKI84155.1 
AKI84146.1 
AKI84137.1 
AKI84128.1 
AKI84119.1 
AKI84110.1 
AKI84101.1 
AKI84092.1 
AKI84083.1 
AKI84074.1 
AKI84065.1 
AKI84056.1 
AKI84047.1 
AKI83471.1 
AKI83462.1 
AKI83453.1 
AKI83444.1 
AKI83435.1 
AKI83426.1 
AKI83408.1 
AKI83399.1 
AKI83390.1 
AKI83984.1 
AKI83975.1 
AKI83966.1 
AKI83957.1 
AKI83948.1 
AKI83939.1 
AKI83930.1 
AKI83921.1 
AKI83912.1 
AKI83903.1 
AKI83894.1 
AKI83885.1 
AKI83876.1 
AKI83867.1 
AKI83858.1 
AKI83849.1 
AKI83840.1 
AKI83831.1 
AKI83822.1 
AKI83813.1 
AKI83804.1 
AKI83795.1 
AKI83786.1 
AKI83777.1 
AKI83768.1 
AKI83183.1 
AKI83174.1 
AKI83165.1 
AKI83156.1 
AKI83147.1 
AKI83138.1 
AKI83129.1 
AKI83120.1 
AKI83111.1 
AKI83984.1 
AKI83975.1 
AKI83966.1 
AKI83957.1 
AKI83948.1 
AKI83939.1 
AKI83930.1 
AKI83921.1 
AKI83912.1 
AKI83903.1 
AKI83894.1 
AKI83885.1 
AKI83876.1 
AKI83867.1 
AKI83858.1 
AKI83849.1 
AKI83840.1 
AKI83831.1 
AKI83822.1 
AKI83813.1 
AKI83804.1 
AKI83795.1 
AKI83786.1 
AKI83777.1 
AKI83768.1 
AKI82904.1 
AKI82895.1 
AKI82886.1 
AKI82877.1 
AKI82868.1 
AKI82859.1 
AKI82850.1 
AKI82841.1 
AKI82832.1 
AKI83705.1 
AKI83696.1 
AKI83687.1 
AKI83678.1 
AKI83669.1 
AKI83660.1 
AKI83651.1 
AKI83642.1 
AKI83624.1 
AKI83615.1 
AKI83606.1 
AKI83597.1 
AKI83588.1 
AKI83579.1 
AKI83570.1 
AKI83561.1 
AKI83552.1 
AKI83543.1 
AKI83534.1 
AKI83525.1 
AKI83516.1 
AKI83507.1 
AKI83498.1 
AKI83489.1 
AKI83480.1 
AKI82626.1 
AKI82618.1 
AKG96269.1 
AKG96260.1 
AKG96251.1 
AKG96242.1 
AKG96233.1 
AKG96224.1 
AKG96215.1 
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AKI83381.1 
AKI83372.1 
AKI83363.1 
AKI83354.1 
AKI83345.1 
AKI83336.1 
AKI83327.1 
AKI83318.1 
AKI83309.1 
AKI83300.1 
AKI83291.1 
AKI83282.1 
AKI83273.1 
AKI83264.1 
AKI83255.1 
AKI83246.1 
AKI83237.1 
AKI83228.1 
AKI83219.1 
AKI83210.1 
AKI83201.1 
AKI83192.1 
AKG96008.1 
AKG95999.1 
AKG95990.1 
AKG95981.1 
AKG95972.1 
AKG95963.1 
AKG95954.1 
AKG95945.1 
AKG95936.1 
AKG95927.1 
AKG95918.1 
AKG95909.1 
AKI83102.1 
AKI83093.1 
AKI83084.1 
AKI83075.1 
AKI83066.1 
AKI83057.1 
AKI83048.1 
AKI83039.1 
AKI83030.1 
AKI83021.1 
AKI83012.1 
AKI83003.1 
AKI82994.1 
AKI82985.1 
AKI82976.1 
AKI82967.1 
AKI82958.1 
AKI82949.1 
AKI82940.1 
AKI82931.1 
AKI82922.1 
AKI82913.1 
AKG95729.1 
AKG95720.1 
AKG95711.1 
AKG95702.1 
AKG95693.1 
AKG95684.1 
AKG95675.1 
AKG95666.1 
AKG95657.1 
AKG95648.1 
AKG95639.1 
AKG95630.1 
AKI82823.1 
AKI82814.1 
AKI82805.1 
AKI82796.1 
AKI82787.1 
AKI82778.1 
AKI82769.1 
AKI82760.1 
AKI82751.1 
AKI82742.1 
AKI82733.1 
AKI82724.1 
AKI82715.1 
AKI82706.1 
AKI82697.1 
AKI82688.1 
AKI82679.1 
AKI82670.1 
AKI82661.1 
AKI82652.1 
AKI82643.1 
AKI82634.1 
AKC37181.1 
AKC37172.1 
AKC37163.1 
AKC37154.1 
AKC37145.1 
AKC37136.1 
AKC37127.1 
AKC37118.1 
AKC37109.1 
AKC37100.1 
AKC37091.1 
AKC37082.1 
AKG96206.1 
AKG96197.1 
AKG96188.1 
AKG96179.1 
AKG96170.1 
AKG96161.1 
AKG96152.1 
AKG96143.1 
AKG96134.1 
AKG96125.1 
AKG96116.1 
AKG96107.1 
AKG96098.1 
AKG96089.1 
AKG96080.1 
AKG96071.1 
AKG96062.1 
AKG96053.1 
AKG96044.1 
AKG96035.1 
AKG96026.1 
AKG96017.1 
AKC36902.1 
AKC36893.1 
AKC36884.1 
AKC36875.1 
AKC36866.1 
AKC36857.1 
AKC36848.1 
AKC36839.1 
AKC36830.1 
AKC36821.1 
AKC36812.1 
AKC36803.1 
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AKG95900.1 
AKG95891.1 
AKG95882.1 
AKG95873.1 
AKG95864.1 
AKG95855.1 
AKG95846.1 
AKG95837.1 
AKG95828.1 
AKG95819.1 
AKG95810.1 
AKG95801.1 
AKG95792.1 
AKG95783.1 
AKG95774.1 
AKG95765.1 
AKG95756.1 
AKG95747.1 
AKG95738.1 
AKC36614.1 
AKC36605.1 
AKC36596.1 
AKC36587.1 
AKC36578.1 
AKC36570.1 
AKC36561.1 
AKC36552.1 
AKC36543.1 
AKC36534.1 
AKC36525.1 
AKC36516.1 
AKC36507.1 
AKC36498.1 
AKC36489.1 
AKG95621.1 
AKG95612.1 
AKG95603.1 
AKG95594.1 
AKG95585.1 
AKG95576.1 
AKG95567.1 
AKG95558.1 
AKG95549.1 
AKG95540.1 
AKC37262.1 
AKC37253.1 
AKC37244.1 
AKC37235.1 
AKC37226.1 
AKC37217.1 
AKC37208.1 
AKC37199.1 
AKC37190.1 
AKC36327.1 
AKC36318.1 
AKC36309.1 
AKC36300.1 
AKC36291.1 
AKC36282.1 
AKC36273.1 
AKC36264.1 
AKC36255.1 
AKC36246.1 
AKC36237.1 
AKC36228.1 
AKC36219.1 
AKC36210.1 
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